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 ABSTRACT	
Natural	 killer	 (NK)	 cells	 reconstitute	 rapidly	 following	 allogeneic	 stem	 cell	transplantation	 (allo-SCT)	 at	 a	 time	 when	 alloreactive	 T	 cell	 immunity	 is	 being	established.	 Important	 differences	 are	 seen	 in	 the	 patterns	 of	 reconstitution	between	T	cell	deplete,	T	cell	replete	and	umbilical	cord	stem	cell	transplants.	82	patients	 who	 received	 T	 cell-deplete	 allo-SCT	 were	 studied	 to	 determine	 the	functional	and	 transcriptional	profile	of	 the	reconstituting	NK	cells	and	 to	assess	the	 relationship	with	clinical	outcome.	NK	cells	at	day	14	 (D14-NK)	were	donor-derived,	 intensely	 proliferating	 and	 expressed	 chemokine	 receptors	 targeted	 to	lymphoid	and	peripheral	tissue.	Spontaneous	production	of	the	immunoregulatory	cytokine	 IL-10	was	observed	 in	over	70%	of	 cells	 and	 transcription	of	 cytokines	and	growth	factors	was	augmented.	D14-NK	cell	number	was	inversely	correlated	with	 the	 incidence	 of	 grade	 II-IV	 acute	 graft	 versus	 host	 disease	 (GVHD).	 These	findings	reveal	that	robust	reconstitution	of	immunoregulatory	NK	cells	by	day	14	after	allo-SCT	is	an	important	determinant	of	clinical	outcome	and	suggest	NK	cells	may	suppress	development	of	 the	T	 cell-mediated	alloreactive	 immune	 response	through	production	of	IL-10.			 	
 	 ii	
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CHAPTER	1:	INTRODUCTION	
	
1.1	Introduction	Natural	Killer	(NK)	cells	are	traditionally	described	as	part	of	 the	 innate	 immune	system	and	seem	to	be	a	relatively	primitive	cell	compared	to	T	and	B	cells	of	the	adaptive	immune	system.	The	“natural”	killing	that	defines	NK	cells	is	spontaneous	and,	 unlike	 T	 cells,	 does	 not	 require	 priming	 by	 antigen-presenting	 cells	 or	recognition	 of	 specific	 major	 histocompatibility	 complex-peptide	 combinations.	Recent	 advances	 in	 NK	 cell	 biology	 describe	 sophisticated	 mechanisms	 and	functions	 similar	 to	 those	 seen	 in	 the	 other	 lymphocyte	 lineages.	We	 now	know	that	NK	cells	can	recognize	cells	that	do	not	express	self-MHC	class	I	molecules	(the	“missing-self”	 hypothesis)(Kärre	 et	 al.,	 1986)	 and	 that	 NK	 cells	 express	 many	different	 inhibitory	 and	 activatory	 receptors	 that	 bind	 to	MHC	 class	 I	molecules.	These	act	in	concert	to	control	and	define	the	NK	cell	response	to	transformed	or	infected	cells.	The	variations	in	MHC	class	I	ligand	expression	between	NK	cells	in	an	individual’s	NK	cell	repertoire	ensures	that	there	is	a	comprehensive	ability	to	target	 infected	 or	 transformed	 cells	 regardless	 of	 the	 different	 permutations	 of	MHC	class	I	expression	that	occur.		At	least	half	a	million	patients	have	undergone	allogeneic	stem	cell	transplantation	(allo-SCT)	since	its	development	in	the	1970s.	Immunological	processes	determine	the	 majority	 of	 the	 clinical	 features	 of	 stem	 cell	 transplantation	 but	 the	
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mechanisms	 of	 immune	 regulation	 after	 transplant	 remain	 very	 poorly	understood.	A	 characteristic	 feature	of	 allo-SCT	 is	 the	 rapid	 reconstitution	of	NK	cells	although	the	biology	of	this	process	has	not	been	investigated	in	detail.	There	is	a	growing	appreciation	of	the	importance	of	NK	cell	function	as	a	determinant	of	clinical	 outcome	 following	 allo-SCT	 and	 this	 research	 project	 focused	 on	 the	biological	features	and	clinical	correlates	of	NK	cell	reconstitution	after	allo-SCT.		This	 introduction	 will	 first	 describe	 NK	 cell	 development	 and	 biology	 and	 then	consider	the	literature	on	the	mechanisms	by	which	NK	cells	can	determine	patient	outcome	following	allo-SCT.			
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1.2	Natural	Killer	cells	
1.2.1	Natural	killer	cell	development	Studies	 have	 shown	 that	 mice	 lacking	 an	 intact	 bone	 marrow	 (following	 either	strontium	 administration(Levy,	 Kumar	 and	 Michael,	 1980),	 chronic	 estradiol	treatment	 resulting	 in	 osteosclerosis(Seaman	 et	 al.,	 1978)	 or	 in	 mice	 with	congenital	osteopetrosis(Seaman	et	al.,	1979))	all	show	depletion	of	natural	killer	cells.	These	studies	all	implicate	bone	marrow	as	being	the	primary	site	of	NK	cell	development.	 In	 contrast,	 T	 and	 B	 cells	 are	 still	 produced	 in	 mice	 with	 bone	marrow	 aplasia,	 and	 under	 these	 conditions,	 the	 spleen	 becomes	 the	 source	 of	myeloid	and	lymphoid	stem	cells.		Culturing	bone	marrow	derived	CD34+	haematopoietic	progenitor	cells	(HPCs)	on	bone	 marrow	 stroma	 in	 vitro	 results	 in	 differentiation	 into	 NK	 cells,	 further	supporting	 the	 important	 role	 of	 bone	 marrow	 in	 NK	 cell	 development	 (Miller,	Verfaillie	and	McGlave,	1992).	NK	cells	are	particularly	dependent	on	the	cytokine	interleukin-15	 (IL-15)	 signaling	 for	 development,	 homeostasis	 and	 function	 and	even	without	bone	marrow	stroma,	the	presence	of	low	concentrations	of	IL-15	in	co-culture	with	CD34+	HPCs	can	induce	NK	cell	differentiation.	IL-2	is	also	able	to	induce	NK	cell	differentiation	under	similar	culture	conditions	but	10-	 to	50-fold	higher	concentrations	are	required(Puzanov,	Bennett	and	Kumar,	1996).	 IL-15	 is	required	not	only	 for	NK	cell	development	and	maturation	 from	progenitor	 cells	but	also	for	homeostasis	and	survival	of	mature	cells	in	the	periphery.	Mature	NK	cells	 that	 are	adoptively	 transferred	 into	 IL15-/-	mice	 fail	 to	proliferate	and	have	reduced	survival(Cooper	et	al.,	2002).			
Chapter One: Introduction 
	 4	
The	current	model	of	NK	cell	development	suggests	that	they	develop	directly	from		CD34+	HPCs	(Shibuya	et	al.,	1995)although	no	one	CD34+	subset	has	been	proven	to	 contain	 all	 human	 NK	 cell	 precursors	 (Colucci,	 Caligiuri	 and	 Di	 Santo,	 2003).	However,	 bone	 marrow-derived	 CD34+CD45RA+	 HPCs	 represent	 an	 important	subset.	 	 These	CD34+CD45RA+	HPCs	 are	 found	 in	 low	numbers	 in	 the	 blood	 and	bone	marrow,	representing	<1%	of	BM	CD34+	HPCs	and	6%	of	blood	CD34+	HPCs	but	are	highly	enriched	within	 lymph	nodes.	Here	 they	make	up	>95%	of	 lymph	node	CD34+	HPCs	and	are	 found	within	the	parafollicular	T	cell	regions	of	 lymph	node.	They	can	develop	into	CD56bright	NK	cells	upon	stimulation	with	either	IL-2,	IL-15	 or	 activated	 T	 cells	 and	 go	 on	 to	 become	 CD56dim	 NK	 cells	 upon	 further	maturation	 (Freud	 et	al.,	 2005).	 A	 diagrammatic	 representation	 of	 this	model	 of	human	NK	cell	development	is	shown	in	Figure	1.1.		Human	in	vivo	studies	have	shown	that	NK	cells	proliferate	more	than	T	cells	with	Ki67+	positivity	of	5.3%	and	1.2%	respectively	in	healthy	human	peripheral	blood.	This	 indicates	 that	 NK	 cell	 proliferation	 is	 4-fold	 faster	 compared	 to	 T	 cells.	Apoptosis	 in	 NK	 and	 T	 cells	 was	 measured	 using	 terminal	 deoxynucleotidyl	transferase	 dUTP	nick	 end	 labeling	 (TUNEL)	 assays	which	 showed	 that	NK	 cells	displayed	 3-4-fold	 greater	 apoptosis	 rates	 compared	 to	 T	 cells	 suggesting	 that	overall	turnover	in	NK	cells	is	3-4	fold	greater	than	T	cells.	(Lutz	et	al.,	2011)		
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migration	of	CD56bright	cells	 to	 the	 tissues	but	may	also	 indicate	differentiation	of	CD56bright	 cells	 into	 CD56dim	 cells.	 Further	 confirmatory	 in	 vitro	 studies	 have	demonstrated	 that	 CD56bright	 cells	 can	 differentiate	 into	 CD56dim	 cells	 after	cytokine	 stimulation	 (Huntington	 et	 al.,	 2009)	 or	 in	 the	 presence	 of	 synovial	fibroblasts	 (Chan	 et	 al.,	 2007).	 The	 majority	 of	 resting	 CD56bright	 NK	 cells	transferred	into	NOD-SCID	mice	will	have	acquired	a	CD56dim	phenotype	after	10	days	demonstrating	this	differentiation	in	vivo.	CD56bright	NK	cells	also	have	longer	telomeres	 compared	 to	 CD56dim	 cells	 providing	 supportive	 evidence	 for	 their	relative	immaturity	(Romagnani	et	al.,	2007).		CD161,	2B4	 (CD244)	and	 the	activating	 receptor	NKp44	are	also	expressed	with	CD56	 in	 the	 earliest	 stages	 of	 NK	 cell	 development.	 Other	 activating	 receptors,	NKp46,	NKp30,	NKG2D	and	DNAM-1	and	the	inhibitory	receptor	CD94/NKG2A	are	subsequently	 acquired	 whilst	 CD16	 and	 killer-immunoglobulin-like	 receptors	(KIRs)	 are	 expressed	 later	 as	 CD56	 is	 downregulated	 and	 NK	 cells	 become	CD56dim(Freud	 and	 Caligiuri,	 2006).	 The	 phenotypic	 changes	 seen	 as	 NK	 cells	differentiate	and	mature	also	define	subsets	with	differing	functions.	The	CD56dim	NK	cell	subset	are	potent	cytotoxic	effector	cells	and	make	up	the	majority	of	NK	cells	 circulating	 in	 the	 peripheral	 blood,	 whilst	 CD56bright	 NK	 cells	 are	 often	referred	to	as	the	primary	source	of	NK	cell	derived	cytokines	(Caligiuri,	2008).		More	 recently,	 an	 intermediate	 stage	 of	 NK	 cell	 differentiation	 has	 been	 found	which	 is	 identified	 by	 expression	 of	 CD62L.	 These	 cells	 are	 able	 to	 combine	 the	functions	of	CD56bright	and	CD56dim	cells	and	can	produce	cytokines	in	response	to	
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both	 cytokine	 stimulation	 and	 activating	 receptor	 engagement.	 Moreover,	 they	proliferate	in	vivo	during	viral	infection	and	are	cytotoxic	(Juelke	et	al.,	2010).		The	expression	of	CD57	defines	a	further	subpopulation	of	NK	cells.	This	receptor	is	expressed	on	50%	of	CD56dim	NK	cells	but	in	a	lower	proportion	of	CD56bright	NK	cells.	However,	there	is	considerable	inter-individual	variation	in	CD57	expression	within	 levels	 varying	 between	 5-70%.	 CD57	 is	 often	 co-expressed	 on	 cells	 with	KIRs	 and	 CD57+	 cells	 have	 reduced	 proliferative	 capacity	 as	 demonstrated	 by	reduced	 Ki67	 expression,	 suggesting	 that	 this	 is	 a	 subpopulation	 of	 highly	differentiated	NK	 cells	 (Björkström	et	al.,	 2010).	 Interestingly,	 very	 few	 fetal	NK	cells	 express	CD57	but	 the	 frequency	of	CD57+	NK	cells	 increases	 as	 individuals’	age	(Abo,	Miller	and	Balch,	1984)(Garff-tavernier	et	al.,	2010).	Models	of	immune	reconstitution,	 for	 example	 in	 patients	 undergoing	 allogeneic	 stem	 cell	transplantation,	reveal	that	levels	of	CD57+	NK	cells	are	low	in	the	first	few	months	following	transplantation	and	that	it	can	take	a	year	before	levels	reach	those	seen	in	 the	 donor	 (Björkström	 et	 al.,	 2010).	 CD57	 can	 be	 induced	 on	 CD57-	NK	 cells	following	 stimulation	 with	 IL-15	 or	 IL-2.	 The	 CD57+	 cell	 population	 is	 potently	cytotoxic	and	can	produce	IFN-γ	after	stimulation	though	CD16,	although	it	is	less	responsive	to	cytokine	stimulation	and	expresses	IL-12R	and	IL-18R	at	low	levels	(Lopez-Vergès	et	al.,	2010).	
	
Chapter One: Introduction 
! V!
$
! P1QQLEIFNR' P0LEIFNR' P0NQGFSR'
%NJNTEGFO'
! 3'/M! 3'/"! 3'/a! +2[N!
13*",! 13*"+!
+2[c7E>G;:!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!+2[cA>@!
&SEGEGUKJKES' S! l! ll! lll! ll!
'
!"#$%&'():)''659$%50';"00&%'8&00'%&8&,9+%'&<,%&--"+2'.$%"2#'67'8&00'/59$%59"+2
H33&'()-$ %K$ .-**8$ -Q2)-88$ %KG#Z$ &4/$ EW7=$ I,'>$ >,@>$ ,4'-48,';"$ B>-8-$ .-**8$ &)-$ *-88$
.;'1'1Q,."$ Z8$ %K$ .-**8$ 3&'()-$ '>-;$ /1I4)-@(*&'-$ EW7=$ &4/$ *18-$ %KG#Z$ -Q2)-88,14"$ B>-;$
8-_(-4',&**;$&._(,)-$KHA$)-.-2'1)8$&4/$%KG#E$I>,*8'$'>-,)$.;'1'1Q,.$21'-4',&*$,4.)-&8-8"$B>-$
2('&',0-$ f3-31);g$ %K$ .-**$ 212(*&',14$ 3&;$ N-$ ,/-4',6,-/$ N;$ '>-$ &//,',14&*$ -Q2)-88,14$ 16$
EW7<"$$
$
!"#"5$%&'()&*$+,**-)$.-**$)-.-2'1)8!
13!K<II=!HE<!>A<C:>F><A!>C!FIBR!K8:B@<:E8!H=!I8@J;BK8:<=!:;H:!IHKO!:;<!+2a!HC:>G<C!
P:;<E<78!<XKI?A>CG!#! K<II=Q!7?:! <XJE<==!+2[cT!#;<8!JB==<==! H!@?I:>:?A<!BF! B:;<E!
E<K<J:BE=U!=B@<!R>:;!HK:>DH:BE8!BE!>C;>7>:BE8!EBI<=!HCA!B:;<E=!:;H:!HE<!@HEO<E=!BF!
13!K<II!A<D<IBJ@<C:!HCA!@H:?EH:>BCT!!
Chapter One: Introduction 
	 9	
CD56	 is	 a	 140-kDa	 isoform	 of	 neural	 cell	 adhesion	 molecule	 (NCAM)	 and	 is	expressed	on	NK	cells	and	a	small	proportion	of	T	cells.	As	previously	mentioned,	the	 intensity	 of	 CD56	 expression	 on	 NK	 cell	 surfaces	 defines	 the	 two	 major	populations	of	NK	cells	in	the	peripheral	blood.	The	CD56dim	population	makes	up	90%	 of	 circulating	 NK	 cells	 and	 is	 a	 more	 mature	 NK	 cell	 that	 exhibits	 greater	cytotoxicity	and	 is	more	granular	 than	 its	CD56bright	 counterpart.	The	majority	of	CD56dim	 NK	 cells	 coexpress	 CD16,	 in	 contrast	 to	 CD56bright	NK	 cells	 that	 do	 not	express	 this	 antigen.	 	 Although	 the	 CD56bright	 population	 is	 less	 able	 to	spontaneously	kill	 transformed	or	 infected	 target	 cells,	 it	 is	unique	 in	 that	 it	 can	produce	 large	 amounts	 of	 cytokines	 and	 chemokines	 rapidly	 following	activation(Cooper,	2001).				
CD16	 is	a	 low-affinity	Fc	 receptor	 for	 immunoglobulin	G	and	mediates	activating	signals	 via	 the	 immunoreceptor	 tyrosine-based	 activating	 motif	 (ITAM).	 It	 is	expressed	 predominantly	 in	 the	 CD56dim	 NK	 cell	 population	 and	 defines	 a	more	potently	cytotoxic	group	of	cells(Caligiuri,	2008).			
Killer	 Immunoglobulin-Like	 Receptors	 (KIRs)	 are	 a	 highly	 polymorphic	 family	 of	diverse	 activating	 and	 inhibitory	 receptors	 that	 are	 part	 of	 the	 immunoglobulin-like	receptor	superfamily.	The	inhibitory	KIRs	have	evolved	as	receptors	for	MHC	molecules	 and	 although	 some	 activatory	 KIRs	 can	 also	 interact	 with	 MHC	molecules,	 their	 ligands	have	yet	 to	be	 fully	 resolved.	KIRs	possess	 either	2	or	3	extracellular	 Ig-like	 domains	 and	 are	 designated	 KIR2D	 and	 KIR3D	 respectively.	The	 cytoplasmic	 domain	 of	 KIRs	 can	 either	 be	 long	 (L),	 indicating	 an	 inhibitory	
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function,	 or	 short	 (S)	 indicating	 a	 stimulatory	 role.	 As	 a	 general	 rule,	 the	KIR2D	receptors	 recognize	 HLA-Cw	 alleles,	 whilst	 KIR3D	 interact	 with	 HLA-A	 and	 –B	alleles.	KIR2D	receptors	can	be	subdivided	into	groups	based	upon	their	ability	to	discriminate	between	HLA-Cw	alleles	with	either	a	Lys	(e.g.	HLA-Cw2,	-Cw4,	-Cw5,	-Cw6)	or	Asn	(e.g.	HLA-Cw1,	-Cw3,	-Cw7,	-Cw8)	at	position	80	of	the	MHCα1	helix	(Campbell	and	Purdy,	2011).			
The	CD94-NKG2	family	of	receptors	are	lectin-like	heterodimers.	The	CD94	subunit	is	 invariant	 and	 encoded	 by	 a	 single	 gene,	 whilst	 NKG2	 represents	 a	multigenic	family	 of	 five	 proteins.	 NKG2A,	 B,	 C	 and	 E	 are	 structurally	 homologous	 and	associate	 with	 CD94	 to	 form	 heterodimers	 whilst	 NKG2D	 forms	 homodimers.	NKG2A/B	have	 long	 cytoplasmic	 domains	 and	 possess	 inhibitory	 function,	while	NKG2D/E	 have	 short	 domains	 and	 form	 activating	 isoforms.	 The	 NKG2D	homodimer	 is	 an	 activating	 receptor	 and	 recognizes	 the	 stress-inducible	 MICA,	MICB	and	ULBP	proteins,	while	the	other	CD94-NKG2	receptors	recognize	HLA-E.	HLA-E	 is	 a	 non-classical	 MHC	 class	 I	 molecule	 that	 binds	 a	 nonamer	 peptide	derived	from	the	signal	sequences	of	the	classical	MHC	class	I	molecules(Hoare	et	
al.,	2008).		Both	KIR	 and	 CD94-NKG2	 receptor	 families	 contain	 inhibitory	 receptors	 specific	for	MHC	class	 I	and	whilst	KIRs	display	allele	specific	recognition	of	MHC,	CD94-NKG2	receptors	broadly	survey	all	MHC	molecules	through	interaction	with	HLA-E.	 The	 existence	 of	 two	 separate	 receptor	 families	 with	 contrasting	 approaches	
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towards	 a	 similar	 purpose	 indicates	 that	 these	 are	 complementary	 rather	 than	redundant	systems	(Cheent	and	Khakoo,	2009).			
Natural	cytotoxicity	receptors	(NCRs)	 are	a	 family	of	 activating	 receptors	 that	 are	unique	 to	 NK	 cells	 and	 consist	 of	 three	 receptors	 named	 according	 to	 their	molecular	 weight:	 NKp46	 (46,000MW),	 NKp30	 (30,000MW)	 and	 NKp44	(44,000MW)(Cheent	 and	 Khakoo,	 2009).	 NKp46	 is	 encoded	 on	 human	chromosome	19	within	the	leukocyte	receptor	complex	(LRC)	along	with	the	genes	encoding	 KIR.	 NKp30	 and	 NKp44	 are	 found	 in	 chromosome	 6.	 These	 three	receptors	 all	 have	 in	 common	 a	 short	 intra-cytoplasmic	 tail	 and	 are	 associated	with	an	ITAM-containing	adaptor	molecule	via	a	positively	charged	residue	in	their	transmembrane	portion.	Whilst	NKp30	and	NKp46	are	expressed	on	most	NK	cells,	NKp44	is	unique	in	that	it	is	selectively	expressed	on	activated	NK	cells	(Moretta	et	
al.,	2001).			Interestingly,	NCR	ligands	are	constitutively	expressed	on	haematopoietic	cells	and	although	 they	are	not	 seen	on	 the	bone	marrow	derived	CD34+	progenitor	 cells,	these	 ligands	 are	 gradually	 acquired	 during	 the	 process	 of	 myeloid	differentiation(Nowbakht	et	al.,	 2005).	This	 interaction	 enables	dendritic	 cells	 to	activate	 NK	 cells	 leading	 to	 proliferation	 and	 subsequently	 these	 NK	 cells	 can	delete	 immature	 dendritic	 cells	 via	 NKp30(Ferlazzo	 et	 al.,	 2002).	 	 Such	 a	mechanism	allows	NK	cells	to	regulate	dendritic	cell	antigen	presentation	and	tune	adaptive	immunity.	
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NCR	 ligands	 are	 also	 expressed	 on	 a	 wide	 range	 of	 cancer	 cells	 including	melanomas,	 carcinomas,	 neuroblastomas	 as	 well	 as	 Epstein-Barr	 virus	 (EBV)	transformed	B	cells	implicating	NCRs	in	NK	mediated	lysis	of	malignant	and	virally	infected	cells(Bottino	et	al.,	2005).	Whilst	NCR	ligands	are	expressed	on	maturing	myeloid	 cells,	 a	 large	 proportion	 of	 myeloid	 leukaemias	 (80%)	 are	 found	 to	express	very	low	levels	of	NCR-specific	ligands	suggesting	that	this	may	represent	a	strategy	by	which	these	malignant	cells	can	evade	NK	cell	killing	(Nowbakht	et	
al.,	2005).		
	
1.2.4	Natural	killer	cell	education	T	cells	are	activated	upon	ligation	of	a	single	rearranged	antigen-specific	receptor,	as	 long	 as	 co-stimulatory	molecules	 are	 simultaneously	 engaged.	 In	 contrast,	NK	cells	express	a	variety	of	germ-line	encoded,	activatory	and	 inhibitory	 receptors;	synergistic	 integration	 of	 signals	 from	 a	 combination	 of	 these	 receptors	 governs	NK	cell	 function.	When	an	NK	cell	encounters	a	healthy	self-cell,	 it	will	not	attack	the	 cell	 as	 the	 expression	 of	 MHC	 class	 I	 on	 the	 healthy	 cell	 should	 provide	sufficient	 inhibitory	 signal	 to	 prevent	 NK	 cell	 activation.	 In	 a	 transformed	 or	infected	 cell	 that	 downregulates	MHC	 class	 I,	 the	 reduction	 in	 inhibitory	 signals	will	 result	 in	 NK	 cell	 activation	 if	 activating	 receptors	 are	 also	 bound.	 In	 other	situations	 of	 genotoxic	 stress,	 ligands	 for	 activating	 receptors	 such	 as	 those	 for	NKG2D	 are	 upregulated	 and	 the	 net	 activating	 signal	 overcomes	 the	 inhibitory	signal	thus	resulting	in	NK	cell	activation	(See	Figure	1.2).	(Elliott	and	Yokoyama,	2011)(Joncker	and	Raulet,	2008)		
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A	successful	immune	system	requires	the	generation	of	effector	cells	that	are	able	to	recognize	non-self	whilst	maintaining	tolerance	to	self.	In	NK	cells	this	process	is	termed	NK	cell	education	or	licensing.	Interestingly,	NK	cells	from	MHC-deficient	mice(Dorfman	et	al.,	 1997)	 and	humans(Zimmer	et	al.,	 1998)	 are	hypofunctional	compared	to	NK	cells	from	healthy	donors.	Although	the	definitive	mechanism	by	which	this	occurs	is	yet	to	be	elucidated,	it	is	clear	that	the	presence	of	MHC	class	I	is	essential	for	optimal	NK	cell	function	and	there	are	several	theories	that	explain	how	this	occurs.		The	‘arming’	theory	suggests	that	an	NK	cell	 is	hypofunctional	until	 it	encounters	self-MHC	class	I	that	engages	an	inhibitory	receptor,	at	which	point	the	NK	cell	 is	educated	 and	 gains	 function.	 The	 ‘disarming’	 theory	 suggests	 that	 the	 repeated	engagement	 of	 a	 self-specific	 activation	 receptor	 results	 in	 anergy,	 although	 this	can	be	reversed	by	a	self-MHC	receptor(Raulet	and	Vance,	2006).			While	these	theories	suggest	that	education	is	an	all	or	none	process,	in	the	‘tuning’	or	 ‘rheostat’	model,	NK	 cells	 acquire	 function	 in	 a	 graded	manner	 depending	 on	receptor-self	 MHC	 interactions(Brodin,	 Kärre	 and	 Höglund,	 2009).	 This	 may	explain	why	 individual	 NK	 cells	 that	 express	more	 inhibitory	 receptors	 for	 self-MHC	 are	 functionally	 more	 responsive	 than	 those	 with	 fewer	 inhibitory	receptors(Joncker	 et	 al.,	 2009).	 Furthermore,	 the	 magnitude	 of	 the	 NK	 cell	response	 is	 not	 just	 determined	 by	 the	 number	 of	 signals	 through	 self-MHC	receptors,	 but	 also	 by	 the	 quality	 of	 the	 stimulus.	 For	 example,	 the	missing	 self	response	of	KIR2DL3	single	positive	NK	cells	was	stronger	in	donors	carrying	the	
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HLA-Cw*07	 compared	 to	 those	 educated	 by	 the	 weaker	 interaction	 with	 HLA-Cw*1402(Yawata	et	al.,	2008).		Additionally,	 when	 NK	 cells	 are	 transferred	 into	 an	 MHC-deficient	 host,	 they	become	 hyporesponsive	 in	 a	 matter	 of	 days,	 indicating	 that	 education	 is	 a	reversible	process	and	that	continual	stimulation	with	MHC	class	 I	 is	required	to	maintain	 function(Joncker	 et	 al.,	 2010).	 Goodridge	 et	 al	 have	 put	 forward	 a	‘Newtonian’	view,	which	takes	inspiration	from	Newton’s	third	law	of	motion	that	for	every	action	on	a	physical	object	there	is	an	equal	and	opposite	reaction.	They	postulate	that	there	is	continual	tuning	of	NK	cell	 function	through	repeated	cell-cell	interactions	and	successive	inhibitory	and	activatory	signals.	This	results	in	an	NK	 cell	 population	 that	 is	 self-tolerant	 and	 can	 also	 respond	 rapidly	 to	 any	antigenic	discontinuity	(Figure	1.3)(Goodridge,	Önfelt	and	Malmberg,	2015).		Although	various	mechanisms	may	be	responsible,	it	is	certain	that	the	presence	of	self-MHC	class	I,	in	addition	to	the	cytokine	IL-15,	is	essential	for	a	developing	NK	cell	to	become	functionally	competent.			 	
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1.2.5	Natural	killer	cells	and	cytokines	Activating	signals	can	stimulate	cells	to	release	small	proteins	called	cytokines.	In	turn,	these	then	mediate	effects	by	binding	to	specific	receptors	and	usually	act	in	an	autocrine	manner	(affecting	the	behavior	of	the	cell	that	produces	the	cytokine)	or	 a	 paracrine	manner	 (affecting	 the	 behavior	 of	 adjacent	 cells).	 Immunological	cytokines	are	most	usefully	categorized	according	to	their	function:			
• Type	1	cytokines		which	enhance	cellular	immune	responses	(Th1)	
o tumour	necrosis	factor	alpha	(TNFα),	interferon	gamma	(IFNγ)	etc.	
• Type	2	cytokines	which	favour	antibody	responses	(Th2)	
o transforming	growth	factor	beta	(TGFβ),	 interleukin-4	(IL-4),	 IL-10,	IL-13	etc.		
Interferon	gamma	In	 addition	 to	 their	 cytotoxic	 effects,	 NK	 cells	 can	 also	 produce	 a	 variety	 of	cytokines	 including	 IFN-γ,	 TNFα,	 granulocyte	 macrophage	 colony-stimulating	factor	 (GM-CSF)	 and	 IL-10.	 IFNγ	 is	 the	 cytokine	 best	 associated	 with	 NK	 cell	function	and	is	predominantly	produced	by	the	CD56bright	NK	cell	subset	located	in	the	 parafollicular	 region	 of	 secondary	 lymphoid	 tissues(Fehniger	 et	 al.,	 2003).	These	 NK	 cells	 require	 two	 signals	 to	 produce	 IFNγ,	 one	 of	 which	 invariably	includes	IL-12.	The	second	can	be	IL-1,	IL-2,	IL-15	or	IL-18	or	engagement	of	an	NK	activating	 receptor	 such	 as	 CD16	 or	NKG2D(Cooper,	 2001)(Parihar	 et	al.,	 2002).	Interestingly,	 NK	 cells	 can	 produce	 cytokines	 within	 minutes	 of	 monokine	
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costimulation,	which	 is	 in	marked	contrast	 to	the	more	delayed	response	seen	 in		naïve	 T	 cells	 (Fehniger	 et	al.,	 1999).	 NK	 cell	 production	 of	 IFNγ	 results	 in	many	downstream	 effects	 including	 the	 upregulation	 of	 MHC	 class	 I	 on	 APCs	 and	increasing	 cytokine	 production	 by	 APCs.	 As	 an	 interesting	 counter	 mechanism,	these	APCs	then	release	the	 immunoregulatory	cytokines	IL-10	and	transforming	growth	factor-beta	(TGF-β),	which	suppresses	the	NK	cell’s	IFNγ	secretion	(Tripp,	Wolf	and	Unanue,	1993)(Yu	et	al.,	2006).		
Interleukin-10	NK	cells	can	also	produce	type	2	cytokines	such	as	IL-10.	IL-10	was	first	described	as	 a	 product	 of	 Th2	 cells	 and	 is	 a	 key	 immunoregulatory	 cytokine	 that	 acts	 to	dampen	down	excessive	Th1	and	cytotoxic	T	cell	responses	in	infections	that	may	otherwise	 cause	 serious	 immunopathology.	 Achieving	 the	 optimal	 level	 of	immunoregulation	is	essential	as	ablation	of	IL-10	signalling	in	Trypanosoma	cruzi	infection	 can	 result	 in	 severe,	 often	 fatal	 immunopathology(Hunter	 et	al.,	 1997).	Conversely,	excessive	IL-10	production	can	inhibit	the	proinflammatory	response	to	Trypanosoma	cruzi	to	the	degree	that	there	is	a	failure	to	control	the	pathogen,	resulting	in	fulminant	infection(Reed	et	al.,	1994).				Various	 combinations	 of	 IL-2,	 IL-12	 and	 IL-15	 have	 been	 shown	 to	 induce	 IL-10	production	in	NK	cells(Mehrotra	et	al.,	1998)(Fehniger	et	al.,	2003).	Interestingly,	in	a	model	of	homeostatic	proliferation,	NK	cells	were	seen	to	undergo	epigenetic	reprogramming	 of	 the	 IL-10	 locus	 and	 switch	 to	 IL-10	 production	 in	 a	
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phenomenon	 termed	 ‘proliferation-dependent	 conditioning’	 of	NK	 cells(Tarrio	et	
al.,	2014).	It	has	been	suggested	that	this	switch	of	NK	cells	from	an	inflammatory	to	regulatory	phenotype	utilizes	the	high	frequency	of	innate	cells	in	order	to	apply	negative	 pressure	 on	 the	 development	 of	 adaptive	 immunity.	 CD56bright	 NK	 cells	predominantly	 reside	 in	 the	 secondary	 lymphoid	 tissues	 in	 close	 proximity	 to	 T	cells	 and	 APCs.	 The	 ability	 of	 NK	 cell	 derived	 IL-10	 to	 suppress	 NK-mediated	licensing	 of	 DC	 activation	 and	 to	 modulate	 NK	 deletion	 of	 DCs	 highlights	 the	importance	of	NK	cells	as	a	bridge	between	innate	and	adaptive	immunity.	
	
1.2.6	Natural	killer	cells	and	chemokines	Chemokines	 are	 chemoattractant	 cytokines,	 which	 act	 on	 G-protein-coupled	receptors	 to	 induce	direct	 chemotaxis	 in	nearby	 responsive	 cells.	 In	 the	 immune	system,	their	main	role	is	to	direct	effector	immune	cells	from	the	blood	to	sites	of	infection,	 although	 some	 chemokines	 have	 alternative	 functions	 in	 lymphocyte	development,	migration	and	angiogenesis.	A	variety	of	different	stimuli	can	induce	chemokine	productions,	ranging	from	bacterial	and	viral	infection	to	physical	cell	damage.	Four	distinct	families	of	chemokines	exist	(CXC,	CC,	XC	and	CX3C)	that	are	defined	by	the	arrangement	of	the	cysteine	residues	in	the	mature	protein.			Chemokine	molecules	are	produced	and	bound	to	the	surfaces	of	endothelial	cells	in	a	concentration	gradient	that	increases	towards	the	target	area.	As	the	leukocyte	rolls	 along	 the	 endothelial	 cells	 at	 the	 sites	 of	 inflammation,	 chemokines	 act	 on	leukocyte	adhesion	molecules	 (integrins)	allowing	 them	to	bind	strongly	 to	 their	
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ligands	on	endothelial	cells.	The	leukocyte	is	then	able	to	migrate	from	the	blood	vessel	 to	the	 inflamed	area	by	squeezing	between	the	endothelial	cells,	a	process	known	as	extravasation.			As	 previously	 described,	 NK	 cells	 are	 heterogenous	 with	 CD56bright	 and	 CD56dim	populations	displaying	important	differences	 in	cytokine	producing	potential	and	cytotoxicity.	NK	cells	express	receptors	for	many	different	chemokines	and	there	is	a	 similar	 level	 of	 diversity	 in	 chemokine	 receptor	 repertoire	 between	 NK	 cell	groups.	For	example,	CD16+	NK	cells	(commonly	expressed	on	the	CD56dim	NK	cell	subset)	express	high	levels	of	CXCR1	and	CX3CR1,	low	levels	of	CXCR2	and	CXCR3	and	 have	 no	 detectable	 levels	 of	 CXCR5.	 However	 the	 CD16neg	 (predominantly	CD56bright)	 NK	 cells	 express	 high	 levels	 of	 CXCR3,	 CCR5	 and	 CCR7,	 low	 levels	 of	CX3CR1	and	are	negative	for	CXCR1,	CXCR2	and	CXCR5.	Both	subsets	express	high	levels	 of	 CXCR4	 although	 expression	 of	 this	 chemokine	 receptor	 reduces	 as	 NK	cells	mature(Bernardini,	Gismondi	and	Santoni,	2012).		Chemokine	receptor	expression	correlates	with	the	ability	of	NK	cells	to	traffic	to	specific	areas	in	the	body.	This	can	be	beneficial	for	the	host:	for	example,	studies	have	 shown	 that	 a	 unique	 population	 of	NK	 cells	migrates	 in	 a	 CCR2-dependent	fashion	in	influenza	virus	infected	mice.	Monocyte	chemotactic	protein-1	(MCP-1),	which	is	a	ligand	for	CCR2,	is	produced	in	the	airways	of	these	infected	mice.(van	Helden,	Zaiss	and	Sijts,	2012)	 	A	murine	study	of	cowpox	virus	 infection	showed	that	NK	cells	are	 recruited	 to	 the	draining	 lymph	nodes	of	 the	affected	mice	and	that	expression	of	CXCR3	is	vital	for	this	migration.	(Pak-wittel	et	al.,	2012)	
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However,	NK	cells	trafficking	can	also	have	pathological	consequences	as	shown	in	the	 case	 of	 psoriasis	 and	 lichen	 planus.	 Both	 conditions	 are	 inflammatory	conditions	 of	 the	 skin	 that	 are	 characterized	 histologically	 by	 prominent	lymphocytic	infiltrates.	These	conditions	are	likely	to	be	mediated	by	autoreactive	T	 cells,	 and	 it	 has	 been	 proposed	 that	 NK	 cells	 may	 also	 have	 a	 role	 in	 their	pathogenesis.	NK	cells	isolated	from	psoriatic	plaques	express	high	levels	of	CXCR3	and	 CCR5,	 which	 are	 the	 receptors	 for	 the	 chemokines	 CXCL10	 and	 CCL5	respectively(Ottaviani	 et	 al.,	 2006).	 Both	 chemokines	 are	 potently	 produced	 by	activated	keratinocytes	in	inflamed	skin	and	in	vitro	studies	confirm	that	NK	cells	bearing	 their	 respective	 receptors	 can	 migrate	 towards	 activated	 keratinocytes,	and	that	this	movement	is	reduced	when	the	chemokine	effect	is	blocked	with	anti-CXCR3	and	anti-CCR5	antibodies.	Biopsies	from	patients	with	lichen	planus	contain	infiltrates	 of	 NK	 cells	 that	 express	 ChemR23,	 CCR6,	 CXCR3	 and	 CCR5	 and	 in	transwell	 migration	 assays	 these	 cells	 migrate	 in	 response	 to	 their	 respective	chemokines:	chemerin,	CCL20,	CXCL10	and	CCL5(Nasorri	et	al.,	2010)	(Parolini	et	
al.,	 2007).	 Activated	 keratinocytes	 in	 lichen	 planus	 produce	 high	 levels	 of	 these	chemokines	providing	further	evidence	that	NK	cells	are	actively	recruited	to	these	inflamed	tissues.	This	population	of	NK	cells	can	secrete	IFN-γ	and	TNF-α	both	of	which	are	proinflammatory	cytokines.		Further	 associations	 between	 NK	 cells,	 chemokines	 and	 disease	 have	 been	demonstrated	 in	 studies	 showing	 increased	 frequency	 of	 circulating	 CXCR3+	 NK	cells	in	advanced	stages	of	liver	fibrosis(Eisenhardt	et	al.,	2012).		
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1.2.7	Natural	killer	cell	memory	The	 traditional	view	of	 the	 immune	system	separates	 it	 into	adaptive	and	 innate	arms.	 The	 innate	 immune	 system,	 comprising	 NK	 cells,	 neutrophils	 and	macrophages,	 responds	 promptly	 but	 non-specifically	 to	 pathogens	 whilst	 the	adaptive	T-	and	B-	lymphocytes	express	rearranged	antigen-specific	receptors	and	respond	more	slowly	to	infections.	After	an	initial	encounter	with	a	pathogen,	the	adaptive	 immune	 system	 expands	 effector	 cells	 specific	 for	 that	 pathogen	 and	generates	a	pool	of	long-lived	memory	cells	that	can	expand	and	respond	quickly	in	 future	 encounters	 with	 the	 same	 pathogen.	 Although	 this	 simplistic	 view	 is	useful,	the	truth	is	that	the	two	arms	of	the	immune	system	do	not	act	in	isolation	of	 each	 other	 and	 the	 perceived	 differences	 between	 these	 cells	 are	 becoming	increasingly	indistinct.		Simple	 organisms	 exist	 that	 lack	 lymphocytes	 with	 rearranged	 antigen-specific	receptors.	 Although	 lacking	 T-	 and	 B-lymphocytes,	 these	 creatures	 exhibit	evidence	 of	 priming	 and	 immunological	memory.	 For	 example,	when	Drosophila	
melanogaster	are	 injected	with	Streptococcus	pneumonia	or	Beauveria	bassiana	(a	fruitfly	pathogen),	 they	exhibit	enhanced	immunity	against	subsequent	 infections	compared	 to	 fruitflies	 that	have	not	been	previously	exposed(Pham	et	al.,	2007).	Furthermore,	 the	 copepod	 Macrocyclops	 albidus	 (a	 crustacean)	 has	 increased	resistance	against	 tapeworms	when	 it	has	been	previously	exposed	to	 its	natural	pathogen	–	a	tapeworm:	Schistocephalus	solidus	(Kurtz	and	Franz,	2003).		
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These	studies	show	that	organisms	without	an	“adaptive”	immune	system	display	properties	 of	 immunological	 memory.	 Increasing	 evidence	 in	 mice	 and	 humans	suggests	 that	NK	 cells	 can	 develop	 into	 long-lasting	 “memory”	 like	 cells	 after	 an	initial	encounter	with	pathogen.		The	 recombination-activating	 gene	 is	 knocked	 out	 in	Rag-/-	mice,	 which	 renders	them	T	and	B	cell	deplete	as	they	are	unable	to	form	T-cell	receptors	(TCR)	or	B-cell	 receptors	 (BCR).	Rag-/-IL2rγ-/-	mice	are	depleted	of	all	 lymphocytes	 including	NK	cells.	The	ability	to	generate	hypersensitivity	responses	to	haptens,	such	as	2,4-dinitrofluorobenzene	(DNFB)	and	oxazolone,	 is	a	 feature	of	 the	adaptive	 immune	system.	 These	 responses	 are	 defined	 as	 those	 in	 which	 subsequent	 encounters	with	an	antigen	generates	qualitatively	enhanced	immune	responses	compared	to	the	 initial	 encounter.	 Rag2-/-Il2rγ-/-	mice	are	 unable	 to	 generate	 hypersensitivity	responses	whilst	 those	 that	 only	 lack	 T	 and	 B	 lymphocytes	 (Rag-/-)	do	 develop	responses.	 When	 NK	 cells	 from	 previously	 sensitized	 mice	 are	 adoptively	transferred	into	Rag2-/-Il2rγ-/-	mice	which	are	subsequently	challenged	with	DNFB	they	develop	hypersensitivity	responses	 further	highlighting	that	NK	cells	can	be	primed	 to	develop	more	effective	responses	at	 second	encounters	with	 the	same	stimuli	(O’Leary	et	al.,	2006).		NK	memory	 is	 also	proposed	 in	murine	models	of	virus	 infection.	C57BL/6	mice	are	resistant	to	mouse	cytomegalovirus	(MCMV),	while	BALB/c	and	DBA/2	mouse	strains	 cannot	 control	 viral	 replication	 and	 display	 high	 lethality	when	 infected.	This	MCMV-specific	immunity	is	due	to	expression	of	Ly49H,	which	is	an	activating	
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isoform	of	the	murine	Ly49	NK	receptor	family.	The	ligand	for	Ly49H	is	an	MCMV	encoded	 protein	 m157	 and	 its	 interactions	 can	 trigger	 NK	 cell	 cytotoxicity,	cytokine	and	chemokine	production	thus	specifically	targeting	MCMV	infected	cells	(Smith	et	al.,	2002).		When	C57BL/6	mice	are	infected	with	MCMV,	they	develop	a	clonal-like	expansion	of	 Ly49H+	NK	 cells.	 This	 expansion	does	not	 occur	 in	mice	 infected	with	mutant	MCMV	 lacking	 m157	 suggesting	 that	 this	 is	 an	 antigen-specific	 response.	Identification	 of	 Ly49H+	 cells	 as	 an	 MCMV-specific	 subpopulation	 of	 NK	 cells	allows	 us	 to	 monitor	 their	 kinetics	 in	 response	 to	 infection.	 During	 MCMV	infection,	 resting	Ly49H+	NK	 cells	 expand	and	are	 stimulated	 to	become	effector	cells.	 After	 two	 weeks,	 this	 population	 gradually	 contracts	 but	 numbers	 do	 not	drop	to	levels	detected	pre-MCMV	infection.	Gene	array	profiles	of	Ly49H+	NK	cells	at	 different	 time	points	 after	 infection	 show	unique	 transcriptional	 signatures	 at	each	time	point	following	infection	in	a	pattern	analogous	to	the	changes	in	gene	expression	 profile	 seen	 as	 CD8+	 T	 cells	 differentiate	 (Sun,	 Lopez-Verges,	 et	 al.,	2011).		Furthermore,	 the	 “memory”	 Ly49H+	NK	 cells	 isolated	 from	mice	 several	months	after	 initial	 infection	 are	 more	 potent	 effectors	 to	 viral	 infection	 compared	 to	resting	NK	cells	from	MCMV	naïve	mice.	When	adoptively	transferred	into	DAP12-deficient	mice,	which	 are	 then	 infected	with	MCMV,	 the	memory	 Ly49+	NK	 cells	proliferate	100-fold	and	are	still	 readily	detected	 in	 the	 liver	and	spleen	50	days	after	initial	transfer(Sun,	Beilke	and	Lanier,	2009).	Recent	studies	have	highlighted	
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the	importance	of	inflammatory	cytokines	in	the	generation	of	memory	NK	cells	as	IL-12	receptor-deficient	NK	cells	do	not	expand	or	exhibit	any	response	to	MCMV	following	infection	(Sun	et	al.,	2012).			There	 is	 some	 indication	 that	 NK	 cell	 memory	 may	 also	 be	 seen	 in	 humans.	Following	acute	infection	with	human	cytomegalovirus	(HCMV),	NKG2C+	NK	cells	expand,	 become	 NKG2Chi	 and	 subsequently	 acquire	 CD57.	 HMCV-seropositive	donors	 have	 higher	 proportions	 of	 NKG2ChiCD57+	 NK	 cells	 when	 compared	 to	HCMV-seronegative	 donors	 and	 it	 has	 been	 proposed	 that	 CD57	 is	 a	 marker	 of	mature	NK	cells	in	humans.(Lopez-Vergès	et	al.,	2011)			
Cytokine	induced	memory-like	NK	cells	Pre-activating	 human	 NK	 cells	 with	 combinations	 of	 IL-12,	 IL-15	 and	 IL-18	followed	by	a	7-21	day	rest	promotes	development	of	a	memory-like	population	of	NK	cells	that	show	enhanced	IFN-γ	production	when	re-stimulated	with	cytokines	or	K562	 leukaemia	cells.	However,	 in	contrast,	 this	pool	of	memory-like	NK	cells	expressed	CD94,	NKG2A	and	NKG2C	but	lacked	CD57	and	KIR(Romee	et	al.,	2012).	Clearly,	more	research	is	needed	to	clarify	whether	there	 is	a	phenotypic	marker	for	human	memory	NK	cells.			The	presence	of	a	long-lived	subset	of	NK	cells	challenges	the	traditional	view	that	innate	 immune	 cells	 have	 a	 short	 life-span	 and	 thus	 have	 no	 requirement	 for	immunological	memory.	Although	NK	cells	are	 frequently	defined	as	cells	able	 to	
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effectively	kill	target	cells	without	prior	sensitization,	there	is	increasing	evidence	that	they	can	become	more	potent	at	a	second	encounter	and	are	able	to	be	primed	against	particular	antigenic	 stimuli	 in	a	manner	previously	only	described	 in	 the	adaptive	immune	system.			
1.2.8	Natural	killer	cell	homeostatic	proliferation		As	highlighted	in	the	previous	section,	the	increasing	evidence	for	NK	cell	memory	blurs	the	distinction	between	NK	and	T	cells.	This,	in	itself,	is	not	too	surprising	as	the	cells	are	derived	from	the	same	common	lymphoid	progenitor	(CLP)	and	also	have	similar	functions	in	terms	of	cytokine	production	and	cytotoxicity.		T-cells	 proliferate	 rapidly	 in	 lymphopenic	 environments,	 such	 as	 following	chemotherapy	or	radiotherapy,	and	NK	cells	act	in	a	similar	fashion.	When	NK	cells	are	 labeled	 with	 carboxyfluorescein	 succinimidyl	 ester	 (CFSE)	 and	 adoptively	transferred	into	irradiated	mice,	they	proliferate	rapidly	but	this	is	not	seen	when	transferred	into	non-irradiated	lymphocyte-replete	mice(Jamieson	et	al.,	2004).	In	a	manner	similar	to	expansion	following	virus	infection,	there	is	a	rapid	expansion	of	 numbers	 in	 the	 first	week	 following	 transfer	 followed	 by	 a	 contraction	 phase	which	 results	 in	 a	 long-lived	 population	 of	 cells	 that	 remain	 functional	 when	stimulated	with	MCMV	infection	60	days	after	transfer(Sun,	Beilke,	et	al.,	2011).			Interactions	 with	 MHC	 class	 I	 appear	 essential	 in	 educating	 NK	 cells	 to	 delete	autoreactive	 cells	 and	 acquire	 functionality.	 However,	 it	 is	 not	 required	 for	
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homeostatic	proliferation	 in	 a	 lymphopenic	 environment	 as	NK	cell	 transfer	 into	irradiated	 β2m-/-	 mice	 does	 not	 result	 in	 a	 significant	 increase	 in	 the	 rate	 of	proliferation(Jamieson	et	al.,	2004).	β2m	is	a	component	of	MHC	class	I	molecules	and	thus	β2m-/-	mice	are	deficient	in	MHC	class	I.			
1.2.9	Natural	killer	cells	have	an	immunoregulatory	role	NK	cells	were	first	described	as	cells	that	are	able	to	kill	 infected	or	transformed	target	cells	without	prior	stimulation.	However,	their	roles	in	immunity	go	beyond	their	cytotoxic	potential	and	they	also	have	an	 important	 immunoregulatory	role	and	can	modulate	the	adaptive	immune	response.			Dendritic	cells	(DCs)	are	important	mediators	of	the	immune	response	and	present	foreign	antigens	 in	MHC	molecules	on	 their	cell	 surface.	Mature	DCs	prime	naïve	CD8+	 T	 cells	 to	 expand	 and	 produce	 a	 pool	 of	 antigen-specific	 MHC	 class	 I-restricted	cytotoxic	T	lymphocytes.	Human	natural	killer	cells	are	activated	by	DCs	and	 are	 stimulated	 to	 expand	 in	 number,	 secrete	 IFN-γ	 and	 acquire	 cytotoxicity	(Caligiuri,	2008).	These	DC-activated	NK	cells	can	then	go	on	to	effectively	kill	DCs	–	particularly	targeting	immature	DCs	while	the	mature	DCs	appear	to	be	spared,	perhaps	through	greater	expression	of	MHC	class	I	on	the	cell	surface	(Della	Chiesa	
et	al.,	2003).	This	has	recently	been	confirmed	in	an	 in	vivo	model	where	tumour	cells	are	infused	into	mice	either	with	or	without	MHC	deficient	cells.	There	was	a	significant	decrease	 in	CD11c+	DCs	 in	 the	draining	 lymph	nodes	of	mice	 that	had	both	 tumour	 and	MHC	 deficient	 cells	 infused	 compared	 to	 those	 that	were	 only	
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stimulated	 with	 tumour	 cells.	 This	 was	 functionally	 relevant	 as	 these	 mice	 also	demonstrated	 greater	 proliferation	 in	 tumour-specific	 cytotoxic	 T-lymphocytes	(CTLs)	 and	 a	 significantly	 increased	 survival.	Depletion	of	NK	 cells	 or	 the	use	 of	perforin-knockout	mice	strongly	decreased	the	tumour	specific	CTL	expansion	and	had	deleterious	effects	on	survival(Morandi	et	al.,	2012).		This	process	is	termed	“immune	editing”	and	is	a	mechanism	by	which	NK	cells	can	modulate	the	adaptive	immune	response	by	influencing	peptide-presentation	and	subsequently	 produce	 a	 more	 immunogenic	 T	 cell	 repertoire.	 Interestingly,	 this	process	 appears	 to	 be	 dependent	 upon	 interactions	 between	 the	 activating	receptor	NKp30	as	in	vitro,	the	addition	of	anti-NKp30	mAb	markedly	reduced	the	degree	of	DC	lysis(Ferlazzo	et	al.,	2002).		In	 a	 murine	 model	 for	 type	 1	 diabetes	 mellitus,	 the	 adoptive	 transfer	 of	 a	population	of	IL-18	stimulated	NK	cells	resulted	delayed	diabetes	development	in	these	 susceptible	 mice.	 Furthermore,	 in	 vitro	 assays	 demonstrated	 that	 this	population	 of	NK	 cells	 could	 directly	 lyse	 insulin-specific	 CD8+	T	 cell,	 suggesting	that	 NK	 cells	 may	 negatively	 modulate	 the	 adaptive	 immune	 system	 through	 a	direct	cytotoxic	effect	against	CD8+	CTLs	(Ehlers	et	al.,	2012).		Additionally,	higher	numbers	of	IL-10	producing	NK	cells	are	found	in	the	decidua	of	 healthy	 pregnant	 women	 compared	 to	 women	 who	 have	 undergone	 a	spontaneous	miscarriage.	 This	 suggests	 that	 NK	 cell	 production	 of	 IL-10	 plays	 a	role	in	inducing	immunological	tolerance	to	the	fetus,	perhaps	by	downmodulating	
Chapter One: Introduction 
	 29	
the	T	cell	response	against	the	allograft	(Higuma-Myojo	et	al.,	2005).		The	presence	of	 NK	 cells	 producing	 IL-10	 has	 also	 been	 implicated	 as	 a	 possible	 reason	 why	many	patients	with	chronic	persistent	hepatitis	C	viral	infection	are	unable	to	clear	the	infection	(De	Maria	et	al.,	2007).				Therefore,	 in	 addition	 to	modulating	 direct	 effects	 in	 the	 immune	 response,	 NK	cells	 also	 modulate	 the	 adaptive	 immune	 response	 in	 a	 variety	 of	 mechanisms	ranging	 from	 a	 direct	 negative	 effect	 on	 T	 cells	 via	 immunoregulatory	 cytokine	release	or	cell	lysis,	or	a	more	indirect	process	by	altering	dendritic	cells	and	their	ability	to	present	peptide.		 	
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1.3	Allogeneic	stem	cell	transplantation	(Allo-SCT)	Allogeneic	 stem	 cell	 transplantation	 is	 a	 commonly	 used	 treatment	 for	 high-risk	leukaemias,	 lymphomas	and	bone	marrow	 failure	 syndromes.	The	 first	 regimens	trialled	 in	 the	 1970s	 involved	 conditioning	 with	 total	 body	 irradiation	 and	cyclophosphamide	 prior	 to	 allo-SCT(Thomas	 et	 al.,	 1977).	 This	 conditioning	regimen	 is	 given	 with	 the	 dual	 aims	 of	 reducing	 tumour	 burden	 (when	 the	transplant	 is	 given	 for	 a	 malignant	 condition)	 and	 to	 suppress	 the	 recipient’s	immune	 system,	 to	 allow	 stem	 cell	 engraftment.	 On	 its	 own,	 the	 conditioning	regimen	 is	 invariably	 fatal	 and	 haematopoietic	 stem	 cell	 transfer	 from	 an	 HLA-matched	 individual	 (donor)	 is	 required	 to	 repopulate	 the	haematopoietic	 system	(Donnall	Thomas	et	al.,	1957).		The	 allograft	 does	 not	 merely	 act	 as	 a	 means	 to	 reconstitute	 the	 patients	haemopoietic	 system	 and,	 in	 fact,	 further	 contributes	 anti-tumour	 activity	 in	addition	to	the	chemo-radiotherapy	given	as	conditioning.	This	beneficial	effect	is	largely	 T-cell	 mediated	 and	 is	 termed	 the	 graft-versus-leukaemia	 (GVL)	 effect.	Even	in	fully	HLA-matched	stem	cell	transplants,	unless	they	are	from	a	syngeneic	twin,	they	will	be	mismatched	for	minor	histocompatibility	antigens	and	these	will	result	 in	 donor-derived	 T	 cells	 that	 can	 recognize	minor	 antigens	 in	 the	 host.	 If	these	minor	antigens	are	expressed	on	residual	tumour	cells	then	the	resultant	cell	lysis	 is	 termed	GVL	 and	 is	 a	 beneficial	 effect.	However,	when	 these	 antigens	 are	expressed	 on	 the	 normal	 host	 cell,	 the	 T	 cells	 can	 cause	 significant	 damage	 in	 a	process	termed	graft-versus-host	disease	(GVHD).	This	is	described	in	more	detail	in	section	1.4.	
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1.3.1	Reduced	intensity	conditioning	The	 combinations	 of	 total	 body	 irradiation	 and	 cyclophosphamide	 (Cy-TBI)	(Thomas	et	al.,	 1977)or	busulphan	and	 cyclophosphamide	 (Bu-Cy)	 (Santos	et	al.,	1983)	were	commonly	given	to	younger	patients	with	 leukaemia	and	 lymphoma.	These	 regimens	 are	 defined	 as	 myeloablative	 (MA):	 “a	 combination	 of	 agents	expected	to	produce	profound	pancytopenia	and	myeloablation	within	1-3	weeks	from	administration;	pancytopenia	is	long	lasting,	usually	irreversible,	and	in	most	instances	 fatal,	 unless	 hematopoiesis	 is	 restored	 by	 hemopoietic	 stem	 cell	infusion”(Bacigalupo	et	al.,	2009).	While	effective,	these	regimens	were	associated	with	 significant	 toxicities	 and	 associated	 mortality.	 The	 transplant	 related	mortality	(TRM)	increased	with	age	such	that	50	years	used	to	be	considered	the	upper	age	limit	for	allo-SCT.			Reduced	 intensity	 conditioning	 (RIC)	 regimens	 were	 developed	 with	 the	 aim	 of	reducing	toxicity	and	enabled	transplantation	in	the	older	patient	population.	The	dose	 of	 alkylating	 agents	 or	 TBI	 is	 reduced	 by	 at	 least	 30%	 and	 these	 regimens	often	 combine	 fludarabine	 with	 reduced	 dose	 alkylating	 agent	 (e.g.melphalan,	busulphan	or	thiotepa),	or	fludarabine	with	reduced	dose	TBI.	In	common	with	MA	regimens,	 RIC	 conditioning	 causes	 a	 prolonged	 period	 of	 cytopenia	 and	 also	requires	 stem	 cell	 infusion	 to	 be	 practical	 in	 the	 clinical	 setting.	 Registry-based	studies	 have	 demonstrated	 that	 RIC	 regimens	 are	 associated	 with	 less	 TRM	compared	to	MA	regimens	although	there	is	a	concomitant	increase	in	relapse	risk	such	that	the	overall	survival	in	patients	receiving	the	two	transplant	types	is	not	significantly	different	(Aoudjhane	et	al.,	2005)(Martino	et	al.,	2006).		
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1.3.2	T	cell	depletion	in	allo-SCT	Graft	versus	host	disease	(GVHD)	is	an	important	cause	of	mortality	and	morbidity	following	 allo-SCT.	 Attempts	 to	 reduce	 the	 impact	 of	 this	 complication	 have	included	 the	 addition	 of	 either	 alemtuzumab	 (CAMPATHTM)	 or	 anti-thymocyte	globulin	(ATG)	into	the	transplant	conditioning	regimen.	This	acts	as	in	vivo	T	cell	depletion	 and	 is	 associated	 with	 a	 significant	 reduction	 in	 the	 risk	 of	 GVHD	 in	myeloablative	 conditioned	 allo-SCT	 without	 an	 associated	 increase	 in	 relapse	risk(Socie	et	al.,	2016)(Das-Gupta	et	al.,	2007)(Deeg	et	al.,	2006).			Although	RIC	 transplant	 regimens	have	enabled	allogeneic	stem	cell	engraftment	while	 limiting	 treatment	 related	 mortality,	 graft	 versus	 host	 disease	 (GVHD)	remains	a	significant	cause	of	mortality	and	morbidity.	The	use	of	alemtuzumab	or	ATG	 in	 RIC	 transplantation	 also	 results	 in	 a	 reduction	 in	 the	 incidence	 of	 GVHD	although	studies	suggest	there	may	be	an	accompanying	increase	in	risk	of	relapse	(Kottaridis	et	al.,	2000)(Baron	et	al.,	2014)(Soiffer	et	al.,	2011).			
1.3.3	Stem	cell	donor	source	The	 first	 stem	 cell	 transplants	 were	 performed	 using	 infusion	 of	 stem	 cells	obtained	 from	 bone	marrow,	 a	 procedure	which	 requires	 the	 donor	 to	 undergo	repeated	 bone	 marrow	 aspiration	 under	 general	 anaesthetic.	 An	 alternative	procedure	 to	 obtain	 stem	 cells	 is	 by	 apheresis	 of	 stem	 cells	 that	 have	 been	mobilized	from	extravascular	bone	marrow	sites	to	the	peripheral	blood	through	injections	of	granulocyte	colony	stimulating	factor	(G-CSF)(Korbling	and	Freireich,	2011).	 Although	 peripheral	 blood	 stem	 cells	 (PBSCs)	 were	 used	 for	 autologous	
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stem	 cell	 transplants	 in	 the	 early	 1980s	 for	 accelerated	 phase	 chronic	 myeloid	leukaemia	(Goldman	et	al.,	1981),	there	were	delays	in	adopting	this	technique	for	allo-SCT	 due	 to	 concerns	 that	 the	 greater	 number	 of	 donor	 T	 cells	 in	 the	 PB	allograft	would	induce	severe	GVHD.	In	fact,	large	registry	studies	have	found	that	rates	 of	 acute	 GVHD,	 leukaemia-free	 survival	 and	 overall	 survival	 were	 similar	after	peripheral	blood	stem	cell	transplants	(PBSCT)	and	bone	marrow	transplants	(BMT),	although	there	is	an	increased	risk	of	chronic	GVHD	after	PBSCT(Ringdén	
et	al.,	 2002)(Schmitz	et	al.,	 2006).	 Peripheral	 blood	 stem	 cells	 are	now	 the	main	source	of	stem	cells	for	allo-SCT.		Only	30%	of	patients	who	require	an	allo-SCT	will	have	a	human	leukocyte	antigen	(HLA)-matched	sibling	donor.	Although	several	 international	registries	exist	with	over	 20	 million	 adult	 volunteer	 donors,	 many	 patients	 will	 not	 have	 a	 suitably	matched,	unrelated	adult	donor	identified.	This	is	a	particular	issue	for	patients	of	diverse	 racial/ethnic	 backgrounds,	who	 are	 poorly	 represented	 in	 the	 registries.	Umbilical	 cord	blood	 is	an	alternative	source	of	haemopoietic	stem	cells	 for	allo-SCT	 and	 is	 used	 in	 paediatric	 and	 increasingly,	 adult	 allo-SCT(Ballen,	 Gluckman	and	Broxmeyer,	2014).	Retrospective	studies	have	found	similar	rates	of	survival	between	adult	patients	undergoing	transplantation	from	umbilical	cord	blood	and	matched	unrelated	donors	(Brunstein	et	al.,	2010)(Eapen	et	al.,	2010)(Wen	et	al.,	2011).	 However,	 umbilical	 cord-blood	 derived	 stem	 cells	 remain	 a	 lesser-used	source	 and	 are	 used	 in	 only	 2%	 of	 adult	 allogeneic	 transplants(Korbling	 and	Freireich,	2011).		
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1.4	Graft	versus	host	disease	Acute	graft	versus	host	disease	(GVHD)	is	caused	by	donor	allogeneic	T	cells	that	are	 transferred	 with	 the	 stem	 cells	 in	 the	 allograft,	 and	 attack	 target	 recipient	organs	 or	 tissues,	 most	 commonly	 skin,	 liver	 and	 gut.	 The	 development	 and	severity	 of	 acute	 GVHD	 is	 influenced	 by	 many	 factors	 including:	 recipient	 age,	conditioning	regimen,	stem	cell	source	and	GVHD	prophylaxis.			
1.4.1	Pathogenesis	of	acute	graft	versus	host	disease	The	 pathogenesis	 of	 acute	 GVHD	 is	 defined	 by	 specific	 phases	 and	 ends	 in	 a	positive	 feedback	 loop	 that	 perpetuates	 the	 immunological	 attack	 on	 recipient	tissues.	 	 The	 inherent	 toxicity	 associated	 with	 conditioning	 regimens	 leads	 to	tissue	 destruction,	 with	 activation	 and	 increased	 function	 of	 antigen-presenting	cells	 (APCs).	 The	 conditioning	 phase	 also	 leads	 to	 the	 release	 of	 pathogen-associated	molecular	patterns	(PAMPs),	 chemokines	and	gut	bacteria	which	 then	activate	 innate	 immune	 cells.	 These	 can	 participate	 in	 direct	 tissue	 damage	 and	contribute	to	the	cytokine	storm(Ball	and	Egeler,	2008).			Both	host	and	donor	APCs	may	have	a	role	in	the	initiation	of	acute	GVHD	although	it	 is	 likely	 that	 host	 APCs	 have	 the	 most	 important	 role.	 These	 APCs	 present	antigens	 to	 T	 cells	 and	 initiate	 a	 strong	 cytokine	 response	 that	 sets	 in	motion	 a	feedback	loop	comprising	further	antigen	presentation	and	recruitment	of	effector	T	cells	and	innate	immune	cells	that	augment	the	pro-inflammatory	cytoine	milieu.	Finally,	the	effector	T	cells,	NK	cells,	macrophages	and	pro-inflammatory	cytokines	(of	which	 tumour	 necrosis	 factor	 (TNF)	 plays	 a	major	 role),	 result	 in	 end	 organ	
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Extent	of	organ	involvement	
Stage	 Skin	 Liver	(bilirubin)	 Gut	 (stool	 output	
per	day)	
0	 No	GVHD	rash	 <2	mg/dL	 <500mL/day	 or	persistent	nausea	
1	 Maculopapular	rash	<25%	BSA	 2-3	mg/dL	 500-1000mL/day	
2	 Maculopapular	 rash	 25-50%	BSA	 3.1-6	mg/dL	 1000-1500mL/day	
3	 Maculopapular	rash	>50%	BSA	 6.1-15	mg/dL	 >1500mL/day	
4	 Generalised	 erythema	 plus	bullous	formation	 >15	mg/dL	 Severe	 abdominal	pain	 with	 or	without	ileus	
Grade	 Skin	 Liver	(bilirubin)	 Gut	 (stool	 output	
per	day	
I	 Stages	1-2	 None	 None	
II	 Stage	3	or	 Stage	1	or	 Stage	1	
III	 -	 Stage	2-3	or	 Stages	2-4	
IV	 Stage	4	or	 Stage	4	 -		
Table	1.1	Acute	GVHD	grading	scale.		
Abbreviations:	BSA	=	body	surface	area.	Adapted	from	Przepiorka	et	al.	1995.		The	 skin	 is	 usually	 the	 first	 organ	 to	 demonstrate	 acute	 GVHD	 and	 this	 is	manifested	 as	 a	 diffuse	maculopapular	 rash	with	 a	 tendency	 to	 affect	 the	 palms,	soles,	ears,	neck	and	dorsal	surfaces	of	the	extremities.	In	its	most	severe	form,	it	can	 progress	 to	 bullae	 formation.	 A	 score	 from	 0-4	 is	 assigned	 based	 upon	 the	percentage	of	body	surface	area	affected.		The	staging	of	liver	GVHD	is	based	upon	the	serum	bilirubin	level.	As	this	marker	can	 also	 be	 raised	 in	 other	 causes	 of	 liver	 dysfunction,	 such	 as	 veno-occlusive	disease	or	drug	 toxicity,	 a	 liver	biopsy	 is	 recommended	 to	histologically	 confirm	the	diagnosis	of	liver	GVHD.	It	is	rare	to	present	with	liver	involvement	in	isolation	and	is	usually	accompanied	by	skin	or	gastrointestinal	features.	
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GVHD	 can	 affect	 both	 the	 upper	 and	 lower	 gastrointestinal	 (GI)	 tract.	 Upper	 GI	GVHD	presents	as	persistent	nausea,	vomiting	and	anorexia,	whilst	lower	GI	GVHD	is	 characteristically	manifest	 as	a	 secretory	diarrhea	 that	 can	progress	 to	bloody	stools	with	abdominal	pain	and/or	ileus	in	its	most	severe	form.		
1.4.3	Treatment	of	acute	graft	versus	host	disease	Pharmacological	 treatments	 aimed	 at	 reducing	 the	 risk	 of	 GVHD	 are	 now	 a	standard	addition	to	the	transplant	regimen.	The	use	of	 the	calcineurin	 inhibitor,	ciclosporin	 is	now	ubiquitous,	whilst	methotrexate	or	mycophenolate	mofetil	are	included	in	certain	clinical	scenarios.		The	 onset	 of	 acute	 GVHD	 requires	 prompt	 clinical	 evaluation	 and,	 ideally,	histological	confirmation	of	the	diagnosis,	through	prompt	biopsy	of	the	suspected	organs	 involved.	 First-line	 therapy	 involves	 glucocorticoid	 therapy	 although	 the	route	and	dose	can	vary.	For	mild	(grade	I)	skin	GVHD,	topical	glucocorticoids	are	often	sufficient	and	this	route	of	administration	also	reduces	the	incidence	of	side	effects.	Grades	II-IV	GVHD	require	systemic	glucocorticoid	use	with	prednisolone-equivalent	treatment	doses	ranging	from	1-2.5mg/kg/day.		Many	agents	have	been	used	as	a	secondary	therapy	for	GVHD	that	has	failed	first	line	 therapy	 with	 glucocorticoids,	 including	 mycophenolate	 mofetil,	 denileukin	(Ontak),	 sirolimus	 (Rapamune),	 infliximab	 (Remicade),	 etanercept	 (Enbrel),	pentostatin	(Nipent),	anti-thymocyte	globulin	(ATG)	and	alemtuzumab	(Campath).	Although,	they	have	all	demonstrated	some	efficacy,	there	is	no	consensus	amongst	
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The	 resulting	 cytokine	 cascade	 stimulates	 fibroblast	 proliferation	 and	 activation.	The	 concomitant	 B	 cell	 dysregulation	 and	 production	 of	 autoreactive	 antibodies	contributes	 to	 an	 autoimmune-like	 systemic	 syndrome	 that	 is	 characterized	 by	fibroproliferative	 changes.	Although	 chronic	GVHD	predominantly	 affect	 the	 oral	and	ocular	mucosa	and	the	skin,	lungs,	kidneys,	liver	and	heart,	these	changes	can	manifest	in	any	organ	of	the	body(Blazar,	Murphy	and	Abedi,	2012).			
1.4.5	Graft	versus	leukaemia	effect	The	increasing	use	of	reduced	intensity	conditioning	in	transplant	regimens	results	in	a	greater	reliance	on	immune	mediated	graft	versus	leukaemia	effects	to	control	the	 underlying	 malignancy.	 T	 cell	 depletion	 from	 the	 stem	 cell	 graft	 eliminates	GVHD	but	comes	at	a	price	of	increased	risk	of	disease	relapse,	strongly	implicating	T	cells	as	an	important	effector	cell	in	mediating	the	graft	versus	leukaemia	(GVL)	effect.	There	is	increasing	recognition	that	NK	cells	can	directly	target	tumour	cells	through	recognition	of	MHC	class	I	molecules	and	so	contribute	to	GVL	(Ruggeri	et	
al.,	2002).		
1.5	The	role	of	NK	cells	in	optimizing	outcome	in	allo-SCT	
1.5.1	Immune	reconstitution	following	allogeneic	stem	cell	transplantation	Successful	 reconstitution	 of	 the	 cellular	 immune	 system	 is	 a	 major	 factor	 in	determining	 the	 outcome	 following	 allo-SCT.	 Within	 a	 few	 weeks	 or	 months	 of	stem	 cell	 transplantation,	 normal	 haematopoiesis	 should	 return	 and	 patients	 no	longer	require	regular	red	cell	and	platelet	transfusion.	However,	it	takes	years	for	
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complete	 regeneration	 of	 the	 T	 and	 B	 cell	 compartments,	 especially	 in	 adult	patients	where	 the	 thymus	 is	 involuted	 and	 therefore	has	 reduced	 function.	 The	thymus	is	also	damaged	by	total	body	irradiation,	which	is	a	common	component	of	pre-transplant	conditioning.	GVHD	and	immunosuppressive	medications	used	in	its	 treatment	or	prevention	can	also	delay	 immune	reconstitution.	 (Li	and	Sykes,	2012)	 As	 a	 result,	 despite	 antimicrobial	 prophylaxis,	 patients	 are	 extremely	susceptible	to	opportunistic	 infections	during	this	time	period	and	normally	mild	infections	can	prove	fatal.			In	 a	 healthy	 individual,	 T	 cells	will	 comprise	 60-70%	of	 circulating	 lymphocytes	whilst	NK	cells	make	up	5-30%(Bisset	et	al.,	2004).	 In	the	post	 transplant	period	this	ratio	 is	skewed	and	NK	cells	make	up	a	 larger	proportion	of	 the	 lymphocyte	pool.	This	 trend	 is	seen	across	many	types	of	 transplants	 including	T-cell	 replete	HLA	matched	(Bühlmann	et	al.,	2011),	T-cell	deplete	HLA-identical	(B	N	Savani	et	
al.,	2007)	and	T-cell	deplete	haploidentical	transplants	(Nguyen	et	al.,	2005).			In	 the	 first	 months	 following	 transplantation,	 NK	 cells	 display	 an	 immature	phenotype	of	CD3-CD56bright	and	express	NKG2A	but	with	 low	expression	of	KIRs	although	 the	phenotype	matures	over	 the	year	 following	 transplant	with	gradual	acquisition	of	KIRs	and	reduction	in	NKG2A.	This	immature	phenotype	correlates	with	 reduced	 cytoxicity	 against	 K562	 cell	 line	 and	 leukaemia	 blasts	 when	compared	to	donor	NK	cells	suggesting	that	they	are	hypofunctional	with	reduced	GVL	capability(Nguyen	et	al.,	2005).	However,	other	studies	have	found	that	those	patients	who	have	higher	numbers	of	NK	cells	at	day	30	following	transplantation	
Chapter One: Introduction 
	 41	
have	a	considerably	 improved	outcome	with	reduced	relapse	risk,	 reduced	acute	GVHD,	 non-relapse	 mortality	 and	 improved	 overall	 survival.(B	 N	 Savani	 et	 al.,	2007),(Dunbar	 et	 al.,	 2008)	 	 These	 results	 suggest	 that	 despite	 their	 reduced	cytotoxicity	in	vitro,	early	reconstituting	NK	cells	in	vivo	are	able	to	exert	positive	effect	on	patient	outcome.		Most	 of	 our	 patient	 cohort	 received	 stem	 cell	 transplants	 with	 T	 cell	 depletion,	with	 alemtuzumab	 being	 the	 most	 commonly	 used	 method.	 Alemtuzumab	 is	 a	monoclonal	antibody	 that	 targets	 the	CD52	antigen.	Memory	B	cells	and	myeloid	dendritic	 cells	 (mDCs)	 display	 the	 highest	 numbers	 of	 CD52	 antigen	 on	 the	 cell	surface	 whilst	 NK	 cells,	 plasmacytoid	 dendritic	 cells	 and	 basophils	 express	 the	lowest	 number	 of	 CD52	molecules	 per	 cell	 (Rao	 et	al.,	 2012).	 Thus,	NK	 cells	 are	relatively	spared	from	alemtuzumab	mediated	cytolysis	compared	to	the	adaptive	immune	 cells.	 In	 addition,	 CD52	 expression	 is	 not	 statistically	 different	 between	CD16-	(predominantly	CD56bright)	and	CD16+	(mostly	CD56dim)	NK	cells	(Rao	et	al.,	2012).	 However,	 patients	 who	 received	 alemtuzumab	 as	 treatment	 for	 multiple	sclerosis	 observed	 significant	 expansion	 of	 the	 CD56bright	 NK	 cell	 susbset	 at	 six	months.	 This	 suggests	 that	 alemtuzumab	may	 be	 responsible	 for	 changes	 in	 the	innate	 immune	 compartment	 (Gross	 et	al.,	 2016)	 in	ways	 that	 cannot	 simply	 be	explained	by	the	cell	surface	expression	of	CD52.			
1.5.2	Optimising	NK	cell	alloreactivity	in	allo-SCT	A	 study	 in	 3625	 Japanese	 people	 found	 that	 individuals	 with	 greater	 NK	 cell	cytotoxicity	experienced	reduced	cancer	incidence	over	an	11	year	follow	up,	thus	
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demonstrating	 the	 role	 of	NK	 cells	 in	 the	natural	 immunological	 defence	 against	cancer	 (Imai	et	al.,	2000).	During	an	allo-SCT,	mature	NK	cells	will	be	adoptively	transfused	into	the	patient	alongside	donor	stem	cells.	As	the	genes	encoding	MHC	and	 KIR	 genes	 are	 segregated	 on	 independent	 chromosomes,	 there	 is	 a	 75%	chance	that	patient	and	donor	will	express	different	KIR	genes	in	an	HLA-identical	sibling	transplant,	and	a	near	100%	chance	of	mismatch	in	an	unrelated	transplant.	The	 presence	 of	 inhibitory	 KIRs	 on	 donor	 NK	 cells,	 in	 the	 absence	 of	 their	 HLA	class	 I	 ligand	 on	 recipient	 target	 cells	 will	 cause	 NK	 cells	 to	 respond	 to	 this	“missing-self”	 and	 mediate	 cytotoxicity.	 There	 is	 evidence	 that	 this	 NK	 cell	alloreactivity	can	influence	outcomes	following	allo-SCT.		The	 Perugia	 group	 in	 Italy	 has	 described	 impressive	 results	 demonstrating	 the	effects	 of	 NK	 cell	 alloreactivity	 in	 haploidentical	 stem	 cell	 transplantation.	Haploidentical	 transplants	 involve	a	donor,	 typically	a	sibling	or	parent,	who	has	only	 one	 HLA	 haplotype	 in	 common	 with	 the	 patient.	 These	 transplants	 are	extensively	 T-cell	 depleted	 to	 reduce	 the	 risk	 of	 fatal	 GVHD	 in	 the	 patient.	 They	defined	KIR	mismatch	as	the	situation	in	which	the	donor	has	a	KIR	ligand	that	is	absent	in	the	recipient.	They	studied	patients	who	received	an	HLA-haploidentical	transplant	 for	 acute	myeloid	 leukaemia	 (AML).	 20	 patients	 received	 transplants	from	KIR	ligand	incompatible	donor	and	their	probability	of	relapse	at	5	years	was	0%	 compared	 with	 a	 75%	 relapse	 rate	 in	 the	 37	 patients	 with	 a	 KIR	 ligand	compatible	donor(Ruggeri	et	al.,	2002).	These	results	were	later	corroborated	in	a	larger	cohort	of	patients(Ruggeri	et	al.,	2007).		
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Whilst	the	beneficial	effect	of	KIR	mismatch	is	tangible	in	haploidentical	allo-SCT,	the	 results	 in	 unrelated	 donor	HLA-matched	 allo-SCT	 are	 less	 clear.	 Studies	 into	the	 effect	 of	 KIR	 ligand	 incompatibility	 in	mismatched	 unrelated	 donor	 allo-SCT	have	either	demonstrated	either	no	beneficial	effect(Davies	et	al.,	2002)(Farag	et	
al.,	 2006)	 or	 even	 a	 deleterious	 effect	 through	 increased	 infection	 related	mortality(Schaffer	et	al.,	2004).			Haploidentical	transplants	differ	from	many	unrelated	donor	allo-SCT	as	they	are	extensively	 T	 cell	 depleted,	 are	 performed	 with	 high	 stem	 cell	 doses	 and	 with	minimal	post	transplant	immunosuppression,	which	results	in	fast	NK	cell	but	slow	T	 cell	 reconstitution(Nguyen	 et	 al.,	 2008).	 The	 differences	 in	 the	 immunological	environment	during	 the	 reconstitution	period	may	account	 for	 the	discrepancies	observed	in	the	studies	of	NK	cell	alloreactivity.			KIR	haplotypes	have	been	divided	into	group	A	and	group	B	haplotypes,	in	which	group	A	haplotypes	possess	predominantly	inhibitory	KIRs	and	a	single	activatory	KIR2DS4.	Group	B	haplotypes	are	distinguished	by	a	 larger	number	of	activatory	KIR	receptors.	Some	groups	have	noted	that	 improved	outcome	can	be	predicted	by	the	presence	of	donor	KIR	group	B	haplotypes	and	therefore	proposed	that	NK	cell	alloreactivity	is	determined	by	the	number	of	activating	KIR	receptors	on	the	donor	NK	 cells.	 This	was	 initially	 determined	 in	 a	 study	 of	 448	 unrelated	 donor	transplants	 for	 acute	 myeloid	 leukaemia	 (AML)(Cooley	 et	 al.,	 2009)	 and	 was	confirmed	on	an	extended	cohort	of	1086	AML	patients.	This	study	identified	that	the	 centromeric	 motifs	 of	 the	 B	 haplotype	 (Cen-B)	 conferred	 the	 most	 benefit	
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(Cooley	 et	 al.,	 2010).	 Transplants	 from	 Cen-B	 homozygous	 donors	 had	 a	 15%	incidence	of	relapse	compared	to	37%	seen	in	transplants	from	Cen-A	homozygous	donors.	 A	 further	 study	 from	 the	 Center	 for	 International	 Blood	 and	 Marrow	Transplant	Research	(CIBMTR)	found	that	patients	with	the	best	survival	after	SCT	are	those	that	have	donors	homozygous	for	KIR3DS1(Venstrom	et	al.,	2010).	This	is	an	activating	KIR	receptor	that	is	hallmark	gene	in	the	telomeric	region	of	the	B	haplotype.			Due	to	linkage	disequilibrium,	activating	and	inhibitory	KIRs	are	not	inherited	in	a	random	 fashion.	For	example,	 the	absence	of	KIR3DS1	 in	 telomeric	motifs	of	 the	KIR	A	haplotype	(Tel-A)	is	equivalent	to	the	presence	of	KIR3DL1.	Thus,	it	must	be	remembered	that	the	beneficial	effect	of	Group	B	haplotypes	may	be	due	to	over-inhibition	of	NK	cell	alloreactivity	in	KIR	A-haplotype	donors	rather	than	improved	NK	cell	function	in	KIR	B-haplotype	donors.	
	Venstrom	et	al	published	a	study	 investigating	1277	patients	with	AML	who	had	received	 haemopoietic	 stem	 cell	 transplants	 from	 unrelated	 donors.	 These	were	either	 fully	matched	 (at	HLA-A,	B,	C,	DR	and	DQ)	or	had	a	 single	HLA-mismatch.	The	 investigators	 looked	 at	 the	 importance	 of	 donor	 KIR	 genotype	 and	donor/recipient	HLA	genotypes	on	outcome.	In	agreement	with	the	KIR	haplotype	model,	they	found	that	patients	who	received	allografts	from	KIR2DS1	donors	had	a	lower	rate	of	relapse	but	this	positive	effect	was	only	seen	if	the	donors	were	also	homozygous	or	heterozygous	for	HLA-C1	antigens.	In	vitro	studies	confirmed	that	the	interaction	of	KIR2DS1	with	high	levels	of	HLA-C2	reduces	NK	reactivity.	This	
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suggests	it	is	not	sufficient	to	simply	select	donors	with	high	numbers	of	activating	KIRs.	 The	 tolerising	 effect	 of	 interactions	 with	 donor	 HLA-C	 are	 important	 in	modifying	the	NK	reactivity	and	must	also	be	taken	into	account	to	obtain	maximal	NK	alloreactivity(Venstrom	et	al.,	2012).	
	Although	 KIR	 genotyping	 is	 not	 currently	 routinely	 incorporated	 into	 the	algorithm	for	donor	selection	in	allo-SCT,	NK	alloreactivity	is	clearly	important	in	determining	 patient	 outcome	 following	 stem	 cell	 transplantation	 and	 its	 role	 is	gaining	recognition.		
	
1.6	Conclusion	There	have	been	rapid	advances	in	our	understanding	of	natural	killer	cell	biology	since	 their	 mechanism	 of	 action	 was	 first	 described	 in	 the	 1980s.	 Rather	 than	simply	being	an	innate	immune	cell,	primed	to	rapidly	kill	infected	or	transformed	cells,	 they	 also	 possess	 immunoregulatory	 properties	 and	 mechanisms	 for	immunological	memory.	Allogeneic	 stem	 cell	 transplantation	 is	 a	 crucial	 therapy	for	patients	with	haematological	malignancy	and	the	role	of	NK	cells	in	mediating	both	beneficial	and	deleterious	effects	on	patient	outcome	is	a	focus	of	stimulating	investigation.			Allo-SCTs	 performed	 in	 our	 centre	 at	 the	 Queen	 Elizabeth	 Hospital	 Birmingham	are	 predominantly	 T	 cell	 depleted.	 Investigating	 reconstitution	 in	 this	 group	 of	patients	allows	us	the	opportunity	to	study	NK	cell	recovery	in	a	clinical	scenario	
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where	T	cells	do	not	outnumber	NK	cells.	We	believe	that	this	will	allow	the	clinical	effects	of	NK	cell	reconstitution	to	be	more	easily	appreciated.				 	
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1.7	Study	aims	1. To	study	the	temporal	relationship	of	NK	and	T	cell	reconstitution	following	T	cell	depleted,	T	cell	replete	and	umbilical	cord	stem	cell	transplantation.	2. To	 appraise	 the	 influence	 of	 NK	 cell	 reconstitution	 on	 patient	 outcomes	following	allo-SCT.	3. To	 study	 the	 immunophenotypic	 and	 functional	 profile	 of	 NK	 cells	 that	reconstitute	following	allo-SCT	4. To	investigate	the	transcriptional	profile	of	NK	cells	that	reconstitute	following	allo-SCT.	
1.8	Hypothesis	NK	 cell	 reconstitution	 following	 allo-SCT	 may	 influence	 patient	 outcome,	 either	through	their	direct	effect	or	due	to	modulation	of	the	adaptive	immune	response.				 	
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CHAPTER	2:	MATERIALS	AND	METHODS	
	
2.1	General	methods	
2.1.1	Media	and	solutions		Wash	media	 	 RPMI	1640	(Gibco	BRL)		 	 	 100U/ml	Penicillin	(Gibco	BRL)		 	 	 100µg/ml	Streptomycin	(Gibco	BRL)	
	General	media	 RPMI	1640	(Gibco	BRL)		 	 	 100U/ml	Penicillin	(Gibco	BRL)		 	 	 100µg/ml	Streptomycin	(Gibco	BRL)		 	 	 2mM	Glutamine	(Gibco	BRL)		 	 	 10%	Fetal	Calf	Serum	(SBS	Biologicals)		MLR	Media	 	 RPMI	1640	(Gibco	BRL)		 	 	 100U/ml	Penicillin	(Gibco	BRL)		 	 	 100µg/ml	Streptomycin	(Gibco	BRL)		 	 	 2mM	Glutamine	(Gibco	BRL)		 	 	 10%	Human	Serum	(SBS	Biologicals)			
Chapter Two: Materials and Methods 
	 47	
Freezing	media	 Fetal	Calf	Serum	(SBS	Biologicals)		 	 	 10%	DMSO	(Sigma)		MACS	Buffer	 	 1	x	PBS	(University	of	Birmingham)		 	 	 0.5%	Bovine	serum	albumin	(Sigma)		 	 	 2mM	EDTA	(Sigma)		 	 	 Sterile	filtered		
2.1.2	Ethical	approval	Clinical	 data	 and	 samples	 were	 obtained	 after	 written	 informed	 consent	 in	accordance	with	the	Declaration	of	Helsinki	as	approved	by	the	South	Birmingham	Research	 Ethics	 Committee	 (Q5/Q2707/175).	 	 All	 samples	 were	 stored	 in	compliance	with	the	requirements	of	the	Human	Tissue	Act	(2004).			
2.1.3	Subjects	and	phlebotomy	Patients	within	the	study	had	undergone	allogeneic	stem	cell	transplantation	as	a	treatment	 for	 a	 haematological	 disease	 at	 the	 Queen	 Elizabeth	 Hospital	Birmingham	between	March	2012	and	October	2013.		Blood	samples	were	taken	1	week	pre-transplantation	and	then	at	7	days	(range	5-8	days),	14	days	(range	12-15),	28	days	(range	3-5	weeks)	and	100	days	(range	3-4	months)	post	transplant.	PBMCs	were	isolated	by	density	gradient	centrifugation	within	24	hours.			
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2.1.4	PBMC	extraction	Peripheral	 blood	 mononuclear	 cells	 (PBMCs)	 were	 obtained	 from	 heparinized	blood	 using	 density	 gradient	 centrifugation	 under	 sterile	 conditions.	 Samples	obtained	from	patients	overnight	or	at	weekends	were	kept	at	room	temperature	and	separated	within	24	hours.	Whole	blood	was	diluted	1:1	 in	wash	media	and	layered	 carefully	onto	 lymphoprep	 (Alere).	This	was	 centrifuged	at	2000rpm	 for	30	minutes	with	the	brake	off.	The	buffy	layer	was	then	removed	using	a	transfer	pipette	 and	 cells	 resuspended	 in	 wash	 media	 up	 to	 50ml	 and	 centrifuged	 for	1800rpm	 for	10	minutes,	with	 the	brake	applied.	Cells	were	washed	one	 further	time	 in	wash	media	 and	 centrifuged	 at	 1500rpm	 for	 10	minutes,	with	 the	brake	applied.	For	the	final	wash,	cells	were	resuspended	in	general	media	and	spun	at	1200rpm	 for	 10	 minutes,	 with	 brake	 applied.	 Cells	 were	 counted	 with	 a	haemocytometer	and	either	used	immediately	in	cellular	assays	or	cryopreserved.			
2.1.5	Preparation	of	cells	from	waste	stem	cell	bags	Waste	stem	cell	bags	were	collected	and	processed	within	24	hours	of	clinical	use.	15ml	of	MACS	buffer	was	used	to	rinse	the	stem	cell	bag	and	resuspend	the	stem	cells	product.	The	resuspended	stem	cell	product	was	washed	in	wash	media	and	centrifuged	at	1800rpm	for	10	minutes	with	the	brake	applied.	A	further	wash	in	wash	 media	 and	 general	 media	 was	 carried	 out	 as	 described	 above.	 Cells	 were	counted	with	a	haemocytometer	and	cryopreserved.			
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2.1.6	Freezing	cells	for	long	term	storage	Cells	were	resuspended	in	general	media	and	pelleted	by	centrifuging	at	1500rpm	for	 5	 minutes.	 The	 supernatant	 was	 carefully	 removed	 and	 the	 cell	 pellet	resuspended	 in	 the	 residual	 media	 before	 being	 cooled	 on	 ice	 for	 10	 minutes.	Freezing	 media	 was	 added	 to	 the	 cells	 in	 a	 dropwise	 manner,	 with	 continual	agitation	 to	 ensure	 even	 resuspension,	 to	 a	 final	 volume	 of	 1mL	 per	 vial	 to	 be	stored.	 The	 cellular	 suspension	 was	 transferred	 to	 pre-cooled	 cryovials	 (Nunc,	Thermo	 Scientific)	 and	 placed	 in	 a	 “Mr	 Frosty”	 (Freezing	 container,	 Nalgene,	C1562-1EA,	Sigma)	in	a	-80°C	freezer	to	control	cooling	to	1°C	per	minute.	After	12	hours,	cells	were	transferred	to	liquid	nitrogen	for	long	term	storage.		
2.1.7	Recovery	of	cells	from	long	term	storage	Cells	 were	 defrosted	 in	 a	 waterbath	 at	 37°C	 for	 no	 longer	 than	 2	 minutes.	 The	thawed	 cell	 suspension	was	 added	 in	 a	 dropwise	manner	 to	 general	media	 and	centrifuged	at	1500rpm	for	10	minutes.	They	were	then	washed	again	in	general	media	prior	to	counting	with	a	haemocytometer.			
2.1.8	Immunophenotyping	
Cell	surface	staining	for	immunophenotyping	For	all	flow	cytometry	experiments	the	following	protocol	was	used.	PBMCs	were	resuspended	 in	100µl	MACS	buffer	at	a	 final	concentration	of	0.5-1x107	cells/ml.	Mononuclear	cells	were	 incubated	with	surface	antibodies	on	 ice	 for	20	minutes,	whilst	 protected	 from	 light,	 and	 compared	 to	 unstained	 controls.	 Cells	 were	
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washed	 once	 in	 MACS	 buffer	 and	 resuspended	 in	 an	 appropriate	 volume	 for	cytometric	analysis.	Propidium	iodide	was	added	just	before	acquisition	to	exclude	dead	cells.		
Flow	cytometry	Flow	cytometric	analysis	was	carried	out	using	a	BD	LSR-II	flow	cytometer	with	BD	FACSDiva	acquisition	software	(Version	6.1.3;	BD	Biosciences).	Additional	analysis	was	carried	out	offline	using	FACSDiva	software.	To	account	for	spectral	overlap	of	fluorochromes	 that	 occurs	 in	 multi-colour	 flow	 cytometry,	 care	 was	 taken	 to	ensure	adequate	compensation.	To	achieve	this,	anti-mouse	IgG-CompBeads	(BD)	were	stained	with	each	fluorochrome	conjugated	antibody	and	run	separately.	The	auto-compensation	function	was	used	to	compensate	spectral	overlap	and	this	was	also	checked	offline	to	ensure	accuracy.			
2.1.9	NK	cell	isolation	for	cellular	experiments	For	 cellular	 experiments,	 NK	 cells	 were	 enriched	 from	 freshly	 isolated	 PBMCs	using	 the	 EasySepTM	 Human	 NK	 Cell	 Enrichment	 Kit	 (Stemcell	 Technologies).	Briefly,	a	suspension	of	PBMCs	was	prepared	at	a	concentration	of	5	x	107	cells/mL	in	MACS	Buffer	and	placed	in	a	5mL	polystyrene	tube.	The	EasySepTM	Human	NK	Cell	Enrichment	Cocktail	was	added	at	50	µL/mL	cells,	mixed	well	and	incubated	at	room	temperature	for	10	minutes.	Prior	to	use,	 the	EasySepTM	Magnetic	Particles	were	vortexed	for	30	seconds	to	ensure	that	there	were	no	visible	aggregates	and	that	 the	particles	were	 in	uniform	suspension.	The	EasySepTM	Magnetic	Particles	
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were	added	at	100µL/mL	cells	and	incubated	at	room	temperature	for	5	minutes.	MACS	buffer	was	added	to	bring	the	total	volume	of	cell	suspension	to	2.5mL	and	the	mixture	mixed	gently	by	pipetting	up	and	down	2-3	times.	The	tube	containing	the	 cell	 suspension	was	placed	 in	 the	Purple	EasySepTM	magnet	 (Catalog	18000)	for	2.5	minutes	without	cap.	 In	one	continuous	motion	 the	magnet	and	tube	was	inverted	and	the	desired	fraction	of	NK	enriched	cells	was	poured	into	a	new	5mL	polystyrene	tube.			
2.2	Assessing	lymphocyte	and	NK	cell	subset	reconstitution	
2.2.1	Samples	and	immunophenotyping	To	 assess	 the	 reconstitution	 of	 lymphocytes	 and	 NK	 cell	 subsets	 following	allogeneic	 stem	 cell	 transplantation,	 samples	 were	 obtained	 from	 108	 patients	undergoing	allo-SCT	at	various	time	points	both	before	and	after	transplantation.	PBMCs	from	samples	taken	at	Day	7	and	Day	14	were	prepared	and	stained	within	24	hours	of	sample	collection.	For	peripheral	blood	samples	taken	at	Day	-7,	Day	28	 and	 Day	 100,	 PBMCs	 were	 isolated	 by	 density	 gradient	 centrifugation	 and	frozen	within	24	hours	of	sample	collection.		Lymphocytes	and	lymphocyte	subsets	were	identified	by	cell	surface	staining	of	either	fresh	or	thawed	frozen	PBMCs	and	flow	cytometric	analysis	as	described	in	Section	2.1.8.	Table	2.1	lists	the	antibodies	used	in	the	panel.					
Chapter Two: Materials and Methods 
	 52	
	 Target	antigen	 Conjugate	 Clone	 Source	CD3	 Qdot655	 S4.1	 Invitrogen	CD56	 APCCy7	 HCD56	 Biolegend	CD16	 V500	 3G8	 BD	Biosciences	CD57	 Pacific	Blue	 HCD57	 Biolegend	CD158a	 PC5.5	 EB6	 Beckman	Coulter	CD158b	 PC7	 GL183	 Beckman	Coulter	CD158e	 AF700	 DX9	 Biolegend	NKG2A	 APC	 Z199	 Beckman	Coulter	NKG2C	 PE	 134591	 R	&	D	
Table	2.1	Panel	One	-	Antibodies	for	surface	markers	used	to	identify	lymphocytes	and	
NK	cell	subsets			Firstly,	 single	 cells	 were	 identified	 using	 the	 FSC-H	 vs.	 FSC-A	 plot	 and	 then	 the	lymphocyte	population	was	 identified	by	 their	FSC-A	and	SSC-A	properties.	Dead	cells	that	stained	propidium	iodide	(PI)	were	gated	out.	Live	T	cells	were	identified	as	 PI-CD3+	 cells.	 Live	 NK	 cells	 were	 identified	 as	 PI-	 CD3-	 CD56+.	 NK	 cells	 were	further	 divided	 into	 subsets	 according	 to	 differential	 expression	 of	 CD56,	 CD16,	KIR,	CD57,	NKG2A	and	NKG2C.	This	gating	strategy	is	depicted	in	Figure	2.1.		 	
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2.3	Predictors	of	outcome	and	survival	analysis	in	stem	cell	transplantation	
2.3.1	Receiver	operating	characteristic	(ROC)	curves	Receiver	 operating	 characteristic	 (ROC)	 curves	 were	 plotted	 to	 assess	 the	prognostic	relationship	between	NK	cell	reconstitution	and	acute	GVHD.	The	area	under	 the	curve	(AUC)	and	95%	confidence	 intervals	 for	 the	NK	cell	 subsets	and	time	points	were	compared	and	the	day	14	NK	cell	population	(D14-NK)	identified	for	further	investigation	based	on	the	higher	cell	numbers	available	at	day	14	for	further	studies.			
2.3.2	Kaplan-Meier	method	To	 assess	 D14-NK	 cell	 count	 as	 a	 predictor	 for	 the	 time-to-event	 outcomes,	 a	landmark	approach	with	 the	 time	 from	day	14	 to	 the	event	of	 interest	was	used.	When	 investigating	 the	 effect	 of	 D14-NK	 cell	 reconstitution	 and	 other	 clinical	variables	on	overall	survival,	survival	curves	were	plotted	using	the	Kaplan-Meier	method	 and	 statistical	 effects	 assessed	 with	 the	 log-rank	 method.	 The	 Cox	proportional	hazards	model	was	used	for	multivariate	analyses.			
2.3.3	Cumulative	incidence	Cumulative	 incidence	 was	 used	 to	 estimate	 the	 probability	 of	 acute	 GVHD	 and	chronic	 GVHD	 with	 death	 from	 any	 cause	 defined	 as	 the	 competing	 risk.	 The	multivariate	 adjustment	 for	 factors	 predicting	 the	 cumulative	 incidence	 of	 acute	GVHD	was	performed	within	the	framework	of	competing	risks	using	the	Fine	and	Gray	method.	A	competing	risk	approach	was	also	taken	in	assessing	the	effect	on	
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TRM	(using	RM	as	the	competing	event)	and	RR/	RM	(using	TRM	as	the	competing	event).			All	statistical	 tests	were	two-sided	and	the	 level	of	statistical	significance	utilized	was	 0.05.	 Statistical	 analysis	 was	 carried	 out	 using	 R	 (version	 3.2.1	 GUI	 1.66	Mavericks	 build	 (6956)),	 SPSS	 (IBM	 version	 22)	 and	 Prism	 (GraphPad	 version	6.0b).	 For	 competing	 risk	 analysis,	 I	 used	 the	 cmprsk	 package	 and	 ccr-addson	function	written	for	R	(http://www.stat.unipg.it/luca/R).		
2.4	Assessing	the	functional	profile	of	NK	cells	
2.4.1	Chemokine	receptor	expression	PBMCs	 from	D14	samples	were	prepared	and	stained	within	24	hours	of	 sample	collection.	 Lymphocytes	 and	 lymphocyte	 subsets	 were	 identified	 by	 cell	 surface	staining	 of	 thawed	 frozen	 PBMCs	 and	 flow	 cytometric	 analysis	 as	 described	 in	Section	2.1.8.	Table	2.2	and	2.3	lists	the	antibodies	and	panels	used.											
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Target	antigen	 Conjugate	 Clone	 Source	CD3	 Qdot655	 S4.1	 Invitrogen	CD56	 APCCy7	 HCD56	 Biolegend	CD16	 V500	 3G8	 BD	Biosciences	CXCR3	 PerCPCy5.5	 1C6	 BD	Biosciences	CCR7	 APC	 150503	 R	&	D	Systems	CCR5	 PeCy7	 2D7	 BD	Biosciences	ChemR23	 FITC	 BZ332	 Bio-Rad	antibodies	(formerly	ABD	serotec)	CXCR4	 AF700	 12G5	 R	&	D	Systems	CCR6	 PE	 G034E3	 Biolegend	PI	 Texas	Red	 	 	
Table	2.2	Panel	Two	-	Antibodies	used	to	identify	chemokine	receptor	expression		
Target	antigen	 Conjugate	 Clone	 Source	CD3	 Qdot655	 S4.1	 Invitrogen	CD56	 APCCy7	 HCD56	 Biolegend	CD16	 V500	 3G8	 BD	Biosciences	CCR9	 APC	 112509	 R	&	D	Systems	CX3CR1	 PerCPCy5.5	 2A9-1	 Biolegend	PI		 Texas	Red	 	 	
Table	2.3	Panel	Three	–	Antibodies	used	to	identify	chemokine	receptor	expression			 	
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2.4.2	Chimerism	analysis	NK	cells	were	enriched	 from	freshly	 isolated	PBMCs	using	 the	EasySepTM	Human	NK	Cell	Enrichment	Kit	 (Stemcell	Technologies).	Purified	NK	cells	were	analysed	by	 micro-satellite	 analysis	 at	 the	 West	 Midlands	 Regional	 Genetics	 Laboratory,	Birmingham	Women’s	NHS	Foundation	Trust,	Birmingham	UK.	DNA	was	extracted	from	 NK	 cells	 using	 the	 Qiagen	 EZ1	 tissue	 kit	 according	 to	 the	 manufacturer’s	instructions	 on	 a	 Qiagen	 BioRobot	 EZ1	 or	 EZ1	 advanced.	 A	 panel	 of	 16	polymorphic	 microsatellite	 markers	 (D4S2366,	 D2S1338,	 D13S742,	 Penta	 D,	D10S2325,	 D12S391,	 D18S51,	 D13S634,	 D18S535,	 D6S957,	 D21S11,	 D18S386,	D13S305,	D21S1437,	FGA	and	Penta	E)	were	PCR	amplified	 from	donor	samples	and	pre	and	post	 transplant	recipient	samples.	PCR	amplification	was	performed	using	 fluorescently	 labelled	 primers	 (ABI)	 in	 a	 single	 reaction	 tube	 (95°C	 for	 15	min,	 94°C	 for	 30s,	 58°C	 for	 1min30s,	 72°C	 for	 1min30s)	 X	 25,	 72°C	 for	 10min).	Peak	 labelling	 was	 performed	 using	 ABI	 GeneMapper	 software.	 Donor	 and	 pre-transplant	 recipient	 traces	 were	 assessed	 and	 informative	 allelic	 configurations	were	identified	(Watzinger,	Lion	and	Steward,	2006)(Watzinger,	Lion,	&	Steward,	2006),	 followed	 by	 data	 export	 and	 chimerism	 analysis	 using	 an	 in-house	developed	 Excel	 spreadsheet.	 	 The	 percentage	 of	 donor	 DNA	 in	 a	 sample	 was	calculated	 from	the	relative	peak	heights	and	peak	areas	 for	donor	and	recipient	from	 a	 minimum	 of	 two	 markers	 with	 an	 informative	 allelic	 configuration.	 	 In-house	corrections	for	stutter	and	preferential	amplification	of	shorter	alleles	were	applied.	 Results	 were	 reported	 as	 the	 median	 value	 of	 the	 markers	 assessed.	Typical	sensitivity	is	1-2%,	therefore	100%	donor	does	not	exclude	up	to	2%	host	
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DNA.	 Full	 donor	 chimerism	 is	 generally	 defined	 as	 98%	 donor	 although	 if	 host	alleles	are	evident	this	would	always	be	reported	as	mixed	chimerism.			
2.4.3	Estimating	proliferating	NK	cells	by	Ki67	expression	NK	 cells	 were	 first	 isolated	 from	 PBMCs	 using	 the	 EasySepTM	 technique	 as	described	 above.	 In	 order	 to	 estimate	 the	proportion	of	 proliferating	 cells,	Ki-67	expression	on	the	resulting	NK	cell	population	was	assessed	using	the	FITC	Mouse	Anti-Human	Ki-67	Set	(BD	Pharmingen).	NK	cells	were	resuspended	in	a	dropwise	fashion	with	cold	80%	ethanol	whilst	being	continually	vortexed.	These	cells	were	stored	 for	up	 to	60	days	 after	 fixing	 at	 -20°C.	When	 ready	 to	use,	 the	 cells	were	washed	 in	 MACS	 buffer	 and	 centrifuged	 for	 10	 minutes	 at	 2000rpm	 before	 the	supernatant	was	carefully	aspirated.	This	step	was	repeated	one	further	time.	The	cells	 were	 resuspended	 to	 a	 concentration	 of	 1x107cells/ml	 and	 100µl	 of	 this	suspension	 was	 transferred	 into	 a	 fresh	 FACs	 tube.	 20µl	 of	 anti-Ki67	 antibody	conjugated	to	FITC	was	added	to	the	cell	suspension	and	mixed	gently.	Tubes	were	incubated	 at	 room	 temperature	 for	 30	minutes	 in	 the	 dark.	 Then	 the	 cells	were	washed	 with	 2ml	 of	 PBS	 washing	 buffer	 at	 2000rpm	 for	 5	 minutes	 and	 the	resulting	 supernatant	 aspirated.	 This	 wash	 step	 was	 repeated	 one	 further	 time.	Finally,	 0.5ml	 of	 MACs	 buffer	 and	 1ul	 of	 propidium	 iodide	 solution	 (Miltenyi	Biotec)	 was	 added	 to	 the	 labeled	 cells	 solution	 prior	 to	 analysis	 on	 the	 FACs	machine.	 Two	 control	 tubes	 were	 also	 made	 to	 enable	 accurate	 gating	 of	 the	labeled	cells:	an	unstained	tube	of	NK	cells	and	a	tube	with	NK	cells	stained	with	an	isotype	control.	
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5.2.4	Ex-vivo	analysis	of	cytokine	production	For	 analysis	 of	 ex-vivo	 cytokine	 production,	 freshly	 isolated	 mononuclear	 cells	from	 either	 the	 peripheral	 blood	 of	 healthy	 donors	 or	 patients	 were	 incubated	with	the	following	surface	antibodies:	CD3-PE	and	CD56-APC-Cy7	for	20	minutes	on	ice	before	being	washed	and	resuspended	in	MACs	buffer.	Cells	were	then	fixed	by	resuspending	in	100µl	of	4%	paraformaldehyde	(Sigma-Aldrich)	and	incubated	at	 room	 temperature	 in	 the	 dark	 for	 15	minutes.	 After	 a	 further	wash	 in	MACS	buffer,	 cells	were	permeabilised	by	resuspending	 in	0.5%	saponin	and	 incubated	for	 5	 minutes	 at	 room	 temperature,	 protected	 from	 light.	 The	 cells	 were	 then	incubated	with	the	monoclonal	intracellular	antibodies	TNFα-PE-Cy7,	IFNγ-AF700	and	 IL-10-PE	 for	 20	minutes	 at	 room	 temperature	 in	 the	 dark.	 Cells	 were	 then	washed	twice	in	MACS	buffer	and	resuspended	in	an	appropriate	volume	for	flow	cytometric	analysis.		 Target	antigen	 Conjugate	 Clone	 Source	CD3	 PE	 UCHT1	 Beckman	Coulter	CD56	 APC-Cy7	 HCD56	 Biolegend	TNFα	 Pe-Cy7	 MAb11	 eBioscience	IFNγ	 AF700	 4S.B3	 Biolegend	IL-10	 PE	 JES3-19F1	 Biolegend	
Table	2.4	Panel	Four	-	Antibody	panel	for	intracellular	cytokine	production	
(The	antibodies	for	CD3	and	CD56	are	surface	antibodies,	whilst	those	for	TNFα,	IFNγ	and	IL-
10	are	intracellular	antibodies.)	
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2.4.5	NK	cell	cytotoxicity	assay	NK	cells	were	purified	using	EasySepTM	Human	NK	cell	enrichment	kit	(See	Section	2.1.9)(Stemcell	 Technologies)	 and	 activated	 overnight	 at	 37°C	with	 Interferon-α	(IFN-α	 PeproTech	 USA).	 Meanwhile,	 K562	 cells	 were	 stained	 with	 CFSE	 dye.	Labelled	 K562	 cells	 were	 then	 incubated	 with	 RPMI	 (negative	 control)	 or	 in	combination	with	activated	NK	cells	at	an	E/T	ratio	of	0.5:1	on	a	96	well	plate	for	16	hours.	Cells	were	 subsequently	extracted	and	a	 fixed	volume	analysed	on	 the	BD	 Accuri	 TM	 flow	 cytometer	 (BD	 Bioscience)	 to	 gain	 an	 absolute	 cell	 count.	 %	specific	lysis	was	calculated	by	100	x	{1-	[(experimental	group	cell	count)/(control	cell	count)]}	LIVE/DEAD®	Cell	Viability	dye	was	used	to	validate	the	gating	of	the	live	and	dead	populations.			
2.4.6	Mixed	lymphocyte	reaction	We	carried	out	a	one-way	mixed	lymphocyte	reaction.	PBMCs	were	obtained	from	two	unrelated	healthy	donors,	one	of	whom	serves	as	a	responder	(donor	1)	while	the	other	serves	as	the	stimulator	(donor	2).	Firstly,	the	PBMCs	from	donor	2	were	irradiated	at	40Gy	to	render	them	non-proliferative	to	serve	as	the	stimulator	cells.	An	 aliquot	 of	 cells	 from	 donor	 1	 were	 also	 irradiated	 to	 act	 as	 autologous	stimulators.	 The	 remaining	 PBMCs	 from	 donor	 1	 were	 divided	 into	 three	 more	groups:	one	group	underwent	magnetic	negative	selection	to	enrich	for	the	NK	cell	population,	 using	 the	 EasySepTM	 technique	 described	 in	 Section	 2.1.9	 and	 were	designated	 the	 suppressor	 population.	 A	 second	 group	 of	 responder	 cells	 was	labeled	with	CellTraceTM	Violet	Cell	Proliferation	Kit	 (ThermoFisher	Scientific)	 to	
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be	 used	 as	 the	 responder	 cells.	 	 Briefly,	 the	 cells	were	washed	 in	 PBS	 and	 then	resuspended	at	a	concentration	of	106cells/ml	in	PBS.	CellTraceTM	Violet	Dye	was	prepared	by	addition	of	DMSO	as	per	kit	 guidelines	and	1µl	 of	CellTraceTM	 stock	solution	 added	 for	 each	 mL	 of	 cell	 suspension	 in	 PBS	 to	 obtain	 a	 working	concentration	 of	 5µM.	 The	 cells	 were	 incubated	 at	 37°C	 for	 20	 minutes	 and	protected	 from	 light.	 To	 quench	 the	 reaction,	 five	 times	 the	 original	 staining	volume	of	GM	was	added	and	left	for	5	minutes	at	room	temperature.	The	presence	of	protein	in	the	media	removes	any	free	dye	remaining	in	the	solution.	The	cells	were	 then	 pelleted,	 resuspended	 in	 MLR	 media	 and	 incubated	 for	 at	 least	 10	minutes	 prior	 to	 use,	 to	 allow	 the	 CellTraceTM	 reagent	 to	 undergo	 acetate	hydrolysis.	The	third	group	of	cells	from	donor	1	were	not	altered	and	were	used	as	 negative	 control	 (no	 stimulation)	 and	 positive	 control	 (with	 the	 addition	 of	PHA).		To	 set	 up	 the	MLR	 reaction,	 a	 round	bottom	96	well	 plate	was	used	 to	 seed	 the	reaction.	 2x105	 stimulator	 cells	 (donor	 2:	 irradiated	 PBMCs)	 were	 mixed	 with	1x105	 responder	 cells	 (donor	 1:	 	 CellTraceTM	 labeled	 PBMCs)	 to	 form	 the	 MLR,	which	is	the	ratio	that	was	optimized	to	trigger	the	ideal	response.	The	suppressor	cells	(donor	1:	 	purified	NK	cells)	were	added	to	 the	reaction	at	ratios	of	1:0	(no	cells),	16:1	(6250	cells),	4:1	(2.5x104	cells),	1:1	(1x105	cells)	and	1:2	(2x105	cells).	All	 reactions	were	 carried	 out	 in	 triplicate	 resuspended	 in	MLR	media	 at	 a	 final	volume	 of	 200µl.	 Several	 controls	 were	 in	 place:	 1)	 unstained	 control	 (2x105	unmanipulated	 PBMCs	 from	 donor	 1),	 2)	 Negative	 control	 (2x105	 CellTraceTM	labeled	 PBMCs	 from	 donor	 1),	 3)	 Positive	 control	 (2x105	 CellTraceTM	 labeled	
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PBMCs	 from	 donor	 1	 and	 PHA),	 4)	 Autologous	 stimulation	 control	 (2x105	CellTraceTM	labeled	PBMCs	from	donor	1	and	2x105	irradiated	PBMCs	from	donor	1)	and	5)	Violet	CellTraceTM	control	(2x105	CellTraceTM	labeled	PBMCs	from	donor	1).	 Controls	were	performed	 in	duplicate	 and	 cell	mixtures	 resuspended	 in	MLR	media	at	a	final	volume	of	200µl.		Half	 of	 the	media	was	 changed	after	48	hours	 (100µl	media	 removed	 from	each	well	and	replaced	with	fresh	MLR	media).	On	day	5,	all	reactions	(except	unstained	control	 and	Violet	CellTraceTM	 control)	were	 stained	with	CD3-PE	as	per	 the	 cell	surface	staining	method	in	Section	2.1.8.	 	After	the	final	wash	in	MACs	buffer,	the	cells	were	pelleted	and	excess	wash	was	removed	using	tissue	paper.	100µl	MACs	was	pipetted	into	each	tube	and	prior	to	running	on	the	flow	cytometer,	100µl	of	Accucheck	 counting	 beads	 was	 pipetted	 into	 each	 tube.	 PI	 was	 also	 added	 to	exclude	dead	cells.			
2.4.7	Statistical	analysis	For	studies	of	phenotypic	and	functional	properties	of	healthy	donor	NK	and	D14-NK	 cells,	Mann-Whitney’s	 non-parametric	method	was	 used	 to	 compare	 the	 two	populations.	 The	Wilcoxon	matched	pairs	 signed	 rank	 test	was	used	 to	 compare	CD56bright	and	CD56dim	NK	cell	subsets.	All	statistical	tests	were	two-sided	and	the	level	of	statistical	significance	utilized	was	0.05.	Statistical	analysis	was	carried	out	using	Prism	(GraphPad	version	6.0b).		
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software	 using	 default	 RMA	 parameters.	 Statistical	 analysis	 of	 differential	expression	was	performed	using	 the	R	package	 limma	 (Ritchie	et	al.,	 2015)	with	Benjamini-Hochberg	method	applied	to	adjust	p-values	for	multiple	testing.		Gene-set	 enrichment	 analysis	was	performed	using	 the	Bioconductor	R	package	GAGE	(Luo	 et	 al.,	 2009).	 Curated	 gene	 sets	 for	 canonical	 signaling	 pathways	 were	obtained	from	the	Molecular	Signalling	Database	(Subramanian	et	al.,	2005).				
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CHAPTER	3:	NATURAL	KILLER	CELL	RECONSTITUTION	AFTER	
ALLOGENEIC	STEM	CELL	TRANSPLANTATION	
	
3.1	Introduction	Allogeneic	 stem	 cell	 transplantation	 (allo-SCT)	 is	 an	 important	 treatment	 for	haematological	disease	that	is	not	curable	by	chemotherapy	or	radiotherapy	alone.	Robust	 cellular	 reconstitution	 is	 vital,	 both	 for	 restoring	 effective	 haemopoiesis	and	also	to	reconstitute	a	 functioning	T	cell	and	NK	cell	repertoire	that	 is	able	to	target	allogeneic	tumour	cells	and	mediate	the	graft	versus	leukaemia	(GVL)	effect.	However,	 reconstituting	allogeneic	T	cells	 can	also	recognize	allogeneic	 recipient	tissue	and	result	in	graft	versus	host	disease	(GVHD).	GVHD	remains	an	important	cause	 of	 patient	 morbidity	 and	 transplant	 related	 mortality	 and	 efforts	 to	dissociate	T	cell	mediated	GVL	and	GVHD	effects	have	not	yet	proven	successful.		For	 example,	 the	use	of	 high-dose	 cyclophosphamide	 at	 days	3-4	 as	 acute	GVHD	prophylaxis	 following	 T	 cell	 replete	 HSCT	 is	 extremely	 effective	 at	 reducing	 the	risk	 of	 acute	 GVHD	 and	 is	 thought	 to	 selectively	 deplete	 the	 donor	 T	 cell	proliferating	in	response	to	alloantigens	whilst	sparing	T	cells	that	are	not	reacting	to	 host	 or	 donor	 alloantigens(Luznik	 and	 Fuchs,	 2010)(Luznik	 et	 al.,	2008)(Castagna	et	al.,	2014).	These	cells	then	provide	immunity	against	 infection	and	 also	 long-term	 immune	 reconstitution.	 However,	 this	 approach	 leads	 to	persistently	 high	 rates	 of	 disease	 relapse	 suggesting	 that	 the	 GVL	 response	 has	
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been	 compromised	 in	 the	 effort	 to	 reduce	 acute	 GVHD	 (Luznik	 et	 al.,	 2008).	Importantly,	it	also	highlights	that	the	alloreactive	T	cell	response	is	generated	in	the	 first	 days-weeks	 following	 allo-SCT,	 in	 line	 with	 primary	 T	 cell	 responses.	Further	 evidence	 that	 the	 first	 days-weeks	 are	 critical	 in	 developing	 the	alloreactive	immune	response	comes	from	studies	of	immune	reconstution.	At	day	14	following	allo-SCT,	higher	numbers	of	donor	CD8+	T	cells	 increases	the	risk	of	acute	 GVHD,	 whilst	 higher	 CD4+	 T	 cell	 and	 invariant	 NKT	 cell	 count	 predicts	improved	overall	survival	and	reduced	risk	of	acute	GVHD	respectively	(Petersen	
et	al.,	2004)(Fedele	et	al.,	2012)(Rubio	et	al.,	2012).		Early	reconstitution	of	NK	cells	following	allo-SCT	has	been	linked	to	a	reduction	in	the	risk	of	acute	GVHD	(Kim	et	al.,	2016)(Soiffer	et	al.,	1993)	although	very	early	immune	reconstitution	(i.e.	in	the	first	few	weeks)	has	not	been	explored	in	detail.	Studies	 have	 also	 suggested	 that	 NK	 cells	 have	 a	 role	 in	 regulating	 the	 adaptive	immune	 response	 by	 directly	 killing	 antigen-presenting	 cells(Morandi	 et	 al.,	2012)(Chiesa	et	al.,	2003)(Walzer	et	al.,	2005)(Wilson	et	al.,	1999)	or	activated	T	cells(Waggoner	et	al.,	 2012)(Cook,	Waggoner	and	Whitmire,	2014).	 It	 is	possible	that	 reconstituting	 NK	 cells	 may	 play	 a	 vital	 role	 in	 modulating	 the	 developing	allogeneic	T	cell	response	and	therefore	reduce	the	risk	of	acute	GVHD.		Given	the	lack	of	studies	in	early	NK	cell	reconstitution,	despite	the	clear	importance	of	this	time	period,	 this	 study	 sets	 out	 to	 characterize	 very	 early	NK	 cell	 reconstitution	following	allo-SCT.		
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Our	 cohort	 of	 108	patients	 received	 three	 distinct	 types	 of	 transplant	which	 are	defined	 by	 both	 the	 source	 of	 the	 donor	 stem	 cells	 and	 whether	 in	 vivo	 T	 cell	depletion	 is	 included	 as	 part	 of	 the	 transplant	 conditioning	 regimen.	 The	 most	commonly	performed	transplant	type	in	our	centre	is	a	peripheral	blood	stem	cell	(PBSC)	derived	allo-SCT	with	in	vivo	T	cell	depletion	achieved	by	infusion	of	either	Alemtuzumab	 or	 anti-thymocyte	 globulin	 (ATG)	 –	 hereafter	 denoted	 TCD	transplant.	This	type	of	transplant	is	utilised	for	older	patients	with	comorbidities	for	whom	the	presence	of	T	cells	in	the	graft	would	increase	the	risk	of	acute	GVHD	to	 a	 level	 deemed	 unsuitable	 by	 the	 treating	 physician.	 A	 T	 cell	 replete	 (TR	transplant)	 is	a	peripheral	blood	stem	cell	derived	allo-SCT	performed	without	T	cell	depletion.	The	presence	of	T	cells	does	confer	an	increased	risk	of	acute	GVHD	but	 also	 an	 improved	 GVL	 effect,	 which	 may	 be	 preferable	 in	 certain	 clinical	scenarios.			The	third	and	final	transplant	type	is	that	carried	out	using	umbilical	cord	derived	stem	cells.	Although	peripheral	blood	stem	cells	from	an	adult	donor	are	the	usual	source	for	stem	cells,	occasionally	stem	cells	derived	from	umbilical	cords	are	used	for	adult	allo-SCTs	when	an	appropriately	HLA	matched	adult	donor	is	not	found	through	family	members	or	registry	searches.	This	type	of	transplant	does	not	use	
in	vivo	T	cell	depletion	although	the	T	cells	that	are	adoptively	transferred	into	the	patient	will	be	uniformly	naïve	T	cells	by	virtue	of	their	source.	This	contrasts	with	the	mixed	phenotype	T	cells	transferred	from	an	adult	donor.		
Chapter 3: NK cell reconstitution following allo-SCT 
	 69	
Direct	comparison	of	these	patients	undergoing	different	transplant	types	offers	a	unique	 opportunity	 to	 investigate	 how	 the	 presence/absence	 of	mature/naïve	 T	cells	influences	NK	cell	reconstitution	following	HSCT.		
3.2	Methods	Detailed	methods	for	the	techniques	used	in	this	chapter	are	described	in	Section	2.2	in	the	Materials	and	Methods	chapter.		Briefly,	 peripheral	 blood	 samples	 were	 obtained	 from	 patients	 undergoing	 allo-SCT	at	the	Queen	Elizabeth	hospital	both	before	transplant	and	at	a	variety	of	time	points	 after	 transplant.	 The	 lymphocyte	 populations	 and	 NK	 cell	 subsets	 were	determined	 using	 cell	 surface	 staining	 with	 fluorescent	 antibodies	 and	 flow	cytometric	 analysis	 (see	Table	 2.1	 for	 antibody	panel).	 Lymphocyte	 counts	were	available	 either	 from	 the	 Queen	 Elizabeth	 clinical	 haematology	 laboratory	 full	blood	counts	or	ascertained	using	Trucount	tubes	(BD	Biosciences).			
3.3	Patient	and	transplant	characteristics	108	 patients	 who	 received	 allo-SCT	 for	 haematological	 disease	 at	 the	 Queen	Elizabeth	 Hospital,	 Birmingham,	 were	 recruited	 onto	 this	 study.	 	 They	 had	 a	median	age	of	50.5	years	(interquartile	range	43-61)	and	the	majority	of	patients	(57/108)	 received	allo-SCT	as	 therapy	 for	AML/MDS.	 	Non	Hodgkin’s	 lymphoma	(NHL)	and	acute	lymphoblastic	leukaemia	(ALL)	represented	14/108	and	18/108	patient	 diagnoses	 respectively,	 whilst	 Hodgkin’s	 lymphoma	 (HL),	 chronic	
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lymphocytic	leukaemia	(CLL),	myeloproliferative	disease	(MPD),	aplastic	anaemia	(AA),	myelofibrosis	(MF)	and	myeloma/other	made	up	the	remaining	diagnoses.		4	 patients	 received	 umbilical	 cord	 derived	 stem	 cell	 transplants.	 The	 remaining	104	patients	all	received	peripheral	blood	derived	stem	cells	(PBSCs)	with	39/104	from	sibling	donors	and	65/104	from	matched	unrelated	donors.	The	majority	of	patients	 received	 reduced	 intensity	 transplants	 (83/108)	 and	 T	 cell	 depletion	achieved	with	either	ATG	(13/108)	or	Alemtuzumab	(81/108).			Full	patient	and	transplant	characteristics	are	listed	in	Table	3.1.			 	
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	 	 Number	 %	
Patient	details	Age	at	transplant	 Median	years	(range)	(IQR)	 50.5	years	(43	–	61)	Sex			 Male	Female	 68	40	 63.0	37.0	Diagnosis	 AML/MDS	NHL	ALL	HL	CLL	MPD	AA	MF	Myeloma/other	
57	14	18	4	2	4	4	3	2	
52.8	13.0	16.7	3.7	1.9	3.7	3.7	2.8	1.9	Sorror	Score		 0	>=1	 80	20	 74.1	25.9	Disease	Risk	Index			 Low		Intermediate	High	Very	High	
18	48	39	3	
16.7	44.4	36.1	2.8	
Transplant	details	Intensity		 Reduced	intensity	Full	intensity	 83	25	 76.9	23.1	CMV	at	risk		 Yes	No	 85	23	 78.7	21.3	Male	Female	mismatch	 Yes	No	 25	83	 23.1	76.9	Donor		 Matched	unrelated	Sibling	Umbilical	cord	 65	39	4	 60.2	36.1	3.7	HLA	mismatch		 None	One	or	more	 88	20	 81.5	18.5	Stem	cell	source		 PBSC	Umbilical	cord	 104	4	 96.3	3.7	
GVHD	prophylaxis	T	cell	depletion	 ATG	Alemtuzumab	No	T	cell	depletion	 13	81	14	 12	75	13	Methotrexate	 Yes	No	 26	82	 24.1	75.9	Ciclosporin	 Yes	 108	 100	
Table	3.1.	108	recipients	of	allogeneic	stem	cell	transplantation	at	Queen	Elizabeth	
Hospital	Birmingham	-	patient	and	transplant	characteristics		
See	overleaf	for	abbreviations	
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Abbreviations:	 IQR,	 interquartile	 range;	 AML,	 acute	 myeloid	 leukaemia;	 MDS,	
myelodysplastic	 syndrome;	 NHL,	 non-Hodgkin’s	 lymphoma;	 ALL,	 acute	 lymphoblastic	
lymphoma;	 HL,	 Hodgkin’s	 lymphoma;	 CLL,	 chronic	 lymphocytic	 leukaemia;	 MPD,	
myeloproliferative	disease;	AA,	aplastic	anaemia;	MF,	myelofibrosis;	HLA,	human	 leukocyte	
antigen;	 PBSC,	 peripheral	 blood	 stem	 cell;	 GVHD,	 graft	 versus	 host	 disease;	 ATG,	 anti-
thymocyte	globulin.	CMV	at	risk	is	defined	as	either	patient	or	donor	being	CMV	seropositive.		
3.4	Sample	acquisition		Samples	 were	 taken	 from	 patients	 at	 the	 following	 time	 points:	 pre-transplant,	between	 days	 5-8,	 between	 days	 12-15,	 between	 3-5	 weeks	 and	 between	 3-4	months	after	 transplant.	 For	 ease	of	understanding,	 these	 time	points	have	been	designated	days	-7,	day	7,	day	14,	day	28	and	day	100	respectively.			Pre-transplant	peripheral	blood	 samples	were	obtained	prior	 to	 conditioning	 for	20	patients	who	received	T	cell	depleted	transplants	(TCD)	and	2	who	received	T-replete	(TR)	transplants.	95	samples	were	taken	at	day	7	from	83	TCD,	3	umbilical	cord	 and	 9	 TR	 transplants.	 95	 samples	 were	 obtained	 at	 day	 14	 for	 82	 TCD,	 4	umbilical	 cord	 and	 8	 TR	 patients.	 Fewer	 samples	 were	 available	 at	 later	 time	points	with	20	TCD	samples	at	Day	28	and	23	TCD	samples	at	Day	100.	A	higher	number	 of	 samples	 at	 the	 later	 time	 points	 would	 have	 been	 beneficial	 and	increased	 confidence	 in	 our	 findings.	 These	 samples	 were	 available	 as	 patients	were	 returning	 to	 clinic	 and	were	 able	 to	 provide	 samples.	 However,	 there	was	insufficient	manpower	within	the	research	project	to	facilitate	sample	analysis.	In	future	 studies,	 it	 would	 be	 advisable	 to	 access	 additional	 technical	 support	 to	address	this	issue.	This	data	is	summarized	in	Table	3.2.	
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Transplant	
type	
	
Day-7	 Day	7	 Day	14	 Day	28	 Day	100	
	TCD		 20	 83	 82	 20	 23		Umbilical	cord		 -	 3	 4	 -	 -		TR		 2	 9	 8	 -	 -	
	
Total	
	
22	 95	 94	 20	 23	
	
Table	3.2.	Samples	
	
3.5	Lymphocyte	reconstitution	following	T	cell	depleted	allo-SCT	To	study	NK	cell	reconstitution,	the	absolute	number	of	NK	cells	in	the	peripheral	blood	 at	 various	 time	 points	was	 obtained	 and	 compared	 to	 the	 absolute	 T	 cell	count	(Figure	3.1	(A+B)).	Prior	to	transplant,	patients	undergoing	a	T	cell	depleted	allo-SCT	have	a	mean	NK	cell	number	of	143	cells/µl	and	a	median	T	cell	number	of	604	cells/µl.	A	healthy	donor	has	an	NK	cell	number	of	between	77-427	cells/µl	(95%	confidence	interval)	and	536-1787	T	cells/µl	(Bisset	et	al.,	2004).	The	mild	lymphopenia	evident	in	our	patient	population,	relative	to	healthy	donors	may	be	indication	 of	 the	 patients’	 underlying	 haematological	 diagnosis	 and	 may	 also	reflect	prior	treatment.	By	Day	7,	there	is	a	precipitous	drop	in	cell	number	to	14	NK	cells/µl	and	2	T	cells/µl.	There	is	a	gradual	increase	in	NK	number	by	Day	14	to	42	cells/µl,	whilst	T	cell	numbers	remain	low	at	5	cells/µl.		
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By	Day	 28,	 NK	 cells	 have	 already	 recovered	 to	 above	 pre-transplant	 levels	 (200	cells/µl)	 remaining	 stable	 at	 208	 cells/µl	 at	 Day	 100.	 T	 cell	 numbers	 recover	slowly	 to	 15	 cells/µl	 at	 Day	 28	 and	 remain	 lower	 than	 pre-transplant	 at	 247	cells/µl	at	Day	100.		The	 dichotomy	 in	 lymphocyte	 reconstitution	 is	 further	 demonstrated	 in	 Figure	3.1(C)	by	observing	the	ratio	of	NK	and	T	cell	number	over	the	transplant	course.	Prior	to	transplant,	the	NK-T	cell	ratio	of	0.99	is	slightly	higher	than	the	NK-T	cell	ratio	of	0.17	seen	in	healthy	donors	but	it	dramatically	increases	to	20	and	42	by	Day	7	and	Day	14	respectively.	At	100	days	post	transplant,	it	remains	higher	than	pre-transplant	levels	at	3.7.			
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Figure	 3.1	 NK	 cells	 reconstitute	 rapidly	 following	 T	 cell	 depleted	 allo-SCT,	 whilst	 T	
cells	recover	slowly	
	The	reconstitution	of	NK	cells	(A)	and	T	cells	(B)	is	plotted	in	cells/µl	from	pre-transplant	to	
day	100	following	allo-SCT.		Whilst	T	cells	reconstitute	slowly	after	conditioning,	the	NK	cell	
population	recovers	quickly	and	 their	number	exceeds	pre-transplant	numbers	by	day	100.	
The	ratio	between	NK	cells	and	T	cells	(NK-T	cell	ratio)(C)	is	also	plotted	for	the	same	time	
period	and	demonstrates	 that	 the	 increase	 in	NK-T	cell	 ratio	 is	particularly	marked	at	day	
14.	Data	is	plotted	as	mean	and	the	error	bars	represent	the	standard	error.	D-7	(n=20),	D7	
(n=83),	D14	(n=82),	D28	(n=20)	and	Day	100	(n=23).	
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3.6	NK	cell	subset	reconstitution	following	T	cell	depleted	allo-SCT	The	 dynamics	 of	 NK	 cell	 reconstitution	 was	 assessed	 using	 flow	 cytometry	 and	Panel	One	of	NK	cell	surface	markers	(see	Table	2.1)	was	used	to	identify	different	subsets.	 NK	 cells	 are	 a	 heterogenous	 group	 of	 cells	 and	 are	 commonly	 defined	according	 to	 the	 intensity	 of	 CD56	 expression.	 Immature	NK	 cells	 express	 CD56	brightly	whilst	this	marker	loses	its’	intensity	as	the	cells	mature	(Caligiuri,	2008).	NKG2A	is	also	expressed	primarily	on	immature	NK	cells.	As	NK	cells	mature	and	gain	cytotoxic	activity,	they	lose	expression	of	both	NKG2A	and	CD56	whilst	other	markers	such	as	NKG2C,	CD57	and	KIR	gain	expression.		The	absolute	number	of	all	NK	cell	subsets	mirrors	the	reconstitution	pattern	seen	in	the	absolute	NK	cell	number	(Figure	3.2)	.	There	is	a	drop	in	number	at	Day	7	as	expected	following	transplant	conditioning	followed	by	a	small	increase	at	Day	14.	By	Day	28	the	absolute	number	of	all	NK	cell	subsets	has	recovered	back	to	pre-transplant	levels.		Figure	 3.3	 depicts	 the	 NK	 cell	 subsets	 as	 a	 proportion	 of	 the	 total	 NK	 cell	population.	 There	 is	 an	 interesting	 biphasic	 pattern	 of	 reconstitution	 clearly	demonstrated	 in	 the	 CD56bright	 and	 CD56dim	 NK	 cell	 subsets	 (Figure	 3.3(A+B)).	Prior	to	transplantation,	the	immature	CD56bright	NK	cell	subset	comprises	23%	of	the	total	NK	cell	population,	whilst	the	more	mature	CD56dim	NK	cell	subset	makes	up	the	remaining	77%.	This	is	in	marked	contrast	to	a	healthy	individual	where	the	CD56bright	NK	cells	makes	up	10%	of	 the	whole	NK	population.	By	Day	7	 there	 is	little	change	 in	 the	proportions	of	CD56bright	 and	CD56dim	NK	cells	but	by	Day	14	
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the	proportion	of	CD56bright	NK	cells	has	dropped	to	13%,	whilst	 the	CD56dim	NK	subset	increases	to	87%.		However,	by	Day	28	the	proportion	of	CD56bright	NK	cells	has	increased	back	to	pre-transplant	 levels	(25%)	and	by	Day	100,	the	immature	CD56bright	NK	cells	comprise	31%	of	the	total	population.	The	inverse	relationship	is	seen	in	the	more	mature	CD56dim	NK	cells,	which	demonstrate	a	sharp	decrease	in	 their	 proportion	 to	 75%	 and	 70%	 by	 Day	 28	 and	 Day	 100	 respectively.	 The	contrasting	patterns	of	reconstitution	in	CD56bright	and	CD56dim	NK	cell	subsets	are	highlighted	in	Figure	3.4.		The	 pattern	 of	 reconstitution	 for	 the	 remaining	 NK	 cell	 subsets	 is	 less	 clearly	appreciated	 (Figure	 3.3(C-F)).	 The	 proportion	 of	 the	 immature	 NKG2A	 NK	 cell	subset	drops	slightly	from	59%	pre-transplantation	to	55%	and	56%	at	Day	7	and	Day	14	 respectively.	By	Day	28,	 it	has	 increased	 to	64%	and	 remains	at	62%	by	Day	100.	 	The	activatory	receptor	NKG2C	defines	a	more	mature	NK	cell,	and	the	proportion	 of	 NK	 cells	 expressing	 this	 marker	 changes	 very	 little	 during	reconstition.	 It	 is	 expressed	 on	 14%	of	NK	 cells	 pre-transplantation	 and	 12%	at	Day	 7	 and	Day	 14	 before	 rising	 slightly	 to	 15%	at	Day	 29	 and	12%	at	Day	 100.	CD57	 expressing	NK	 cells	make	 up	 37%	of	NK	 cells	 pre	 transplant	with	 a	 slight	increase	 to	42%	by	Day	7	before	dropping	 to	37%	at	Day	14	and	Day	28	before	dropping	 further	 to	 30%	 by	 Day	 100.	 A	 similar	 relationship	 is	 seen	 for	 KIR	expressing	NK	cells:	KIR+	NK	cells	comprise	35%	of	the	total	NK	cell	population	pre	transplantation	and	increase	slightly	to	40%	at	Day	7	and	Day	14	before	gradually	falling	to	39%	at	Day	28	and	31%	at	Day	100.		
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Figure	3.2	There	is	a	rapid	reconstitution	of	the	absolute	number	of	all	NK	cell	subsets	
following	T	cell	depleted	allo-SCT	
The	total	number	of	NK	cells	subsets:	(A)	CD56bright,	(B)	CD56dim,	(C)	NKG2A+,	(D)	NKG2C+,	(E)	
CD57+	and	(F)	KIR+	is	plotted	as	cells/µl	from	pre-transplant	to	day	100	following	allo-SCT.	
The	 absolute	 number	 of	 all	 NK	 cell	 subsets	 rapidly	 drops	 after	 transplant	 conditioning	 is	
delivered.	However,	there	is	rapid	reconstitution	of	all	NK	cells	subsets	by	day	100	following	
allo-SCT.	 Data	 is	 plotted	 as	 the	 mean	 and	 error	 bars	 represent	 the	 standard	 error.	 D-7	
(n=20),	D7	(n=83),	D14	(n=82),	D28	(n=20)	and	Day	100	(n=23).	 	
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Figure	3.3	Varying	patterns	of	NK	cell	subset	reconstitution	in	T	cell	depleted	allo-SCT	
when	this	is	defined	as	a	percentage	of	the	NK	cell	population.	
The	reconstitution	pattern	of	NK	cell	subsets	has	been	plotted	as	a	percentage	of	the	total	NK	
cell	population	over	the	time	period	from	pre-transplant	to	day	100	following	allo-SCT:	(A)	
CD56bright,	 (B)	CD56dim,	(C)	NKG2A+,	(D)	NKG2C+,	(E)	CD57+	and	(F)	KIR+.	There	are	varying	
patters	 of	 reconstitution	 between	 all	 subsets.	 There	 is	 a	 biphasic	 pattern	 of	 reconstitution	
that	is	seen	in	the	CD56bright	and	CD56dim	subsets	that	is	shown	in	more	detail	 in	Figure	3.4.	
Data	is	plotted	as	the	mean	with	error	bars	representing	the	standard	error.	D-7	(n=20),	D7	
(n=83),	D14	(n=82),	D28	(n=20)	and	Day	100	(n=23).		 	
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Figure	3.4	Biphasic	 reconstitution	of	 CD56bright	 and	CD56dim	NK	 cells	 following	T	 cell	
depleted	allo-SCT	
(A)	 This	 graph	 displays	 the	 similar	 patterns	 of	 reconstitution	 of	 the	 absolute	 number	 of	
CD56dim	 and	CD56bright	NK	 cells	 over	 time.	 (B)	When	defined	as	 proportion	 of	 total	NK	 cell	
population,	the	mature	CD56dim	NK	subset	increases	and	peaks	at	day	14	before	diminishing	
rapidly	by	day	100.	The	opposite	relationship	is	seen	in	the	more	immature	CD56bright	NK	cell	
subset.	 Data	 plotted	 represents	 the	mean	 result.	 D-7	 (n=20),	 D7	 (n=83),	 D14	 (n=82),	 D28	
(n=20)	and	Day	100	(n=23).			
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3.7	Lymphocyte	reconstitution	following	T	cell	replete	allo-SCT	We	went	 on	 to	 examine	 lymphocyte	 reconstitution	 following	 T	 cell	 replete	 (TR)	allo-SCT.	In	our	patient	cohort,	a	smaller	number	of	patients	received	TR	allo-SCT	with	 fewer	 samples	 tested	 at	 later	 time	 points.	 Therefore,	 reconstitution	 data	 is	available	for	only	three	time	points:	pre-transplantation	(D-7),	Day	7	and	Day	14.		Prior	 to	 transplantation,	 patients	 receiving	 T	 cell	 replete	 and	 T	 cell	 deplete	transplants	 have	 similar	 absolute	 numbers	 of	 NK	 and	 T	 cells	 (NK:	 143	 vs	 143	cells/µl;	 T:	 627	 vs	 604	 cells/µl).	 However,	 their	 lymphocyte	 populations	 exhibit	strikingly	different	reconstitution	patterns	after	transplantation,	as	demonstrated	in	Figure	3.5.	In	common	with	TCD	transplants,	there	is	a	similar	dramatic	drop	in	NK	cell	number	from	to	9	cells/µl	at	Day	7,	followed	by	an	increase	by	Day	14	to	47	NK	 cells/µl.	 T	 cell	 number	 drops	 to	 26	 cells/µl	 by	 D7,	 with	 a	 small	 rise	 to	 30	cells/µl	 by	 D14,	 contrasting	 with	 TCD	 transplants	 where	 T	 cell	 number	 has	dropped	to	nearly	0	cells/µl	at	this	time	point.	Improved	T	cell	reconstitution	in	TR	transplants	 compared	 to	 TCD	 transplants	 is	 perhaps	 unsurprising	 since	 TCD	transplants	 have,	 by	 definition,	 received	 either	 alemtuzumab	 or	 ATG	 as	 part	 of	transplant	 conditioning,	 both	 of	 which	 result	 in	 in	 vivo	 T	 cell	 depletion.	 This	difference	 is	highlighted	 in	 the	NK-T	cell	 ratio	(Figure	3.5.C),	which	 is	similar	 for	TCD	 and	 TR	 transplants	 prior	 to	 transplantation	 (0.99	 vs	 0.75,	 p=0.89)	 but	 is	markedly	 increased	 in	 TCD	 transplants	 at	 Day	 7	 and	 Day	 14	 (D7:	 20	 vs	 3,	p=0.0005;	D14:	42	vs	11,	p=0.016).	 	
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Figure	 3.5	 NK	 and	 T	 cell	 number	 drops	 rapidly	 after	 conditioning	 for	 T	 cell	 replete	
allo-SCT	
The	reconstitution	pattern	of	 the	absolute	number	of	NK	cells	 (A)	and	T	cells	 (B)	has	been	
plotted	 as	 cells/µl	 from	 the	 time	 period	 pre	 transplantation	 to	 day	 14	 following	 allo-SCT.	
There	 is	a	rapid	drop	 in	 the	number	of	both	cell	 types	after	 transplant	conditioning	with	a	
small	increase	in	the	NK	cell	number	by	day	14,	whilst	the	T	cell	number	remains	low.	This	is	
reflected	by	the	rapid	increase	in	the	NK-T	cell	ratio	over	the	same	time	period	(C).	Graphs	
display	the	mean	with	error	bars	representing	the	standard	error.	D	-7	(n=2),	D	7	(n=9),	D	14	
(n=8)	
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3.8	NK	cell	subset	reconstitution	following	T	cell	replete	allo-SCT	We	 then	 went	 on	 to	 study	 the	 pattern	 of	 reconstitution	 within	 NK	 cell	 subsets	following	 T	 cell	 replete	 (TR)	 allo-SCT	 (Figure	 3.6).	 In	 keeping	 with	 the	 pattern	observed	 in	 the	whole	NK	population,	 the	 absolute	 number	 of	NK	 cells	 drops	 to	nearly	 0	 cells/µl	 in	 each	 NK	 cell	 subset	 by	 Day	 7	 in	 TR	 allo-SCT.	 However,	observing	reconstitution	from	Day	7	to	Day	14	reveals	striking	differences	 in	the	CD56bright	subset.	The	absolute	number	of	this	immature	population	drops	from	9	cells/µl	pre	transplantation,	to	3	cells/µl	at	Day	7,	before	undergoing	an	extremely	rapid	expansion	to	reach	23	cells/µl	by	Day	14.	The	absolute	number	of	CD56dim,	NKG2A+,	NKG2C+,	CD57+	and	KIR+	NK	cells	displays	a	limited	expansion	by	Day	14,	with	levels	reaching	between	19-42%	of	pre-transplant	levels,	in	marked	contrast	to	the	260%	increase	for	the	CD56bright	subset.		When	 studied	 as	 a	 proportion	 of	 total	 NK	 cell	 population	 the	 differences	 in	reconstitution	 of	 CD56bright	 and	 CD56dim	 NK	 cell	 subsets	 is	 evident	 (Figure	 3.7).	CD56bright	 NK	 cells	 comprise	 6%	 of	 total	 NK	 cells	 prior	 to	 transplantation	 and	increase	to	49%	by	Day	14	(p=0.04),	 in	contrast	 to	CD56dim	NK	cells,	which	drop	from	94%	to	52%	of	NK	cells	 (p=0.04)	over	 the	same	 time	period.	For	 the	other	subsets	 there	 is	 little	 variation	 in	 their	 proportion	 within	 the	 whole	 NK	 cell	population	when	 you	 compare	Day	 14	with	 pre	 transplant	 levels:	 NKG2A+	 (Pre-transplant:	60%,	Day	14:	72%,	p=ns),	NKG2C+	(Pre-transplant:	19%,	Day	14:	17%,	p=ns),	CD57+	(Pre-transplant:	31%,	Day	14:	36%,	p=ns)	and	KIR+	(Pre-transplant:	30%,	 Day	 14:	 37%,	 p=ns).	 Interestingly,	 despite	 these	 similarities,	 the	 NKG2A+	population	shows	a	decrease	in	proportion	at	Day	7	before	increasing	back	to	pre	
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transplant	levels	by	Day	14,	whilst	the	CD57+	population	demonstrates	the	inverse	with	 an	 increase	 in	 proportion	 at	 Day	 7	 and	 then	 regaining	 pre	 transplant	proportions	 by	 Day	 14.	 The	 NKG2C+	 and	 KIR+	 populations	 do	 not	 exhibit	 these	fluctuations.		Figure	 3.8	 displays	 both	 CD56bright	 and	 CD56dim	NK	 cell	 subset	 reconstitution	 on	the	same	axes,	highlighting	that	the	numbers	of	each	subset	are	nearly	equal	at	Day	14.	In	fact	the	CD56bright:CD56dim	NK	cell	ratio	is	0.92	at	Day	14	compared	to	0.07	prior	to	transplantation.			 	
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Figure	3.6	The	absolute	number	of	all	NK	cell	subsets	drops	rapidly	after	conditioning	
for	T	cell	replete	allo-SCT	with	some	recovery	by	day	14	
The	absolute	number	of	the	following	NK	cell	subsets:	(A)	CD56bright,	(B)	CD56dim,	(C)	NKG2A+,	
(D)	 NKG2C+,	 (E)	 CD57+,	 (F)	 KIR+	 was	 plotted	 as	 cells/µl	 over	 a	 time	 period	 from	 pre-
transplantation	to	day	14	following	allo-SCT.	There	is	a	rapid	drop	in	the	absolute	number	of	
all	the	NK	cell	subsets	by	day	7	with	only	a	small	recovery	in	counts	by	day	14.		Data	plotted	
as	 the	mean	with	 error	 bars	 representing	 the	 standard	 error.	D	 -7	 (n=2),	D	 7	 (n=9),	D	 14	
(n=8)	
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Figure	3.7	There	are	varying	patterns	of	NK	cell	subset	reconstitution	following	T	cell	
replete	allo-SCT	–	defined	as	a	proportion	of	the	total	NK	population		
The	reconstitution	pattern	of	NK	cell	subsets	has	been	plotted	as	a	percentage	of	the	total	NK	
cell	population	over	 the	 time	period	 from	pre-transplant	 to	day	14	 following	T	cell	 replete	
allo-SCT:	(A)	CD56bright,	(B)	CD56dim,	(C)	NKG2A+,	(D)	NKG2C+,	(E)	CD57+	and	(F)	KIR+.	There	
are	 varying	 patters	 of	 reconstitution	 between	 all	 subsets.	 Data	 plotted	 as	 median	 and	
interquartile	range.	D	-7	(n=2),	D	7	(n=9),	D	14	(n=8)	
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Figure	3.8	 	At	28	days	after	T	 cell	 replete	allo-SCT,	 there	 is	an	 inverted	 relationship	
between	CD56bright	and	CD56dim	NK	cell	subsets	
(A)	 The	 absolute	 number	 of	 both	 CD56bright	 and	 CD56dim	 NK	 cells	 drops	 rapidly	 after	
conditioning	for	T	cell	replete	allo-SCT	with	some	recovery	of	numbers	by	day	14.	However,	
the	 proportion	 of	 CD56bright	 NK	 cells	 in	 the	 total	 NK	 population	 increases	 over	 this	 time	
period,	with	a	reciprocal	decrease	in	the	proportion	of	CD56dim	NK	cells	(B).	The	mean	result	
is	plotted.	D	-7	(n=2),	D	7	(n=9),	D	14	(n=8)	
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3.9	Lymphocyte	reconstitution	following	umbilical	cord	allo-SCT	Umbilical	 cord	stem	cell	 transplantation	 is	 carried	out	 infrequently	 in	our	centre	and	only	4	patients	in	our	cohort	received	this	type	of	transplant.	Peripheral	blood	samples	 were	 obtained	 from	 these	 patients	 at	 D7	 and	 D14.	 Unfortunately,	 pre-transplant	blood	samples	were	not	available.			The	absolute	NK	cell	count	at	Day	7	was	low	at	3	cells/µl	and,	in	common	with	TCD	and	TR	 transplants,	 rapidly	 increases	 to	 34	 cells/µl	 by	Day	 14	 (Figure	 3.9).	 The	absolute	 T	 cell	 number	 is	 stable	 at	 25	 cells/µl	 and	 26	 cells/µl	 at	Days	 7	 and	14	respectively.	This	results	in	an	increasing	NK-T	ratio	from	0.4	at	Day	7	to	1.1	at	Day	14.	 Figure	 3.12	 compares	 CD56bright	 and	 CD56dim	 NK	 cell	 subset	 reconstitution	following	umbilical	cord	allo-SCT.	 	
Chapter 3: NK cell reconstitution following allo-SCT 
	 89	
	
Figure	3.9	There	 is	rapid	NK	cell	reconstitution	between	day	7	and	day	14	 following	
umbilical	cord	stem	cell	transplantation	
The	absolute	number	of	NK	and	T	cells	is	plotted	as	cells/µl	over	the	time	period	from	day	7	
to	day	14,	following	umbilical	cord	stem	cell	transplantation.	The	number	of	NK	cells	rapidly	
rises	over	this	time	period	(A),	whilst	the	number	of	T	cells	is	static	(B).	As	a	consequence	the	
NK-T	cell	ratio	rises	over	the	same	time	period	(C).	Data	is	represented	as	mean	with	error	
bars	representing	the	standard	error.		D7	(n=3)	and	D14	(n=4).			
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3.10	NK	cell	subset	reconstitution	following	umbilical	cord	allo-SCT	In	keeping	with	the	analysis	 for	TCD	and	TR	allo-SCT,	we	then	went	on	to	assess	NK	 cell	 reconstitution	 for	 individual	 subsets	 of	 NK	 cells.	 When	 defined	 as	 an	absolute	number	of	NK	cells,	the	pattern	of	reconstitution	was	similar	for	all	of	the	subsets	in	the	study.	For	CD56bright,	CD56dim,	NKG2A+,	NKG2C+,	CD57+	and	KIR+	NK	cell	subsets,	the	absolute	number	of	cells	was	nearly	0	cells/µl	at	Day	7	and	then	increased	by	Day	14	(Figure	3.10).			However,	assessing	reconstitution	as	a	proportion	of	 the	total	NK	cell	population	revealed	differences	between	the	NK	cell	subsets	(Figure	3.11).	At	Day	7,	CD56bright	NK	cells	comprise	29%	of	NK	cells	and	drop	to	21%	by	Day	14	(p=ns).	There	is	a	reciprocal	 increase	 in	 the	CD56dim	NK	cell	 subset	 from	71%	to	79%	between	 the	same	time	points	(p=ns).	NKG2A+,	NKG2C+	and	CD57+	NK	cell	subsets	all	increase	in	between	Days	7	and	14:	NKG2A+	(Day	7:	50%,	Day	14:	69%,	p=ns),	NKG2C+	(Day	7:	 23%,	Day	14:	28%,	p=ns),	 CD57+	 (Day	7:	 44%,	Day	14:	53%,	p=ns).	 	KIR+	NK	cells	demonstrate	a	slight	decrease	from	42%	at	Day	7	to	40%	at	Day	14	(p=ns).	It	is	worth	noting	that	the	differences	in	proportion	of	NK	cell	subsets	at	the	two	time	points	 is	 not	 statistically	 significant	 and	 this	 may	 reflect	 the	 small	 number	 of	patient	samples	in	the	umbilical	cord	cohort	of	transplant	recipients.		 	
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Figure	3.10	The	absolute	number	of	all	NK	cell	subsets	increases	between	days	7	and	
14	following	umbilical	cord	stem	cell	transplantation	
The	absolute	number	of	the	following	NK	cell	subsets:	(A)	CD56bright,	(B)	CD56dim,	(C)	NKG2A+,	
(D)	NKG2C+,	(E)	CD57+,	(F)	KIR+	was	plotted	from	day	7	to	day	14	following	umbilical	cord	
stem	 cell	 transplantation.	 Over	 this	 time	 period,	 the	 numbers	 of	 all	 the	 NK	 cell	 subsets	
increases.	Data	plotted	as	mean	with	error	bars	representing	 the	standard	error.	D7	(n=3)	
and	D14	(n=4).			
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Figure	3.11	There	are	varying	patterns	of	NK	cell	subset	reconstitution	after	umbilical	
cord	allo-SCT	when	expressed	as	a	proportion	of	total	NK	cell	population		
The	reconstitution	pattern	of	NK	cell	subsets	has	been	plotted	as	a	percentage	of	the	total	NK	
cell	population	over	the	time	period	from	day	7	to	day	14	following	umbilical	cord	stem	cell	
transplantation:	(A)	CD56bright,	(B)	CD56dim,	(C)	NKG2A+,	(D)	NKG2C+,	(E)	CD57+	and	(F)	KIR+.	
There	are	varying	patters	of	reconstitution	between	all	 subsets.	Data	plotted	as	mean	with	
error	bars	representing	standard	error.	D7	(n=3)	and	D14	(n=4).	
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Figure	 3.12	 Differential	 CD56bright	 and	 CD56dim	 NK	 subset	 reconstitution	 following	
umbilical	cord	stem	cell	transplantation	
(A)	The	absolute	number	of	CD56dim	and	CD56bright	NK	cells	increases	between	days	7	and	14,	
following	umbilical	cord	allo-SCT.	 (B)	When	these	subsets	are	expressed	as	a	proportion	of	
the	 total	NK	cell	population,	 it	 is	 evident	 that	 the	CD56dim	NK	cells	are	 increasing	between	
days	 7	 and	 14	 with	 a	 reciprocal	 decrease	 in	 the	 CD56bright	 NK	 cell	 subset.	 Data	 plotted	
represents	mean	values.	D7	(n=3)	and	D14	(n=4).	
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3.11	Differential	NK	cell	reconstitution	according	to	transplant	type	The	period	of	 very	 early	 immune	 reconstitution	 in	 the	 first	 few	weeks	 following	allo-SCT	demonstrates	 sharp	differences	 between	 the	 three	 groups	 of	 transplant	types	 (Figure	3.13).	 Interestingly,	 the	 absolute	NK	 cell	 number	at	D7	and	D14	 is	not	statistically	different	between	the	three	groups,	but	the	absolute	T	cell	number	at	 D7	 and	 D14	 is	 significantly	 lower	 in	 the	 TCD	 cohort	 compared	 to	 both	 TR	(p<0.001	 and	 p<0.05	 respectively)	 and	 umbilical	 cord	 (p<0.005	 and	 p<0.005	respectively)	 transplants.	 This	 is	 reflected	 in	 statistically	 different	 NK:T	 ratios	between	TCD	and	umbilical	cord	transplants	at	both	D7	and	D14	and	between	TCD	and	TR	patients	at	D7	(Figure	3.13.C).			
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Figure	 3.13	 Direct	 comparison	 of	 NK	 and	 T	 cell	 reconstitution	 following	 umbilical	
cord,	T	cell	replete	and	T	cell	deplete	stem	cell	transplantation		
Mean	and	standard	error	of	the	mean	plotted.	(A)	Absolute	NK	cell	number,	(B)	Absolute	T	
cell	 number	and	 (C)	NK-T	 cell	 ratio.	 P<0.05	 (*),	 P<0.005	 (**),	 P<0.001(***),	Mann-Whitney	
test,	two-tailed.		 	
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3.12	 NK	 cell	 subsets	 display	 contrasting	 reconstitution	 patterns	 in	 the	
different	transplant	types	Although	the	absolute	NK	cell	number	at	D7	and	D14	is	comparable	between	the	three	 transplant	 types,	 there	 is	 an	 interesting	 contrast	 in	 the	 pattern	 of	 NK	 cell	subset	 reconstitution	 between	 these	 two	 time	 points.	 The	 absolute	 number	 of	CD56bright	NK	cells	at	D14	is	higher	in	TR	transplants	compared	to	TCD	transplants	(p<0.001)(Figure	3.14).			Furthermore,	when	expressed	as	a	proportion	of	the	total	NK	cell	population,	the	CD56bright	NK	cell	subset	 in	TR	transplants	 is	significantly	 larger	than	that	seen	in	umbilical	 cord	 and	 TCD	 transplants	 at	 D14	 (p<0.001	 and	 p<0.001	 respectively).	The	 inverse	 is	 seen	 for	 the	 CD56dim	NK	 cell	 subset	 (Figure	 3.15).	 There	 are	 also	significant	 differences	 in	 the	 percentages	 of	 NKG2A+	 NK	 cells	 in	 TR	 and	 TCD	transplants	 at	 Day	 14	 (p<0.05)	 and	NKG2C+	NK	 cells	 in	 umbilical	 cord	 and	 TCD	transplants	at	Day	14.		Figure	 3.16	demonstrates	 the	 contrasting	 patterns	 of	 reconstitution	 in	 CD56bright	and	 CD56dim	 NK	 cells	 subsets	 between	 the	 three	 transplant	 types.	 For	 TCD	 and	umbilical	cord	allo-SCT,	the	rate	of	CD56dim	NK	cell	expansion	between	Day	7	and	Day	 14	 is	 higher	 than	 the	 rate	 of	 expansion	 in	 CD56bright	 NK	 cells,	 resulting	 in	broadly	 similar	 proportions	 of	 CD56bright	 (TCD:	 13%;	 umbilical	 cord:	 20%)	 and	CD56dim	 NK	 cells	 (TCD:87%;	 umbilical	 cord:	 80%)	 at	 day	 14	 in	 the	 these	 two	transplant	types.	However,	 the	rate	of	NK	cell	expansion	between	Day	7	and	Day	14	is	similar	for	both	subsets	in	TR	transplants,	which	dramatically	skews	the	NK	
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cell	subsets	such	that,	by	day	14,	that	CD56bright	and	CD56dim	NK	cells	are	equally	represented	in	the	whole	NK	cell	pool.			
	
Figure	 3.14	 Comparing	 absolute	 NK	 subset	 cell	 count	 at	 D7	 and	 D14	 following	
umbilical	cord,	T	cell	replete	and	T	cell	deplete	stem	cell	transplantation	
(A)	 CD56bright,	 (B)	 CD56dim,	 (C)	 NKG2A+,	 (D)	 NKG2C+,	 (E)	 CD57+,	 (F)	 KIR+.	 Data	 plotted	 as	
mean	and	 standard	 error.	 P<0.05	 (*),	 P<0.005	 (**),	 P<0.001(***),	Mann-Whitney	 test,	 two-
tailed.			
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Figure	3.15	 	Comparing	NK	subsets	as	a	proportion	of	total	NK	cell	population	at	D7	
and	 D14	 following	 umbilical	 cord,	 T	 cell	 replete	 and	 T	 cell	 deplete	 stem	 cell	
transplantation	
(A)	 CD56bright,	 (B)	 CD56dim,	 (C)	 NKG2A+,	 (D)	 NKG2C+,	 (E)	 CD57+,	 (F)	 KIR+.	 Data	 plotted	 as	
mean	and	 standard	 error.	 P<0.05	 (*),	 P<0.001	 (**),	 P<0.005(***),	Mann-Whitney	 test,	 two-
tailed.		 	
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Figure	3.16	Reconstitution	of	NK	cell	 subsets	 in	 the	 first	14	days	 following	umbilical	
cord,	T	cell	replete	and	T	cell	deplete	stem	cell	transplantation	
(A)	The	absolute	number	of	CD56bright	and	CD56dim	NK	cells	increases	between	days	7	and	14	
for	all	three	transplant	types.	However,	in	TCD	and	UCB	allo-SCT,	the	rate	of	increase	is	much	
higher	for	CD56dim	NK	cells	relative	to	CD56bright	NK	cells.	In	TR	transplants,	the	two	subsets	
have	similar	rates	of	reconstitution.	The	effect	of	these	contrasting	patterns	of	reconstitution	
is	seen	when	the	NK	cell	subets	are	plotted	as	a	proportion	of	the	total	NK	cell	population	(B).	
In	 TCD	 and	 UCB	 transplants	 the	 proportion	 of	 mature	 CD56dim	 NK	 cells	 in	 the	 NK	 cell	
population	 increases	 between	 days	 7	 and	 14	 whilst	 there	 is	 a	 decrease	 in	 the	 immature	
CD56bright	NK	 cell	 population.	The	opposite	 relationship	 is	 seen	 in	TR	 transplants.	 For	both	
graphs	the	mean	data	point	has	been	plotted.		
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3.13	Discussion	
3.13.1	Differential	lymphocyte	reconstitution	between	different	transplant	types	Pre-transplant	NK	and	T	cell	counts	were	available	for	patients	who	received	T	cell	deplete	and	T	cell	replete	allo-SCT.	These	patients	had	mean	pre-transplant	NK	cell	counts	of	143	cells/µl	and	143	cells/µl	respectively	and	mean	pre-transplant	T	cell	counts	of	604	 cells/µl	 and	627	 cells/µl	 respectively.	These	values	 fall	within	 the	normal	 reference	 ranges	 for	 lymphocyte	 counts	 determined	 in	 a	 healthy	 adult	population	 in	 Switzerland	 (Bisset	 et	al.,	 2004)(NK	 cells:	 77-427	 cells/µl;	 CD3+	 T	cells:	 536-1787	 cells/µl),	 although	 these	 values	 are	 at	 the	 lower	 end	 of	 both	ranges.	 As	 our	 patients	 will	 have	 all	 undergone	 chemotherapy	 and/or	radiotherapy	 for	 their	 haematological	malignancy	 in	 the	weeks/months	 prior	 to	the	allo-SCT,	this	may	reflect	their	previous	treatment.	It	is	also	possible	that	these	values	may	reflect	the	underlying	disease	process.			As	 expected,	 both	NK	and	T	 cell	 counts	 rapidly	dropped	after	 conditioning	 in	 all	three	 transplant	 types	 and	 the	 lowest	 values	 were	 observed	 at	 day	 7	 following	stem	cell	infusion.	Cell	counts	increased	slightly	between	day	7	and	day	14	and	we	found	that	NK	cells	recovered	rapidly	subsequent	to	this,	with	numbers	returning	to	pre-transplant	levels	by	day	28	(Martıńez	et	al.,	1999)(Komanduri	et	al.,	2007).			There	 were	 particularly	 interesting	 differences	 in	 lymphocyte	 reconstitution	between	 the	 three	 transplant	 types	 in	 the	 first	 two	 weeks	 following	 allo-SCT.	Although	total	NK	cell	reconstitution	between	the	three	transplant	types	was	very	
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similar,	 the	 absolute	 T	 cell	 count	 was	 significantly	 reduced	 in	 TCD	 transplants	compared	to	umbilical	cord	and	T	cell	 replete	 transplants	at	both	days	7	and	14.	Since	TCD	transplants	are	defined	by	in	vivo	depletion	of	T	cells,	it	is	unsurprising	that	 TR	 and	 umbilical	 cord	 transplants	 (which	 are	 not	 T	 cell	 depleted)	 display	higher	absolute	T	cell	numbers	in	the	very	early	reconstitution	period.	It	is	known	that	the	dose	of	T	cell	inoculum	in	the	stem	cell	product	is	a	major	determinant	of	T	cell	recovery	(Martıńez	et	al.,	1999).			However,	the	marked	differences	in	T	cell	recovery	between	the	transplant	types,	in	 the	 absence	 of	 significant	 differences	 in	 NK	 cell	 reconstitution,	 leads	 to	inevitable	 imbalances	 in	 the	 NK:T	 cell	 ratio.	 The	 NK:T	 cell	 ratio	 in	 a	 healthy	individual	 is	 approximately	 0.17	 with	 T	 cells	 outnumbering	 NK	 cells	 in	 the	peripheral	 blood.	 Following	 stem	 cell	 transplantation,	 this	 relationship	 is	disrupted	 and	 in	 TCD	 transplants,	 NK	 cells	 outnumber	 T	 cells	 by	 40	 to	 1,	representing	a	greater	 than	200	 fold	change	 in	NK:T	cell	 ratio.	This	disruption	 is	less	marked	in	TR	and	umbilical	stem	cell	transplants	with	day	14	NK:T	cell	ratios	of	10.8	and	1.2	respectively.		The	 extreme	 numerical	 dominance	 of	 NK	 cells	 over	 T	 cells	 in	 the	 very	 early	reconstitution	period	and	especially	in	TCD	transplants,	suggests	that	NK	cells	may	play	a	important	role	in	shaping	the	developing	adapative	immune	response	in	this	clinical	scenario.		
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3.13.2	Differential	NK	cell	subset	reconstitution	between	different	transplant	types	There	 was	 no	 variation	 in	 the	 reconstitution	 of	 the	 total	 NK	 cell	 population	between	 the	 three	 transplant	 types	 but,	 importantly,	 there	 were	 significant	differences	seen	in	the	recovery	of	specific	NK	cell	subsets,	most	noticeably	in	the	CD56bright	and	CD56dim	NK	cell	subsets.	The	intensity	of	CD56	expression	identifies	two	 groups	 of	 NK	 cells	 with	 distinct	 functions.	 In	 healthy	 donors,	 10-15%	 of	circulating	 NK	 cells	 display	 a	 high	 surface	 expression	 of	 CD56,	 can	 secrete	cytokines	rapidly	after	activation	but	have	a	reduced	cytotoxic	capacity.	In	contrast	the	 remaining	 85-90%	 are	 CD56dim	 NK	 cells	 that	 can	 spontaneously	 lyse	susceptible	target	cells	but	are	less	able	to	secrete	cytokines	(Caligiuri,	2008).	It	is	believed	 that	 CD56bright	 NK	 cells	 downregulate	 expression	 of	 CD56	 and	 become	CD56dim	 NK	 cells	 as	 they	 mature	 and	 gain	 cytotoxic	 function	 (Melsen	 et	 al.,	2016)(Chan	et	al.,	2007)(Romagnani	et	al.,	2007).		At	Day	7,	CD56dim	NK	cells	predominate	in	the	NK	cell	population	for	all	patients.	Whilst	 the	 absolute	 number	 of	 both	 CD56bright	 and	 CD56dim	 NK	 subsets	 in	 all	transplant	types	 increases	from	D7	and	D14,	Figure	3.16.A	demonstrates	that	 for	TCD	 and	 umbilical	 cord	 allo-SCT,	 the	 CD56dim	 NK	 cell	 population	 expands	preferentially	 compared	 to	 the	 CD56bright	 NK	 cell	 subset.	 However,	 in	 TR	transplants	 the	 CD56bright	 NK	 cells	 expand	 at	 a	 faster	 rate.	 Therefore,	 when	 the	subsets	 are	 examined	 as	 a	 proportion	 of	 the	 total	 NK	 cell	 population	 (Figure	3.16.B),	 patients	 receiving	 a	 TR	 transplant	 display	 a	 marked	 expansion	 of	 the	CD56bright	NK	cell	subsets	between	D7	and	D14,	whilst	patients	receiving	a	TCD	or	
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umbilical	 cord	 transplant	 show	 only	 a	modest	 expansion	 of	 the	 CD56dim	NK	 cell	subset.		Nguyen	et	al	(Nguyen	et	al.,	2008)	studied	the	effect	of	mature	donor	T	cells	on	NK	cell	reconstitution	following	haploidentical	stem	cell	transplantation	by	comparing	transplants	 that	were	 either	 partially	 T	 cell	 depleted	 (pTD)	 or	 extensively	T	 cell	depleted	 (eTD).	 They	 found	 that	 the	 expansion	 of	 CD56bright	 NK	 cells	 was	 less	evident	 in	 pTD	 transplants	 compared	 to	 eTD	 transplants,	 which	 is	 in	 direct	contrast	 to	 our	 results.	 Furthermore,	 Bjorklund	 et	 al	 (Björklund	 et	 al.,	2011)carried	 out	 the	 same	 comparison	 in	 HLA-identical	 sibling	 donor	 stem	 cell	transplantation	and	found	that	the	presence	of	donor	T	cells	in	the	graft	had	little	effect	on	NK	cell	reconstitution.			However,	 these	 studies	 achieved	 T	 cell	 depletion	 using	 either	 immunomagnetic	bead	 selection	 systems	 or	 through	 an	 immunoadsorption	 biotin-avidin	 column.	These	techniques	allow	depletion	of	T	cells	without	adversely	affecting	other	cell	types	In	our	study,	TCD	transplants	receive	an	infusion	of	either	Alemtuzumab	or	anti-thymocyte	 globulin	 (ATG)	 as	 part	 of	 transplant	 conditioning,	 both	 of	which	can	 adversely	 affect	natural	 killer	 cells	 in	 addition	 to	 the	planned	depletion	of	T	cells.	The	use	of	ATG	following	kidney/pancreas	transplantation	results	in	a	rapid	depletion	of	NK	cells	and	treatment	of	NK	cells	with	ATG	and	alemtuzumab	in	vitro	leads	to	impairment	in	cytotoxicity	and	induction	of	apoptosis	(Stauch	et	al.,	2009).	Alemtuzumab	is	a	monoclonal	antibody	that	is	targeted	to	CD52	expressed	on	the	cell	surface	of	lymphocytes	leading	to	cytolysis.	CD52	is	expressed	at	low	levels	on	
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NK	cells	in	comparison	to	B	and	T	cells	and	this	is	reflected	by	the	observation	that	NK	cells	are	relatively	spared	from	alemtuzumab	mediated	cytolysis	compared	to	the	 adaptive	 immune	 cells	 (Rao	 et	 al.,	 2012).	 It	 should	 be	 considered	 that	 the	observed	 differences	 in	 NK	 cell	 subset	 reconstitution	 after	 TCD	may	 be	 a	 direct	result	 of	 alemtuzumab/ATG	 activity	 against	 specific	 NK	 cell	 subsets.	 However,	CD52	 expression	 is	 not	 statistically	 different	 between	 CD16-	 (predominantly	CD56bright)	 and	CD16+	 (mostly	CD56dim)	NK	cells	 (Rao	et	al.,	 2012).	Although	 this	observation	 renders	 this	 theory	 less	 likely,	 6	 month	 follow	 up	 of	 patients	 who	received	 alemtuzumab	 as	 treatment	 for	 multiple	 sclerosis	 observed	 significant	expansion	of	 the	CD56bright	NK	 cell	 susbset,	 indicating	 that	 alemtuzumab	may	be	responsible	for	long	term	remodeling	of	the	innate	immune	compartment	(Gross	et	
al.,	2016)	in	ways	that	cannot	simply	be	explained	by	the	cell	surface	expression	of	CD52.			Our	 results	 demonstrate	 contrasting	 patterns	 of	 very	 early	NK	 cell	 development		following	 allo-SCT	 between	 TR	 and	 TCD	 transplants.	 	 Although	 NK	 cell	development	was	first	observed	to	occur	in	the	bone	marrow,	the	last	decade	has	demonstrated	 that	 crucial	 steps	 in	 NK	 cell	 development	 can	 occur	 in	 multiple	extramedullary	 sites	 including	 the	 liver,	 gravid	 uterus	 and	 also	 secondary	lymphoid	 tissues	 such	 as	 tonsils	 and	 lymph	 nodes	 (Freud	 et	 al	 2014).	 At	 these	sites,	there	is	an	enrichment	of	NK	cell	developmental	intermediates	(NKDI),	which	range	from	an	oligopotent	CD34+CD45RA+	haematopoietic	precursor	cell	(HPC)	to	a	 mature	 NK	 cell	 with	 cytolytic	 potential.	 In	 particular,	 a	 novel	CD34dimCD45RA+β7bright	 	HPC	has	been	 identified	that	makes	up	>95%	of	HPCs	 in	
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the	 lymph	 node	 but	 <1%	 of	 bone	 marrow	 HPCs.	 Crucially,	 when	 stimulated	 by	endogenous	 cytokines	 (IL-15	 or	 IL-2)	 or	 activated	 lymph	 node	 T	 cells,	 these	 LN	HPCs	become	CD56bright	NK	cells	(Freud	et	al.,	2005).	The	importance	of	T	cells	in	this	 extramedullary	 NK	 cell	 development	 has	 been	 confirmed	 in	murine	models	where	 CD4+	 T	 cells	 have	 been	 shown	 to	 provide	 IL-2	 required	 for	 expansion	 of	immature	 CD127+	 NK	 cells	 (Gasteiger	 et	 al.,	 2013)	 and	 may	 characterize	 the	mechanism	behind	the	CD56bright	NK	cell	expansion	in	our	TR	patient	cohort.		During	 a	 TR	 transplant,	 the	 adoptively	 transferred	 T	 cells	 interact	 with	 novel	minor	histocompatibility	antigens	(mHAgs)	expressed	on	recipient	cells	and	go	on	to	develop	the	alloreactive	immune	response	that	determines	both	the	graft	versus	leukaemia	 (GVL)	 effect	 and	acute	 graft	 versus	host	disease	 (GVHD).	 For	 antigen-driven	proliferation	to	occur,	T	cells	require	TCR/MHC	interactions,	co-stimulation	and	 pro-inflammatory	 cytokines.	 The	 latter	 two	 factors	 are	 also	 vital	 in	 NK	 cell	development	 and	 homeostatic	 proliferation	 and	 it	 is	 possible	 that	 the	 lack	 of	competition	 for	 these	 signals	 in	TCD	and	umbilical	 cord	 transplant	 enables	 their	reconstituting	NK	 cells	 to	 differentiate	 into	 the	more	mature	 CD56dim	NK	 cell.	 It	must	also	be	considered	that	the	lack	of	mature	T	cells	competing	for	cytokines	in	TCD	 and	 umbilical	 cord	 transplants	 may	 specifically	 induce	 proliferation	 within	the	CD56dim	NK	cell	population.		Of	 note,	 umbilical	 cord	 transplants	 display	 a	 similar	 pattern	 of	 CD56bright	 and	CD56dim	reconstitution	to	TCD	transplants	but	do	not	receive	either	Alemtuzumab	
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or	ATG,	suggesting	that	it	is	the	presence	of	antigen	experienced	T	cells	rather	than	naïve	T	cells	that	has	an	impact	on	NK	reconstitution.	
3.13.3	Conclusion	This	 study	 highlights	 important	 differences	 in	 very	 early	 immune	 reconstitution	between	T	cell	depleted	(TCD),	T	cell	replete	(TR)	and	umbilical	cord	allo-SCT.	As	expected,	 TR	 transplants	 and	 umbilical	 cord	 transplants	 reconstitute	 higher	absolute	numbers	of	 circulating	T	 cells	 compared	 to	TCD	 transplants	 at	 both	D7	and	D14.		Although	there	is	no	significant	difference	in	the	absolute	number	of	NK	cells	 at	 day	 7	 and	 14	 between	 the	 three	 transplant	 types,	 there	 are	 interesting	differences	 in	 the	 proportions	 of	 NK	 cell	 subsets	 that	make	 up	 the	 total	 NK	 cell	pool.	Figure	3.17	illustrates	the	relative	numbers	of	T	cells,	CD56bright	and	CD56dim	NK	 cells	 at	 days	 7	 and	14	demonstrating	 the	 expansion	 of	 the	 CD56bright	NK	 cell	population	in	the	T	cell	replete	transplants	between	days	7	and	14	not	seen	in	TCD	stem	cell	transplants.			We	 hypothesise	 that	 the	 presence	 of	 T	 cells	 in	 TR	 transplants	 encourages	development	of	CD56bright	NK	cells	from	lymph	node	HPCs	and	may	also	compete	for	essential	cytokine	and	co-stimulation	signals	necessary	for	NK	cell	maturation	so	 that	 adoptively	 transferred	 NK	 cells	 do	 not	 develop	 into	 a	 more	 mature	phenotype.						
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CHAPTER	4:	HIGHER	NUMBERS	OF	D14-NK	CELLS	IS	ASSOCIATED	
WITH	IMPROVED	PATIENT	OUTCOME	
4.1	Introduction	Studies	have	shown	that	high	NK	cell	number	at	day	30-60	after	transplantation	is	associated	with	a	 reduced	 rate	of	disease	 relapse	and	 improved	survival.	Robust	NK	cell	reconstitution	can	also	predict	for	a	 lower	risk	of	acute	GVHD	(Dunbar	et	
al.,	2008)(B	N	Savani	et	al.,	2007)(Kim	et	al.,	2016)(Ruggeri	et	al.,	2002)(Ullrich	et	
al.,	2016)(Soiffer	et	al.,	1993)(Pical-izard	et	al.,	2015)(Huttunen	et	al.,	2015).	These	studies	have	measured	NK	cell	reconstitution	at	day	30	following	transplant,	or	at	later	time	points.	However,	there	is	evidence	that	the	alloreactive	T	cell	response	is	generated	 in	 the	 first	 few	 weeks	 following	 stem	 cell	 transplant.	 This	 has	 been	demonstrated	 elegantly	 by	 the	 marked	 reduction	 in	 the	 risk	 of	 acute	 GVHD	 in	patients	 who	 receive	 cyclophosphamide	 at	 day	 3-4	 after	 adult	 haploidentical	 or	unrelated	 donor	 allo-SCT.	 Cyclophosphamide	 selectively	 depletes	 donor	 T	 cells	that	 are	 proliferating	 in	 response	 to	 alloantigens	 and	 the	 success	 of	 this	intervention	 indicates	 that	 the	 priming	 of	 alloreactive	 T	 cells	must	 occur	 in	 the	very	 early	 period	 following	 infusion	 of	 donor	 cells	 (Luznik	 and	 Fuchs,	2010)(Luznik	et	al.,	2008)(Castagna	et	al.,	2014).				Furthermore,	 the	 clinical	 studies	 demonstrating	 associations	 between	 NK	 cell	reconstitution	and	patient	outcome	have	been	heterogenous	in	terms	of	stem	cell	source	and	the	presence	of	T	cells	within	the	graft.	Many	studies	have	used	mixed	
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cohorts	of	patients,	who	may	or	may	not	have	received	T	cell	depletion(Dunbar	et	
al.,	 2008)(Huttunen	 et	al.,	 2015)(Ullrich	 et	al.,	 2016),	whilst	 others	 have	 infused	stem	cells	depleted	of	CD6(Soiffer	et	al.,	1993).	Others	have	used	stem	cell	sources	that	are	negatively	selected	for	T	cells	and	then	received	T	cell	add	back(B	N	Savani	
et	 al.,	 2007),	 or	 have	 used	 stem	 cells	 from	 haploidentical	 donors(Ruggeri	 et	 al.,	2002).			We	 have	 observed	 clear	 differences	 in	 NK	 cell	 reconstitution	 between	 patients	receiving	TCD,	TR	and	umbilical	cord	stem	cell	transplants,	and	so	wished	to	assess	the	effect	of	NK	cell	reconstitution	on	clinical	outcome	in	a	group	of	patients	who	had	all	 received	the	same	type	of	stem	cell	 transplant.	 	We	believe	 that	 the	early	period	 following	 allo-SCT	 (i.e.	 before	 day	 14),	 is	 critical	 in	 developing	 the	allogeneic	T	cell	response	that	mediates	both	GVHD	and	GVL,	and	so	focused	our	assessment	 on	 whether	 reconstitution	 at	 earlier	 time	 points	 could	 also	 be	informative	 in	 predicting	 clinical	 outcome.	 This	 part	 of	 the	 research	 study	 was	carried	out	on	 the	 cohort	of	82	patients	who	 received	TCD	allo-SCT	as	 the	 small	numbers	 of	 TR	 and	 umbilical	 cord	 stem	 cell	 transplants	 in	 our	 cohort	 was	insufficient	for	further	subanalysis.		
4.2	Methods	Receiver	 operating	 characteristic	 curves	were	plotted	 to	 assess	 the	 ability	 of	NK	cell	and	NK	cell	subset	reconstitution	at	varying	time	points	following	allo-SCT,	to	predict	the	clinical	end-points	of	overall	survival	and	acute	GVHD.		To	assess	D14-NK	cell	count	as	a	predictor	for	the	time-to-event	outcomes,	a	landmark	approach	
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was	 used,	 with	 the	 time	 defined	 as	 from	 day	 14	 to	 the	 event	 of	 interest.	 The	statistical	 significance	 of	 NK	 cell	 number	 and	 other	 patient/transplant	characteristics	 in	 determining	 overall	 survival	 was	 assessed	 using	 the	 Kaplan-Meier	method	and	 tested	using	 the	 log-rank	 test.	Multivariate	 analysis	 of	 factors	influencing	 OS	 was	 carried	 out	 using	 the	 Cox	 proportional	 hazards	 model.	Cumulative	 incidence	 was	 used	 to	 estimate	 the	 probability	 of	 acute	 GVHD	 and	chronic	 GVHD	 with	 death	 from	 any	 cause	 defined	 as	 the	 competing	 risk.	 The	multivariate	 adjustment	 for	 factors	 predicting	 the	 cumulative	 incidence	 of	 acute	GVHD	was	performed	within	the	framework	of	competing	risks	using	the	Fine	and	Gray	method.	A	competing	risk	approach	was	also	taken	in	assessing	the	effect	on	TRM	(using	RM	as	the	competing	event)	and	RR/	RM	(using	TRM	as	the	competing	event).			Detailed	 methods	 for	 the	 analysis	 in	 this	 results	 chapter	 are	 described	 in	 the	materials	and	methods	section	2.3.			
4.3	Patient	characteristics	and	treatments		Clinical	 characteristics	 and	 transplant	 details	 for	 82	 patients	 in	 the	 study	 are	summarised	in	Table	4.1	and	4.2	respectively.	The	median	follow	up	time	for	the	patient	cohort	was	1.8	years	(95%	CI	1.67-1.97	years).	The	median	age	was	52.5	(range	 17-71)	 years	 and	 63%	 of	 patients	 were	 male.	 52%	 of	 patients	 received	allogeneic	stem	cell	transplantation	(allo-SCT)	for	acute	myeloid	leukaemia	(AML)	or	 myelodysplastic	 syndrome	 (MDS),	 16%	 for	 non-Hodgkin’s	 lymphoma	 (NHL)	and	15%	 for	 acute	 lymphoblastic	 leukaemia	 (ALL).	The	 remaining	patients	were	
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treated	 for	aplastic	anaemia	(AA)(4%),	myelofibrosis	 (4%),	Hodgkin’s	 lymphoma	(HL)(4%),	 chronic	 lymphocytic	 leukaemia	 (CLL)(2%)	 and	 myeloproliferative	disease	(MPD)(2%).		The	choice	of	conditioning	regimen	for	each	patient	depended	on	patient	age,	co-morbidities	 and	 disease	 under	 treatment.	 87%	 of	 patients	 received	 a	 reduced	intensity	 transplant.	 59%	 received	 a	 fludarabine-melphalan-Campath	 (FMC)	conditioned	allo-SCT	most	often	given	for	older	patients	with	AML/MDS.	Younger	patients,	 with	 less	 co-morbidity,	 were	 assigned	 cyclophosphamide-TBI	myeloablative	 conditioning	 (13%)	whilst	 FLAMSA-busulphan	 (9%)	was	 given	 to	patients	with	residual	disease	at	allo-SCT.		The	remaining	patients	with	low-grade	lymphomas,	lymphoproliferative/	myeloproliferative	conditions	and	bone	marrow	failure	 syndromes	 were	 treated	 with	 fludarabine-BEAM-Campath	 (6%),	 BEAM-Campath	(5%),	fludarabine-cyclophosphamide	(5%)	and	other	(4%)	regimens.			32%	of	patients	 received	HLA-identical	 transplants	 from	siblings.	The	 remaining	68%	received	transplants	from	unrelated	donors	of	which	42	were	fully	matched	(at	HLA-A,	 -B,	 -C,	 -DRB1	and	–DQB1),	and	14	had	1	or	more	allelic	mismatch.	All	haemopoietic	stem	cells	were	derived	from	peripheral	blood.	All	patients	received	T	 cell	 depletion	 (13%	 with	 ATG,	 87%	 with	 Campath)	 and	 ciclosporin	 as	 GVHD	prophylaxis.	Methotrexate	(17%)	was	added	for	those	patients	who	received	HLA	non-identical,	myeloablative	 transplants	 and	 those	 felt	 to	be	 at	 particular	 risk	of	GVHD.		
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Patient	details	 	 Number	 %	Age	at	transplant	 Median	years	(range)		(IQR)	 52.5	(17-71)		(44-61)	Sex	 Male	Female	 52	30	 63.4	36.6	Diagnosis	 AML/MDS	NHL	ALL	AA	MF	HL	CLL	MPD	
43	13	12	4	3	3	2	2	
52.4	15.9	14.6	4.9	3.7	3.7	2.4	2.4	Sorror	Score		 0	≥1	 63	19	 76.8	23.2	Disease	Risk	Index			 Low		Intermediate	High	Very	High	
14	36	29	3	
17.1	43.9	35.4	3.7	
Table	4.1	Patient	characteristics	
AML,	 acute	 myeloid	 leukaemia;	 MDS,	 myelodysplastic	 syndrome;	 NHL,	 non-Hodgkin’s	
lymphoma;	 ALL,	 acute	 lymphoblastic	 leukaemia;	 AA,	 aplastic	 anaemia;	 MF,	 myelofibrosis;	
HL,	 Hodgkin’s	 lymphoma;	 CLL,	 chronic	 lymphocytic	 leukaemia;	 MPD,	 myeloproliferative	
disease.	
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Transplant	details	 Number	 %	Intensity		 Reduced	intensity	Myeloablative	 71	11	 86.6	13.4	Conditioning	regimen	 FMC	Cy-TBI	FLAMSA/Bu	Flu/BEAM/Campath	BEAM/Campath	Flu/Cy	Other	(Cy/TBI/Flu/Campath,	Cy/Campath,,Flu/Bu/ATG)	
48	11	7	5	4	4	3	
58.5	13.4	8.5	6.1	4.9	4.9	3.7	CMV	at	risk	 Yes	 67	 81.7	MF	mismatch	 Yes	 20	 24.4	Donor		 Unrelated	Sibling	 56	26	 68.3	31.7	HLA	mismatch		 None	One	or	more	 68	14	 82.9	17.1	Stem	cell	source	 PBSC	 82	 100	
	
GVHD	prophylaxis	T	cell	depletion	 ATG	Alemtuzumab	 11	71	 13.4	86.6	Methotrexate		 Yes	 14	 17.1	Ciclosporin	 Yes	 82	 100	
	
Table	4.2.	Transplant	characteristics	and	GVHD	prophylaxis.	
FMC,	 fludarabine-melphalan-Campath;	 Cy,	 cyclophosphamide;	 TBI,	 total	 body	 irradiation;	
FLAMSA,	 fludarabine-cytarabine-amsacrine;	 Bu,	 busulphan;	 Flu,	 fludarabine;	 BEAM,	
carmustine,	 cytarabine,	 etoposide,	 melphalan;	 ATG,	 anti-thymocyte	 globulin;	 CMV,	
cytomegalovirus;	 MF	 mismatch,	 male	 female	 mismatch;	 HLA,	 human	 leukocyte	 antigen;	
PBSC,	 peripheral	 blood	 stem	 cell.	 A	 patient	 is	 deemed	 CMV	 at	 risk	 if	 either	 they	 or	 their	
transplant	donor	is	CMV	seropositive.		 	
Chapter 4: Higher D14-NK cell count is associated with improved patient outcome 
	114	
4.4	Transplant	outcomes	The	cumulative	incidence	of	grade	II-IV	acute	GVHD	at	100	days	was	25%	and	29%	for	 chronic	 GVHD	 at	 3	 years.	 At	 3	 years,	 the	 cumulative	 incidence	 of	 relapse,	relapse	mortality	 (RM)	 and	 transplant	 related	mortality	 (TRM)	was	 30%,	 22.5%	and	19.5%	respectively.	The	overall	survival	at	3	years	was	53%	(Table	4.3).			 Cumulative	Incidence	or	Overall	
Survival		(95%	CI)	Grade	II-IV	acute	GVHD	at	100	days	 24.6%	(15.8-34.5%)	Chronic	GVHD	at	3	year	 29.2%	(19.5-39.6%)	TRM	at	3	years	 19.5%	(11.4-29.2%)	Relapse	at	3	years	 29.8%	(19.8-40.3%)	Relapse	mortality	at	3	years	 22.5%	(13.2-33.4%)	Survival	at	3	years	 53.0%	(38.5-73.0%)	
Table	4.3	Transplant	outcomes	
	
4.5	Very	early	NK	cell	reconstitution	predicts	overall	survival	The	 allogeneic	T	 cell	 response	 responsible	 for	 graft	 versus	 leukaemia	 (GVL)	 and	graft	 versus	host	 disease	 (GVHD)	develops	within	 the	 first	 few	days-weeks	 after	allo-SCT	 (Luznik	 and	 Fuchs,	 2010).	 Our	 patient	 cohort	 illustrates	 a	 remarkable	situation	 where	 the	 reconstituting	 immune	 system	 is	 skewed	 to	 a	 200-fold	increase	in	NK:T	cell	ratio	in	the	first	2	weeks.	We	hypothesise	that	in	this	unique	circumstance	 we	 can	 observe	 how	 the	 NK	 cell	 population	 modulates	 the	developing	allogeneic	T	cell	response	and	subsequently	patient	outcome.		
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Receiver	 operating	 characteristic	 (ROC)	 curves	 are	 a	 statistical	method	 that	 can	assess	 the	 accuracy	 of	 a	 test,	 with	 a	 continuous	 spectrum	 of	 test	 results,	 in	determining	a	binary	outcome.	 It	 is	a	graphical	plot	of	 the	test	sensitivity	against	(1-specificity)	 of	 all	 possible	 binary	 tests	 that	 are	 possible	 using	 this	 continuous	biomarker,	 so	 that	 each	 cut-off	 level	 corresponds	 to	 a	point	 on	 the	 graph.	A	 test	that	has	perfect	discrimination	between	the	two	populations	will	closely	follow	the	left-hand	 border	 and	 will	 have	 an	 area	 under	 the	 curve	 (AUC)	 of	 1.	 A	 test	 that	follows	the	45°	diagonal	of	the	ROC	plot	will	have	no	predictive	ability	and	an	AUC	of	0.5.	 	The	AUC	 is	 therefore,	a	measure	of	 the	overall	diagnostic	accuracy	of	 the	test,	and	along	with	the	ROC	curve,	can	be	used	to	identify	the	cut-off	value	for	the	test,	which	has	the	best	sensitivity	and	specificity.		Overall	 survival	 is	 an	 important	 patient	 outcome	 that	 determines	 the	 success	 of	any	 clinical	 intervention,	 including	 stem	 cell	 transplantation.	 Receiver	 operating	curve	analysis	found	that	the	absolute	D14-NK	cell	count	was	predictive	of	overall	survival	 at	 1	 year	 (Figure	 4.3).	 Furthermore,	 some	 NK	 cell	 subsets	 at	 day	 14	(CD56bright,	CD56dim,	NKG2A+	and	NKG2C+)	and	day	7	(CD56bright	and	NKG2A+)	were	also	predictive	of	overall	survival	(Table	4.4).		Interestingly,	absolute	NK	cell	count	and	 absolute	 NK	 cell	 subset	 number	 at	 D28	 and	 D100	 were	 not	 predictive	 of	overall	 survival.	 This	 may	 reflect	 the	 smaller	 numbers	 of	 patients	 with	 data	available	 at	 D28	 and	 D100	 and	 does	 not	 necessarily	 indicate	 that	 NK	 cell	reconstitution	 at	 these	 time	 points	 is	 less	 important	 in	 determining	 patient	outcome.			
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D7	 Area	 Standard	error	 Asymptotic	
significance	
Asymptotic	
95%	CI	total	NK	 0.630	 0.067	 0.054	 0.499-0.761	
CD56bright	 0.647	 0.065	 0.029	 0.520-0.774	CD56dim	 0.626	 0.067	 0.062	 0.495-0.757	
NKG2A	 0.659	 0.066	 0.018	 0.530-0.788	NKG2C	 0.616	 0.067	 0.086	 0.485-0.747	CD57	 0.616	 0.068	 0.086	 0.483-0.748	KIR	 0.626	 0.068	 0.062	 0.494-0.758	CD16	 0.621	 0.078	 0.114	 0.469-0.774		
D14	 Area	 Standard	error	 Asymptotic	
significance	
Asymptotic	
95%	CI	
total	NK	 0.658	 0.065	 0.017	 0.530-0.787	
CD56bright	 0.643	 0.064	 0.031	 0.517-0.769	
CD56dim	 0.660	 0.066	 0.015	 0.532-0.789	
NKG2A	 0.670	 0.065	 0.010	 0.543-0.796	
NKG2C	 0.631	 0.068	 0.047	 0.498-0.765	CD57	 0.626	 0.068	 0.058	 0.492-0.759	KIR	 0.631	 0.069	 0.050	 0.496-0.766	CD16	 0.623	 0.076	 0.098	 0.473-0.773		
D28	 Area	 Standard	error	 Asymptotic	
significance	
Asymptotic	
95%	CI	total	NK	 0.552	 0.135	 0.700	 0.288-0.816	CD56bright	 0.438	 0.138	 0.643	 0.167-0.708	CD56dim	 0.635	 0.127	 0.316	 0.386-0.885	NKG2A	 0.500	 0.137	 1.000	 0.232-0.768	NKG2C	 0.667	 0.134	 0.217	 0.404-0.930	CD57	 0.646	 0.131	 0.280	 0.389-0.903	KIR	 0.573	 0.138	 0.589	 0.302-0.844	CD16	 0.519	 0.199	 0.926	 0.128-0.909		
D100	 Area	 Standard	error	 Asymptotic	
significance	
Asymptotic	
95%	CI	total	NK	 0.511	 0.147	 0.941	 0.223-0.799	CD56bright	 0.422	 0.163	 0.602	 0.103-0.742	CD56dim	 0.578	 0.157	 0.602	 0.270-0.885	NKG2A	 0.422	 0.155	 0.602	 0.119-0.725	NKG2C	 0.600	 0.138	 0.502	 0.329-0.871	CD57	 0.711	 0.144	 0.157	 0.428-0.994	KIR	 0.767	 0.155	 0.074	 0.463-1.000	CD16	 0.500	 0.150	 1.000	 0.205-0.795	
Table	4.4.	ROC	curve	analysis	for	absolute	NK	cell	number	and	NK	cell	subset	number	
in	relation	to	overall	survival	(OS)	
This	 table	 lists	 the	 ROC	 curve	 analysis	 that	was	 performed	 to	 assess	whether	 the	 absolute	
number	of	NK	cells	 in	NK	cell	 subsets	could	predict	OS.	Those	values	 that	were	statistically	
significant	are	highlighted	in	bold.			
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4.6	Choosing	the	optimum	D14-NK	cell	count	to	determine	overall	survival	In	 the	 previous	 section,	 ROC	 curve	 analysis	 determined	 that	 Day	 14	 NK	 cell	number	may	 be	 an	 important	 biomarker	 in	 predicting	 overall	 survival	 following	TCD	allo-SCT.	A	test	cut-off	of	5	NK	cells/µl	was	chosen	as	it	corresponded	with	a	test	sensitivity	of	48%,	specificity	of	78%,	PPV	of	58%	and	NPV	of	71%.			Choosing	 a	 higher	 NK	 cell	 cut	 off	 e.g.	 25	 NK	 cells/µl	 provides	 an	 improved	sensitivity	 (74%)	 with	 a	 corresponding	 reduction	 in	 specificity	 (43%).	 This	actually	 led	 to	 a	 reduction	 in	 the	 PPV	 of	 44%	whilst	 the	NPV	 remained	 broadly	similar	at	73%.	Reducing	the	NK	cell	cut	off	to	1	NK	cell/µl	led	to	a	reduction	in	the	sensitivity	(26%)	with	an	improved	specificity	(92%).	The	PPV	and	NPV	of	the	test	were	both	67%	(See	Table	4.5).			A	value	of	D14-NK	<5	cells/µl	was	chosen	as	the	optimum	cut	off	 for	 the	prediction	of	OS	as	 it	provided	a	useful	balance	between	sensitivity	and	specificity.		
D14-NK	cell	cut	off	 <1	cell/µ l	 <5	cells/µ l	 <25	cells/µ l	
Sensitivity	in	
determining	OS	
26%	 48%	 74%	
Specificity	in	
determining	OS	
92%	 78%	 43%	
PPV	 67%	 58%	 44%	
NPV	 67%	 71%	 73%	
Table	 4.5	 Determining	 the	 optimum	 D14-NK	 cell	 cut	 off	 as	 a	 biomarker	 for	 overall	
survival		
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4.7	 D14-NK	 <5	 cells/µl	 is	 an	 independent	 predictor	 of	 OS	 in	 multivariate	
analyses	Patient	 and	 transplant	 characteristics	 are	 important	 in	 influencing	 OS	 following	allo-SCT.	 It	 is	 important	 to	study	the	relative	 importance	of	D14-NK	cell	count	 in	determining	 OS,	 whilst	 also	 taking	 into	 account	 the	 many	 other	 factors	 that	contribute	 to	 this	 clinical	 end-point.	 The	 first	 step	 in	 this	 process	 is	 univariate	analysis,	 which	 assesses	 whether	 each	 factor	 has	 an	 influence	 on	 OS	 without	considering	other	factors.			The	 effect	 of	 patient	 age,	 patient	 sex,	 haematological	 diagnosis,	 Sorror	 score,	Disease	 Risk	 Index,	 conditioning	 intensity,	 CMV	 risk	 status,	 male	 to	 female	mismatch,	donor	type,	presence	of	T	cell	depletion,	HLA	mismatch	and	D14-NK	cell	count	 in	 influencing	 overall	 survival	 were	 all	 assessed	 using	 the	 log-rank	 test	(Table	4.6).	 	D14-NK	<5	cells/µl	 and	myeloablative	conditioning	are	significantly	associated	with	a	worse	overall	 survival	on	univariate	analysis	 (HR	2.51,	95%	CI	1.25-5.04,	p=0.0098	and	HR	3.37,	95%	CI	1.43-7.93,	p=0.0055	respectively).		A	multivariate	model	was	then	constructed	using	the	factors	found	to	be	significant	on	univariate	analysis.	By	assessing	these	factors	 in	combination,	 it	 is	possible	to	assess	the	‘net’	effect	of	each	variable	and	also	to	control	for	confounding	that	may	occur.	The	Cox	proportional	hazards	model	was	used	and	we	found	that	the	both	D14-NK	<5	cells/µl	 and	conditioning	 intensity	 remain	significant	on	multivariate	analysis	 (HR	 2.16,	 95%	 CI	 1.06-4.41,	 p=0.034	 and	 HR	 2.69,	 95%	 CI	 1.25-5.04,	
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	 	 HR	 95%	CI	 P-value	
Univariate	analysis	 	 	 	Age				 <50	
≥50	 1	0.74	 	0.37-1.49	 	0.4	Sex	 Male	Female	 1	1.39	 	0.67-2.87	 	0.37	Diagnosis	 myeloid	lymphoid	marrow	failure	 1	1.31	**	 	0.63-2.87	**	 	0.47	**	Sorror	score	 0	≥1	 1	1.47	 	0.70-3.08	 	0.3	DRI	 low-int	high-v	high	 1	1.99	 	0.99-4.02	 	0.055	Intensity	 RIC	MA	 1	3.37	 	1.43-7.93	 	0.0055	CMV	at	risk	 Yes	No	 1.91	1	 0.65-5.63	 0.24	MF	mm	 Yes	No	 0.77	1	 0.34-1.76	 0.54	Donor	 Unrelated	Sibling	 1.45	1	 0.65-3.25	 0.37	TCD	 Campath	ATG	 1	1.03	 	0.35-3.07	 	0.96	HLAmm	 0	
≥1	 1	0.75	 	0.32-1.78	 	0.58	D14-NK	 <25	
≥25		<5	
≥5	
1.57	1		2.51	1	
0.70-3.53			1.25-5.04	
0.28	
	
	
0.0098	
Multivariate	analysis	Intensity	 RIC	MA	 1	2.69	 	1.18-6.09	 	0.018	D14-NK	 <5	
≥5	 2.16	1	 1.06-4.41	 0.034	
	
Table	4.6	Univariate	and	multivariate	analysis	of	factors	predicting	overall	survival		
Statistical	 significance	 was	 evaluated	 using	 the	 univariate	 log-rank	 method.	 Multivariate	
analyses	were	performed	using	 the	Cox	proportional-hazards	model.	A	 landmark	approach	
was	required	with	time	from	day	14	to	death	or	censoring	used	for	analysis.			 	
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4.8	The	survival	advantage	conferred	by	high	D14-NK	cell	count	 is	due	to	a	
reduction	in	transplant	related	mortality		Section	 4.6	 has	 identified	 that	 an	 absolute	 D14-NK	 cell	 count	 >	 5	 cells/µl	 is	independently	 associated	 with	 a	 significant	 survival	 advantage	 for	 patients	undergoing	a	T	cell	depleted	stem	cell	transplant.	Disease	relapse	is	an	important	cause	of	mortality	following	allo-SCT.	However,	it	is	also	important	to	consider	that	transplant	is	an	extremely	toxic	treatment	and	transplant	related	mortality	(TRM)	can	 sometimes	 exceed	 relapse	 mortality.	 The	 main	 causes	 of	 transplant	 related	mortality	 are	 death	 from	 graft	 versus	 host	 disease	 or	 death	 from	 infectious	complications.			We	went	on	to	investigate	whether	an	improvement	in	a	specific	cause	of	mortality	contributed	to	the	improved	survival	seen	in	patients	who	had	D14-NK	cell	counts	>5	 cells/µl.	 Interestingly,	 patients	 with	 D14-NK	 cell	 counts	 of	 either	 <5	 or	 >5	cells/µl	 did	 not	 demonstrate	 any	 difference	 in	 relapse	 risk	 or	 relapse	mortality	(p=0.34	and	p=0.58	respectively)(Figure	4.5(A+B)),	even	though	it	 is	well	known	that	 NK	 cells	 are	 important	 anti-tumour	 immune	 cells.	 Instead,	 cumulative	incidence	graphs	illustrating	these	clinical	end-points	shows	that	a	higher	D14-NK	cell	number	is	significantly	associated	with	an	improvement	in	transplant	related	mortality	(p=0.014)(Figure	4.5(C)).		 	
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acute	GVHD.	We	defined	cases	of	acute	GVHD	as	those	of	grade	2	or	above,	as	these	cases	 are	 clinically	 relevant	 and	 require	 systemic	 immunosuppression,	 whilst	grade	1	 is	 typically	 treated	with	 topical	 corticosteroids.	The	 clinical	 grading	was	determined	 prospectively	 by	 myself	 from	 clinical	 notes,	 histological	 reports	and/or	discussion	with	the	treating	clinician(s).	The	diagnosis	of	acute	GVHD	was	assigned	if	there	was	histological	evidence	of	GVHD	on	biopsy	specimens	and/or	if	there	evidence	of	clinical	improvement	in	symptoms	with	GVHD	treatment.			ROC	curve	analysis	(Fig.	4.6)	 identified	that	the	absolute	NK	cell	count	at	D7	and	D14	could	discriminate	the	risk	of	acute	GVHD	with	an	AUC	0.683	(p<0.05;	95%	CI	0.541-0.824)	and	0.657	 (p<0.05;	95%	CI	0.513-0.801)	 respectively.	The	absolute	cell	 count	 of	 many	 NK	 cell	 subsets	 at	 these	 early	 time	 points	 (D7:	 CD56bright,	CD56dim,	 NKG2A+,	 NKG2C+,	 KIR+,	 CD57+	 and	 CD16+;	 D14:	 CD56dim,	 NKG2A+	 and	NKG2C+)(Table	 4.7)	 was	 also	 predictive	 but	 no	 single	 subset	 was	 uniquely	associated.	In	contrast,	absolute	NK	cell	number	and	NK	subset	cell	number	at	the	later	 time	 points	 did	 not	 show	 any	 association	 with	 the	 development	 of	 acute	GVHD.	 However,	 the	 small	 number	 of	 patients	with	 data	 available	 at	 these	 time	points	means	it	is	difficult	to	be	certain	whether	this	is	a	true	effect	or	due	to	the	differences	in	sample	size.			
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D7	 Area	 Standard	
error	
Asymptotic	
significance	
Asymptotic	
95%	CI	
total	NK	 0.683	 0.072	 0.021	 0.541-0.824	
CD56bright	 0.673	 0.072	 0.029	 0.531-0.815	
CD56dim	 0.678	 0.073	 0.024	 0.535-0.822	
NKG2A	 0.696	 0.073	 0.013	 0.553-0.839	
NKG2C	 0.659	 0.069	 0.045	 0.523-0.794	
CD57	 0.708	 0.068	 0.009	 0.574-0.841	
KIR	 0.694	 0.072	 0.014	 0.553-0.836	
CD16	 0.678	 0.080	 0.042	 0.522-0.834		
D14	 Area	 Standard	
error	
Asymptotic	
significance	
Asymptotic	
95%	CI	
total	NK	 0.657	 0.073	 0.035	 0.513-0.801	CD56bright	 0.635	 0.069	 0.07	 0.5-0.771	
CD56dim	 0.664	 0.074	 0.028	 0.518-0.809	
NKG2A	 0.667	 0.069	 0.025	 0.532-0.801	
NKG2C	 0.655	 0.072	 0.038	 0.514-0.796	CD57	 0.610	 0.075	 0.139	 0.464-0.757	KIR	 0.638	 0.078	 0.069	 0.486-0.790	CD16	 0.647	 0.088	 0.085	 0.474-0.820		
D28	 Area	 Standard	
error	
Asymptotic	
significance	
Asymptotic	
95%	CI	total	NK	 0.507	 0.163	 0.965	 0.188-0.825	CD56bright	 0.573	 0.163	 0.631	 0.253-0.894	CD56dim	 0.480	 0.146	 0.896	 0.194-0.766	NKG2A	 0.547	 0.161	 0.760	 0.232-0.862	NKG2C	 0.440	 0.157	 0.694	 0.132-0.748	CD57	 0.480	 0.151	 0.896	 0.184-0.776	KIR	 0.480	 0.165	 0.896	 0.158-0.802	CD16	 0.593	 0.197	 0.644	 0.207-0.978		
D100	 Area	 Standard	
error	
Asymptotic	
significance	
Asymptotic	
95%	CI	total	NK	 0.434	 0.153	 0.685	 0.135-0.734	CD56bright	 0.316	 0.142	 0.256	 0.037-0.595	CD56dim	 0.408	 0.159	 0.570	 0.096-0.720	NKG2A	 0.316	 0.127	 0.256	 0.067-0.565	NKG2C	 0.474	 0.181	 0.871	 0.119-0.828	CD57	 0.434	 0.162	 0.685	 0.116-0.752	KIR	 0.421	 0.160	 0.626	 0.108-0.734	CD16	 0.434	 0.166	 0.685	 0.108-0.760	
Table	4.7	ROC	curve	analysis	for	absolute	NK	cell	number	and	NK	cell	subset	number	
in	relation	to	the	risk	of	developing	acute	GVHD	(Grade	2+)	
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4.10	 Choosing	 the	 optimum	 D14-NK	 cell	 count	 to	 determine	 risk	 of	 acute	
GVHD	Having	determined	that	NK	cell	count	at	day	7	and	day	14	is	able	to	discriminate	the	risk	of	acute	GVHD	on	ROC	curve	analysis,	we	went	on	to	assess	what	test	cut	off	value	would	be	appropriate.	Previous	analysis	had	identified	D14-NK	cell	count	<5cells/µl	 is	 an	 independent	 predictor	 for	 reduced	 survival	 and	 so	we	 chose	 to	concentrate	on	the	D14-NK	cell	count	to	allow	comparison.			We	felt	that	it	was	important	to	use	a	cut	off	value	that	provided	a	high	sensitivity	in	 identifying	 patients	 at	 risk	 of	 acute	 GVHD	 so	 that,	 in	 clinical	 practice,	 these	patients	 could	 receive	 more	 intensive	 monitoring	 or	 additional	 acute	 GVHD	prophylaxis.	Table	4.8	shows	that	as	the	test	cut	off	increases	to	25	NK	cells/µl	the	sensitivity	increases	whilst	the	specificity	decreases.	We	chose	to	use	D14-NK	cell	cut	off	values	of	25	cells/µl	and	5	cells/µl	in	our	univariate	analysis.			
D14-NK	cell	cut	off	 <1	cell/µ l	 <5	cells/µ l	 <25	cells/µ l	
Sensitivity	 25%	 50%	 85%	
Specificity	 89%	 74%	 44%	
PPV	 42%	 38%	 33%	
NPV	 79%	 82%	 90%	
Table	4.8	Determining	the	optimum	D14-NK	cell	cut	off	as	a	biomarker	for	acute	GVHD	 	
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4.11	 D14-NK	 <25	 cells/µl	 is	 an	 independent	 predictor	 of	 acute	 GVHD	 in	
multivariate	analyses	To	 assess	 the	 prognostic	 utility	 of	 D14-NK	 cell	 number	 in	 evaluating	 the	 risk	 of	acute	 GVHD,	 the	 cumulative	 incidence	 of	 this	 outcome	was	 assessed	with	 death	from	any	cause	defined	as	a	competing	risk.	Two	cut-off	values	(5	cells/µl	and	25	cells/µl)	of	D14-NK	cell	number	were	compared.	A	landmark	approach	with	time	from	day	14	to	the	development	of	acute	GVHD	was	used	for	analysis.	D14-NK	<25	cells/µl	(HR	3.52,	95%	CI	1.02-12.1,	p=0.046),	D14-NK	<5	cells/µl	(HR	2.5,	95%	CI	1.05-5.92,	 p=0.038),	 HLA	 mm	 ≥1	 (HR	 4.41,	 95%	 CI	 1.81-10.7,	 p=0.0011)	 and	myeloablative	 conditioning	 (HR	 4.24,	 95%	 CI	 1.81-9.96,	 p=9.1x10-4)	 were	 all	statistically	significant	in	predicting	an	increased	risk	of	acute	GVHD	on	univariate	analysis.	(Table	4.9)			In	multivariate	 analysis	 D14-NK	 <25	 cells/µl	 (but	 not	 D14-NK	 <5	 cells/µl),	 HLA	mm	≥1	 and	myeloablative	 conditioning	 remained	 independently	 associated	with	an	 increased	 risk	 of	 acute	 GVHD	 (p=	 3.5x10-2,	 p=	 5.1x10-6	 and	 p=	 9.1x10-4	respectively)	 (Table	 4.10).	 	 Figure	 4.7	 demonstrates	 the	 reduction	 in	 the	cumulative	 incidence	 of	 acute	 GVHD	 in	 patients	 who	 reconstitute	 D14-NK	 >25	cells/µl.		 		 	
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Univariate	analysis	 HR	 95%	CI	 p-value	Age				 <50	
≥50	 1	0.496	 	0.208-1.18	 	0.11	Sex	 Male	Female	 1	0.976	 	0.392-2.43	 	0.96	Diagnosis	 myeloid	lymphoid	marrow	failure	 1	1.53	0.734	 	0.639-3.65	0.112-4.8	 	0.34	0.75	Sorror	score	 0	
≥1	 1	2.11	 	0.856-5.19	 	0.1	DRI	 low-int	high-v	high	 1	1.37	 	0.576-3.27	 	0.48	Intensity	 RIC	MA	 1	4.24	 	1.81-9.96	 	9.1x10-4	CMV	at	risk	 Yes	No	 0.888	1	 0.3-2.62	 0.83	MF	mm	 Yes	No	 1.79	1	 0.726-4.41	 0.21	Donor	 Unrelated	Sibling	 1.99	1	 0.676-5.86	 0.21	TCD	 Campath	ATG	 1	1.07	 	0.34-3.4	 	0.9	HLA	mm	 0	
≥1	 1	4.41	 	1.81-10.7	 	0.0011	D14-NK	 <25	
≥25		<5	
≥5	
3.52	1		2.5	1	
1.02-12.1			1.05-5.92	
0.046	
	
	
0.038	
Table	 4.9	 Univariate	 analysis	 of	 factors	 predicting	 development	 of	 acute	 GVHD	
(grades	2-4)	
The	 Fine	 and	 Gray	model	 for	 subdistributional	 hazard	 based	 on	 the	 cumulative	 incidence	
function	 was	 used	 with	 death	 as	 a	 competing	 risk	 for	 development	 of	 acute	 GVHD.	 	 A	
landmark	approach	was	required	with	time	from	day	14	to	development	of	acute	GVHD	used	
for	analysis.	DRI,	disease	risk	index;	RIC,	reduced	intensity	conditioning;	MA,	myeloablative;	
CMV,	 cytomegalovirus;	 MF	 mm,	 male	 female	 mismatch;	 TCD,	 T	 cell	 depletion;	 ATG,	 anti-
thymocyte	globulin;	HLA	mm,	Human	Leukocyte	Antigen	mismatch.			 	
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4.12	The	absolute	NK	cell	count	at	day	14	predicts	severity	of	skin	acute	
GVHD	Having	determined	that	the	number	of	D14-NK	cells	predicts	the	overall	incidence	of	acute	GVHD	(grades	II-IV),	we	next	went	on	to	evaluate	whether	there	was	any	relationship	 between	 the	 absolute	 number	 of	 NK	 cells	 and	 the	 severity	 of	subsequent	acute	GVHD	(Figure	4.8).	Although	there	was	no	significant	difference	between	 the	 groups	 when	 analsysed	 using	 the	 Mann-Whitney	 test,	 closer	inspection	of	the	scatter	plot	shows	two	clear	outliers	within	the	grade	III	cohort	that	 skew	 the	 relationship.	 If	 these	 outliers	 are	 discounted	 then	 there	 is	 trend	towards	a	reduction	in	D14-NK	cell	number	as	acute	GVHD	severity	increases.		
	
Figure	4.8	There	is	no	significant	difference	in	the	absolute	D14-NK	cell	count	between	
different	grades	of	acute	GVHD	
D14-NK	cell	number	was	plotted	according	to	the	severity	of	acute	GVHD.	The	Mann-Whitney	
statistical	test	was	used	to	analyse	groups	and	no	significant	difference	was	found	between	
the	groups.		These	two	patients	were	further	investigated	to	determine	whether	they	displayed	any	 unique	 characteristics	 to	 account	 for	 their	 outlier	 status.	 	 Both	 patients	
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developed	acute	GVHD	that	involved	the	gastrointestinal	tract,	and	when	patients	were	 subsequently	 differentiated	 according	 to	 the	 grade	 and	 site	 of	 disease,	 it	becomes	 apparent	 that	 D14-NK	 cell	 number	 is	 able	 to	 predict	 severity	 of	 acute	GVHD	when	it	solely	affects	the	skin	and	spares	the	gastrointestinal	tract	(Figure	4.9).		
	Furthermore,	 acute	 GVHD	 onset	 in	 these	 two	 patients	 occurred	 soon	 after	 the	blood	sampling	(days	17	and	30	respectively)	and	Figure	4.10	illustrates	that	cases	of	 acute	 GVHD	 with	 an	 earlier	 onset	 do	 appear	 to	 have	 a	 higher	 D14-NK	 cell	number,	 although	 this	 observation	 is	 limited	 to	 those	 cases	 that	 involve	 the	gastrointestinal	tract	and	is	not	seen	in	patients	who	develop	acute	GVHD	affecting	the	skin	only.	It	should	be	noted	that	this	observation	is	not	statistically	significant	(Spearman	rank	correlation:-	Skin	–	Grade	I:	r	=	-0.22,	p=0.59	(n=8);	Skin	–	Grade	II:	 r=	 -0.046,	 p=0.86	 (n=13);	 GI	 tract:	 r=0.23,	 p=0.67	 (n=6))	 although	 the	 small	patient	numbers	involved	are	likely	to	have	limited	this	analysis.						
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Figure	 4.9	 The	 absolute	D14-NK	 cell	 count	 is	 reduced	 in	more	 severe	 cases	 of	 acute	
skin	GVHD	
D14-NK	cell	count	was	plotted	according	to	the	severity	and	site	of	acute	GVHD.	It	appears	
that	D14-NK	cell	count	may	be	predictive	of	the	severity	of	acute	GVHD	when	it	solely	affects	
the	skin	and	spares	the	gastrointestinal	tract.			
	
Figure	4.10	Cases	of	acute	GVHD	involving	the	gastrointestinal	tract	that	occur	within	
the	first	30	days	following	allo-SCT	have	a	high	D14-NK	cell	count	
D14-NK	cell	count	is	plotted	according	to	site	and	severity	of	acute	GVHD	and	also	according	
to	the	time	of	GVHD	onset.	There	 is	a	pattern	emerging	that	cases	of	acute	GVHD	affecting	
the	GI	tract	have	a	higher	D14-NK	cell	count	when	symptoms	have	an	earlier	onset.		
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4.14	Discussion	
4.14.1.	Higher	D14-NK	cell	count	predicts	improved	overall	survival	As	a	treatment	for	malignant	disease,	the	main	goal	for	stem	cell	transplantation	is	to	 reconstitute	 a	 functional	 immune	 system	 that	 generates	 a	 graft	 versus	leukaemia	 response	 and	 provides	 robust	 protection	 against	 infection.	 Ineffective	immune	reconstitution	is	associated	with	an	increased	relapse	risk	(Parkman	et	al.,	2006),	 an	 increased	 risk	 of	 infections	 (Paloczi,	 2000)	 (Storek	 et	al.,	 1997)	 and	 a	poor	overall	survival	(Bipin	N	Savani	et	al.,	2007)(Fedele	et	al.,	2012)(Bartelink	et	
al.,	2013).				The	quality	(Triplett	et	al.,	2009)	and	quantity	of	NK	cell	recovery	following	stem	cell	 transplant	 correlates	 with	 poor	 survival	 in	 T	 cell	 replete	 (Minculescu	 et	 al.,	2016)(Bühlmann	et	al.,	 2011),	T	 cell	 deplete	 (Kim	et	al.,	 2016)(B	N	Savani	et	al.,	2007)	 and	 umbilical	 cord	 (Bergerson	 et	 al.,	 2016)	 stem	 cell	 transplants.	 These	studies	 focused	 on	NK	 cell	 reconstitution	 in	 the	 time	 period	 between	 day	 30-90	with	little	study	of	NK	cell	reconstitution	in	the	very	early	post	transplant	period.	We	found	an	extreme	numerical	dominance	of	NK	cells	over	T	cells	in	the	first	two	weeks	and	investigated	whether	the	number	of	NK	cells	at	these	early	time	points	could	also	provide	information	as	a	predictive	marker	for	clinical	outcome.		This	 study	 has	 found	 that	 very	 early	NK	 cell	 reconstitution,	 specifically	 the	 time	period	in	the	first	two	weeks	following	stem	cell	infusion,	is	critical	with	total	NK	cell	count	at	day	14	(D14-NK)	being	a	significant	determinant	of	overall	survival.		A	D14-NK	 cell	 count	 <5	 cells/µl	 remained	 an	 independent	 predictor	 of	 overall	
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survival	in	our	T	cell	depleted	cohort	of	patients	when	clinical	variables	such	as	the	intensity	 of	 the	 conditioning	 regimen	 were	 added	 into	 a	 multivariate	 model.		Although	 some	NK	cell	 subsets	 also	demonstrated	a	 significant	 relationship	with	overall	 survival,	 no	 single	 subset	 was	 uniquely	 associated.	 Whilst	 NK	 cell	reconstitution	 at	 day	 7	 demonstrated	 some	 predictive	 ability	 with	 certain	 NK	subsets,	it	is	notable	that	NK	cell	reconstitution	at	the	later	time	points	of	28	days	and	 100	 days	 did	 not	 discriminate	 patient	 outcomes.	 This	 highlights	 that	 the	important	 immune	relationships	are	 forged	 in	the	very	 first	 two	weeks	 following	stem	 cell	 transplantation,	 although	 the	 smaller	 numbers	 of	 samples	 available	 at	later	time	points	may	have	hampered	our	ability	to	detect	a	difference.			We	then	went	on	to	investigate	whether	higher	numbers	of	D14-NK	cells	were	able	to	exert	a	protective	effect	over	all	or	only	a	subset	of	the	potential	causes	of	death.	We	found	that	the	beneficial	effect	of	higher	D14-NK	cell	count	on	overall	survival	was	 related	 to	 a	 decrease	 in	 transplant	 related	 mortality.	 Infections	 and	 acute	GVHD	 are	 important	 causes	 of	 transplant	 related	mortality	 and	we	were	 able	 to	confirm	 that	 D14-NK	 cell	 reconstitution	 also	 has	 an	 impact	 on	 the	 risk	 of	 acute	GVHD.			Whilst	 higher	 numbers	 of	 reconstituting	 NK	 cells	 do	 not	 lead	 to	 a	 reduction	 in	relapse	 mortality,	 it	 is	 interesting	 to	 note	 that	 there	 is	 a	 trend	 to	 reduction	 in	relapse	risk	with	higher	numbers	of	D14-NK	cells	even	though	this	does	not	reach	statistical	 significance	 (Figure	 4.5(A)).	 Although	 alloreactive	 T	 cells	 are	 the	primary	 immune	 mediator	 of	 graft-versus-leukaemia,	 NK	 cell	 reconstitution	 is	
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important	in	determining	risk	of	relapse	following	allo-SCT	and	adoptive	transfer	of	NK	cell	is	an	important	emerging	therapy	for	haematological	malignancies	(B	N	Savani	et	al.,	2007)(Domogala,	Madrigal	and	Saudemont,	2015).			Therefore,	an	absolute	D14-NK	cell	count	>	5	cell/µl	appears	to	confer	a	significant	survival	advantage	demonstrating	 that	effective	very	early	NK	cell	 reconstitution	may	 be	 an	 important	 factor	 in	 determining	 outcome	 for	 patients	 who	 have	undergone	a	T	cell	depleted	stem	cell	transplant.			
4.14.2.	Higher	D14-NK	cell	number	predicts	a	reduced	risk	of	acute	GVHD	but	has	no	
relationship	with	the	incidence	of	chronic	GVHD	The	 pathogenesis	 of	 acute	 GVHD	 is	 initiated	 by	 transplant	 conditioning	 (Blazar,	Murphy	and	Abedi,	2012),	which	can	activate	APCs	through	tissue	destruction	and	also	activate	 innate	 immune	cells	that	continue	the	process	of	tissue	damage	and	contribute	 to	 the	 cytokine	 storm.	 Subsequent	 to	 antigen	 presentation	 to	 T	 cells,	effector	T	cells	and	innate	immune	cells	are	recruited	which	initiate	a	cycle	of	pro-inflammatory	cytokine	release	and	tissue	destruction	leading	to	end-organ	damage	and	the	clinical	presentation	of	acute	GVHD	(Zeiser,	Socié	and	Blazar,	2016).			NK	cells	reconstitute	early	following	allo-SCT	and	in	line	with	their	known	“killer”	function,	contribute	to	graft	versus	leukaemia	(GVL)	with	high	NK	cell	numbers	in	the	30-60	days	after	 transplantation	associated	with	 low	 relapse	 rate	 and	better	survival	 (Pical-izard	 et	 al.,	 2015)(Dunbar	 et	 al.,	 2008)(B	 N	 Savani	 et	 al.,	
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2007)(Huttunen	 et	 al.,	 2015)(Kim	 et	 al.,	 2016).	 However,	 whilst	 robust	 NK	 cell	reconstitution	has	been	associated	with	GVL,	it	has	also	been	seen	to	predict	for	a	lower	risk	of	acute	GVHD	(Dunbar	et	al.,	2008)(B	N	Savani	et	al.,	2007)(Ruggeri	et	
al.,	 2002)(Kim	 et	 al.,	 2016)	 and	 infusion	 of	 NK	 cells	 can	 protect	 against	 acute	GVHD,	 whilst	 retaining	 GVL	 in	 murine	 models	 (Ruggeri	 et	 al.,	 2002)(Asai	 et	 al.,	1998).	These	observations	suggest	that	NK	cells	may	have	the	potential	to	mediate	GVL	responses	directly	whilst	also	being	able	to	suppress	the	development	of	T	cell	mediated	acute	GVHD	through	undefined	mechanisms.			As	D14-NK	cell	count	is	a	significant	predictor	of	overall	survival	and	TRM	in	our	cohort,	we	then	went	on	to	 investigate	whether	 it	was	also	 important	 in	defining	risk	 of	 acute	 GVHD.	 Receiver	 operating	 character	 curves	 demonstrated	 that	 the	absolute	NK	cell	number	at	days	7	and	14	following	stem	cell	transplantation	could	discriminate	between	 the	patients	and	 their	 subsequent	 risk	of	developing	acute	GVHD.	Although	some	NK	cell	subsets	were	also	able	to	demonstrate	some	effect,	no	one	subset	was	uniquely	associated.			Regression	modeling	of	the	cumulative	incidence	of	acute	GVHD	was	assessed	with	death	 from	any	cause	as	a	competing	risk.	HLA	mismatch,	conditioning	 intensity,	D14-NK	<	5	cells/µl	and	D14-NK	<	25	cells/µl	were	all	statistically	significant	on	univariate	 analysis.	 Whilst	 HLA	 mismatch	 and	 conditioning	 intensity	 remained	significant	on	multivariate	analysis,	out	of	the	immune	reconstitution	parameters,	only	D14-NK	<	25	cells/µl	remained	significant.		
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Very	 early	 NK	 cell	 reconstitution	 is	 clearly	 important	 in	 determining	 clinical	outcome	with	a	threshold	of	>25	cells/µl	defined	as	protective	against	acute	GVHD	whilst	 a	 value	 of	 <5	 cells/µl	 increased	 risk	 of	mortality.	 Furthermore,	 it	 reveals	that	whilst	relatively	few	NK	cells	are	sufficient	to	protect	against	mortality	a	more	robust	reconstitution	is	required	to	provide	protection	against	acute	GVHD.			Chronic	GVHD	is	characterized	by	polarization	of	CD4+	T	cells	into	T	helper	2	(TH2)	cells	 whilst	 acute	 GVHD	 is	 mainly	 driven	 by	 T	 helper	 1	 (TH1)-	 and	 TH17-type	immune	responses(Blazar,	Murphy	and	Abedi,	2012).	The	development	of	chronic	GVHD	is	initiated	by	damage	to	the	thymus,	which	is	often	caused	by	the	transplant	conditioning	regiment	or,	 importantly,	by	a	previous	episode	of	acute	GVHD.	The	resulting	 reduction	 in	 the	 negative	 selection	 of	 alloreactive	 CD4+	 T	 cells	 then	causes	a	skew	to	a	TH2-type	cytokine	response	(IL-4,	IL-5	and	IL-11),	the	release	of	fibrogenic	 cytokines	 (IL-2,	 IL-10	 and	 TGFβ1)	 and	 macrophage	 activation	 that	produces	 platelet-derived	 growth	 factor	 (PDGF)	 and	 more	 TGFβ1.	 This	combination	 of	 cytokines	 activates	 tissue	 fibroblasts	 and	 induces	 them	 to	proliferate.	 Furthermore,	 chronic	 GVHD	 is	 characterized	 by	 low	 numbers	 of	regulatory	 T	 (Treg)	 cells	 and	 dysregulated	 B	 cells	 producing	 autoreactive	antibodies.	This	combination	of	immune	dysregulation	produces	an	autoimmune-like	 systemic	 syndrome	 characterized	 by	 fibroproliferative	 changes	 that	 most	commonly	affect	the	oral	and	ocular	mucosa,	and	the	skin,	lungs,	kidneys,	liver	and	gut.			
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Acute	 and	 chronic	 GVHD	 have	 clearly	 different	 pathophysiologies	 and	 although	acute	GVHD	can,	in	itself,	cause	the	thymic	damage	that	is	required	to	initiate	the	pathogenesis	of	chronic	GVHD,	D14-	NK	cell	number	did	not	predict	risk	of	chronic	GVHD.	This	contrasts	with	previous	studies	showing	that	a	higher	NK	cell	count	at	3	months	was	associated	with	a	reduced	risk	of	chronic	GVHD	(Kheav	et	al.,	2014).		
4.14.3.	A	lower	D14-NK	cell	number	predicts	a	more	severe	clinical	presentation	in	
patients	with	acute	GVHD	affecting	the	skin	The	clinical	presentation	of	acute	GVHD	is	broad	and	is	graded	using	the	modified	Glucksberg	recommendation	(Glucksberg	et	al.,	1974)(Thomas	et	al.,	1975).	It	can	vary	from	a	mild	skin	rash	(Grade	I)	to	life-threatening	liver	and	intestinal	failure	and/or	 erythroderma	 (Grade	 IV).	 Within	 the	 cohort	 of	 patients	 who	 had	 acute	GVHD	 limited	 to	 the	 skin,	 the	 D14-NK	 cell	 number	 was	 significantly	 lower	 in	patients	 who	 developed	 more	 severe	 acute	 GVHD	 (Grade	 II-IV)	 compared	 to	patients	who	had	Grade	I	skin	acute	GVHD.	This	is	in	keeping	with	a	recent	study,	which	 found	 that	 the	 severity	 of	 acute	 GVHD	 correlated	 with	 a	 delayed	reconstitution	of	the	CD56high	NK	cell	subset	(Ullrich	et	al.,	2016).	In	fact,	the	D14-NK	 cell	 number	 was	 not	 significantly	 changed	 between	 patients	 who	 did	 not	develop	acute	GVHD	and	those	who	had	Grade	I	acute	GVHD.	This	is	of	particular	importance	from	a	clinical	perspective	as	Grade	I	acute	GVHD	is	typically	treated	with	 topical	 corticosteroids	 whilst	 Grade	 II-IV	 acute	 GVHD	 is	 treated	 by	immunosuppression	 with	 systemic	 corticosteroids	 with	 the	 inevitable	 increased	risk	of	infection	and	complications	that	result	(Martin	et	al.,	2012).			
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Among	 stem	 cell	 transplant	 physicians,	 it	 is	 often	 commented	 that	 Grade	 I	 skin	acute	 GVHD	 may	 in	 fact	 be	 a	 good	 sign	 for	 patients	 as	 it	 suggests	 that	 the	transplant	 has	 induced	 sufficient	 T	 cell	 alloreactivity	 to	 result	 in	 some	 graft-versus-leukaemia	whilst	falling	short	of	serious	acute	GVHD	that	requires	systemic	immunosuppression.	 Therefore,	 a	 low	 D14-NK	 cell	 number	 may	 specifically	identify	patients	where	 the	manipulation	of	 the	balance	 in	T	cell	alloreactivity	 to	maximize	GvL	has	tipped	too	far	and	resulted	in	clinically	detrimental	acute	GVHD	(Grade	 II-IV).	 In	addition,	 it	 suggests	 that	 it	may	be	useful	as	a	predictive	 tool	 to	identify	at	risk	patients	early	in	the	post-transplant	period.			Although	 our	 cohort	 of	 82	 individuals	 is	 relatively	 small	 and,	 on	 their	 own,	 our	results	do	not	provide	definitive	proof	of	 the	relationship	between	very	early	NK	cell	reconstitution	with	clinical	outcome,	they	do	corroborate	findings	from	studies	assessing	the	relationship	between	NK	cell	reconstitution	at	later	time	points	and	patient	outcomes.	However,	using	an	earlier	 time	point	as	a	predictive	marker	 is	clinically	 advantageous	 as	 it	 provides	 an	 earlier	 indication	 to	 the	 clinician	 and	patient	as	to	the	possible	outcome	of	allo-SCT.	Potentially,	it	also	affords	more	time	for	 intensive	monitoring	 of	 patients	 and/or	modification	 of	 immunosuppressive	medications	in	an	attempt	to	mitigate	the	increased	risk	of	acute	GVHD.		 	
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CHAPTER	5:	INVESTIGATING	THE	PROFILE	OF	D14-NK	CELLS	
	
5.1	Introduction	The	previous	 two	 chapters	have	demonstrated	 that	NK	cells	 reconstitute	 rapidly	after	transplantation	in	the	three	main	transplant	types	carried	out	at	our	centre:	T	cell	depleted,	T	cell	replete	and	umbilical	cord	stem	cell	transplants.	For	all	three	types	of	 transplant,	NK	cells	display	a	 striking	numerical	dominance	over	T	cells	that	 is	most	 noticeable	 in	 the	 first	 few	weeks.	 This	 is	marked	 in	 T	 cell	 depleted	transplants	where	NK	cells	outnumber	T	cells	40-fold	at	day	14	and	is	particularly	remarkable	when	it	is	considered	that	the	normal	NK:T	cell	ratio	is	0.2	in	a	healthy	donor.			Furthermore,	 higher	 numbers	 of	 D14-NK	 cells	 after	 TCD	 transplant	 predict	improved	overall	survival	and	lower	rates	of	acute	GVHD	suggesting	that	NK	cells	may	alter	 the	clinical	manifestations	of	alloreactive	T	cells.	This	next	stage	of	 the	study	profiles	the	phenotype,	origin	and	function	of	D14-NK	cells	with	the	aim	of	understanding	how	these	cells	may	be	impacting	on	the	clinical	outcomes	for	our	patient	cohort.			
5.2	Methods	The	immunophenotype	of	D14-NK	cells	was	ascertained	by	staining	for	cell	surface	antigens	 with	 fluorescent	 markers	 and	 analysed	 by	 flow	 cytometry.	 The	 same	technique	was	used	to	determine	the	profile	of	chemokine	receptor	expression.	We	
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then	went	 on	 to	 consider	 the	 origin	 of	 the	D14-NK	 cell	 population	by	 extracting	DNA	from	sorted	NK	cells	and	assessing	chimerism	through	microsatellite	analysis.	Rates	of	proliferation	were	examined	through	the	expression	of	Ki67.	The	profile	of	 cytokine	 production	 was	 determined	 using	 intracellular	 staining	 and	 a	 cell-based	assay	targeted	against	K562	cells	was	used	to	assess	the	cytotoxic	function	of	 D14-NK	 cells.	 Finally,	 a	 mixed	 lymphocyte	 reaction	 was	 set	 up	 to	 provide	 a	model	 for	MHC	mismatch	 induced	 T	 cell	 proliferation	 into	which	 NK	 cells	 were	added	 in	 at	 varying	 ratios.	 	 This	 experiment	 tested	 the	 hypothesis	 that	 NK	 cells	could	 suppress	 T	 cell	 proliferation.	 Detailed	methods	 for	 the	 techniques	 used	 in	this	chapter	are	specified	in	Section	2.2.1	and	2.4.			
5.3	D14-NK	cell	phenotype	The	phenotype	of	NK	cells	at	day	14	from	82	patients	was	examined	and	compared	to	the	profile	of	NK	cells	 from	12	healthy	donors	(Figure	5.1).	The	patient	cohort	comprised	 consecutive	 patients	 receiving	 T	 cell	 depleted	 allo-SCT	 for	 a	haematological	 condition,	 between	 March	 2012	 and	 October	 2013	 at	 Queen	Elizabeth	 Hospital	 Birmingham.	 D14-NK	 cells	 have	 a	 significantly	 higher	proportion	 of	 CD56bright	 NK	 cells,	 and	 a	 correspondingly	 lower	 proportion	 of	CD56dim	 NK	 cells,	 compared	 to	 healthy	 donors	 (13%	 vs	 5%	 and	 87%	 vs	 95%	respectively).	 CD56bright	 NK	 cells	 are	 regarded	 as	 less	 mature	 than	 CD56dim	populations	 and	 have	 undergone	 less	 rounds	 of	 division	 and	 retain	 longer	telomere	 lengths.	 They	 have	 a	 characteristic	 profile	 of	 increased	 expression	 of	NKG2A,	together	with	reduced	expression	of	NKG2C,	CD57,	CD16	and	KIR.	Overall,	the	 D14-NK	 cells	 show	 a	 immature	 phenotype	 in	 keeping	 with	 a	 increased	
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proportion	 of	 CD56bright	 NK	 cells.	 There	 is	 a	 significant	 increase	 in	 NKG2A	expressing	cells	and	a	reduced	CD57+	population	(49%	vs	23%	and	39%	vs	59%	respectively)	 compared	 to	 healthy	 donor	 NK	 cells.	 There	 is	 no	 significant	difference	 in	 the	 NKG2C+,	 CD16+	 and	 KIR+	 NK	 subsets	 between	 D14-NK	 and	healthy	donor	NK	cells.			Tracking	 NK	 cell	 subset	 reconstitution	 following	 TCD	 transplant	 revealed	 a	biphasic	pattern	of	reconstitution	within	the	CD56bright	and	CD56dim	NK	cell	subsets	(Figure	3.4).	By	day	14,	the	proportion	of	CD56dim	NK	cells	had	increased	from	pre-transplant	levels	of	77%	to	87%	and	subsequently	reduced	to	nearly	50%	by	day	100.	In	view	of	this,	the	immunophenotypic	profile	of	NK	cells	within	the	CD56bright	and	CD56dim	NK	cell	subsets	was	assessed.		NKG2A	expression	was	markedly	increased	on	D14-NK	cells	and	this	was	seen	for	both	the	CD56dim	and	CD56bright	populations.	In	particular,	NKG2A	expression	was	observed	 on	 23%	 and	 46%	 of	 CD56dim	 and	 CD56bright	 NK	 cells	 within	 healthy	donors	whereas	 this	 increased	 to	 47%	and	 70%	on	D14-NK	 cells	 (Figure	 5.1(B)	and	(C)).	The	activating	receptor	NKG2C	demonstrated	higher	expression	in	both	CD56dim	 and	 CD56bright	 populations	 in	 our	 control	 group	 (9%	 and	 15%	respectively)	 compared	 to	our	patient	 cohort	 (4%	and	4%).	Expression	of	CD57,	which	is	generally	associated	with	a	terminally	differentiated	phenotype,	showed	a	differential	 pattern	 of	 staining	 on	 D14-NK	 cells.	 The	 expression	 of	 CD57	 on	CD56bright	 cells	 increased	 from	21%	within	healthy	donors	 to	31%	 in	 the	patient	group.	In	contrast,	expression	on	CD56dim	cells	at	day	14	was	only	43%	compared	
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to	61%	within	the	control	group.	The	expression	of	NKG2C	and	CD16	was	similar	in	 both	 patient	 and	 healthy	 donor	 groups	 and	 within	 CD56dim	 and	 CD56bright	populations.			
		(Legend	on	next	page)	
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Figure	5.1	D14-NK	cell	have	an	 immature	phenotype	compared	 to	healthy	donor	NK	
cells		
(A)	Within	the	total	NK	cell	population,	D14-NK	cells	have	a	significantly	higher	proportion	
of	 immature	 CD56bright	 and	 NKG2A+	 NK	 cells	 compared	 to	 healthy	 donor	 NK	 cells	 with	
reciprocal	decrease	in	the	proportion	of	mature	CD56dim	and	CD57+	NK	cells.	Even	within	the	
CD56dim	(B)	and	CD56bright	(C)	NK	cell	subsets,	D14-NK	cells	display	a	more	immature	profile	
with	a	higher	proportion	of	cells	expressing	NKG2A	(CD56bright	and	CD56dim)	and	a	reduced	
proportion	 of	 cells	 expressing	 NKG2C	 (CD56bright)	 and	 CD57	 (CD56dim).	 D14-NK	 (n=82);	
healthy	donors	(n=12).	Graphs	depict	the	mean	with	error	bars	displaying	the	standard	error	
of	 the	mean.	 	 For	all	 experiments	 *p<0.05,	 **p<0.01,	 ***p<0.005,	 two	 tailed	Mann-Whitney	
test.	
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5.4	D14-NK	cell	chemokine	receptor	expression	We	 next	 went	 on	 to	 examine	 the	 expression	 profile	 of	 a	 range	 of	 chemokine	receptors	that	determine	the	ability	of	cells	to	traffic	to	tissue	sites.	These	included	three	 receptors	 for	 homeostatic	 chemokines	 (CCR7,	 CXCR4	 and	 CCR9),	 three	receptors	for	chemokines	that	guide	cells	to	the	gastrointestinal	tract	(CCR9,	CCR5	and	 CCR6)	 and	 three	 for	 chemokines	 that	 can	 guide	 cells	 to	 the	 skin	 (CMKLR1;	ChemR23,	CX3CR1	and	CXCR3).			Interestingly,	 expression	 of	 receptors	 for	 the	 homeostatic	 chemokines	 was	markedly	different	between	the	two	cohorts,	with	CCR7	and	CCR9	receptor	levels	of	 8%	 and	 7%	 on	 healthy	 donors	 compared	 to	 17%	 and	 25%	 on	 D14-NK	 cells	(p=0.02	and	p<0.0001	respectively).	There	was	a	particularly	marked	increase	in	expression	of	the	receptor	for	CXCR4	from	1%	of	healthy	donor	NK	cells	to	13%	of	D14-NK	 cells	 (p<0.0001)	 (Figure	 5.2	 (A)).	 In	 view	of	 the	 unexpected	phenotypic	findings	on	the	CD56bright	and	CD56dim	NK	cell	subsets	in	the	section	5.3,	we	went	on	to	assess	 the	specific	chemokine	receptor	profile	within	these	subsets	(Figure	5.2	(B)).	We	found	that	chemokine	receptor	expression	is	higher	on	the	CD56bright	NK	cell	subset	 for	all	 three	receptors	 in	both	healthy	donor	NK	cells	and	D14-NK	cells.	 The	 only	 exception	 is	 the	 expression	 of	 CXCR4	 receptor	 on	 D14-NK	 cells,	which	is	uniformly	high	for	both	CD56bright	and	CD56dim	subsets.		There	 is	 more	 variation	 in	 receptor	 expression	 for	 the	 chemokines	 that	 guide	trafficking	 to	 the	 gastrointestinal	 tract	 with	 higher	 expression	 levels	 in	 D14-NK	cells	for	CCR9	and	CCR5	(25%	and	7%	respectively)	compared	to	healthy	donors		
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Figure	5.2	There	is	higher	expression	of	homeostatic	chemokine	receptors	on	D14-NK	
cells	compared	to	healthy	donor	NK	cells	
(A)	The	expression	of	chemokine	receptors	for	the	homeostatic	cytokines	(CCR7,	CXCR4	and	
CCR9)	is	significantly	higher	on	D14-NK	cells	compared	to	healthy	donor	NK	cells.	(B)	This	is	
also	 seen	 within	 the	 CD56bright	 and	 CD56dim	 NK	 cell	 subsets.	 D14-NK	 (n=32)	 and	 healthy	
donors	 (n=12).	 For	 all	 graphs,	 the	 mean	 and	 standard	 error	 of	 the	 mean	 are	 depicted.	
*p<0.05,	 **p<0.01,	 ***p<0.005,	 two-tailed	 Mann-Whitney	 for	 unpaired	 analyses,	 Wilcoxon	
matched-pairs	 signed	 rank	 test	 for	paired	analyses	between	CD56bright	 and	CD56dim	NK	cell	
subsets.					
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	(7%	and	2%),	whilst	the	opposite	relationship	is	found	for	CCR6	(5%	vs	21%).	The	chemokine	 receptors	 that	 guide	 NK	 cells	 to	 skin	 sites	 also	 demonstrate	 a	 split	relationship	with	higher	levels	of	ChemR23	receptor	on	D14-NK	cells	whereas	the	receptors	for	CX3CR1	and	CXCR3	are	expressed	more	on	healthy	donor	NK	cells.			
5.5	D14-NK	chimerism	We	next	went	on	to	investigate	the	origin	and	phenotype	of	the	NK	cell	populations	at	 day	 14	 in	 more	 detail.	 Microsatellite	 chimerism	 analysis	 was	 performed	 on	magnetically	 selected	and	purified	CD3-CD56+	cells	 taken	at	day	14	and	revealed	that	NK	cells	were	derived	exclusively	from	the	transplant	donor	at	this	very	early	timepoint	(n=3)	(Figure	5.3).		
5.6	D14-NK	cell	proliferation	Given	 the	 remarkably	 high	 rate	 of	 NK	 cell	 reconstitution	 in	 the	 first	 few	weeks	after	 transplant,	we	then	went	on	to	determine	the	proliferative	status	of	 the	NK	cell	population	at	day	14.	The	profile	of	Ki67	expression	was	examined	in	D14-NK	cells	and	compared	to	healthy	donors.	Remarkably,	although	Ki67	was	expressed	in	 only	 2.8%	 of	 NK	 cells	 within	 healthy	 donors,	 virtually	 all	 NK	 cells	 expressed	Ki67	 at	 day	 14	 after	 transplant,	 reflecting	 an	 intense	 pattern	 of	 NK	 cell	proliferation	in	the	early	post-transplant	period	(Figure	5.3).		
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5.7	D14-NK	cell	cytokine	production	To	investigate	the	functional	properties	of	NK	cells	at	day	14	after	allo-SCT	we	then	investigated	 their	profile	of	 cytokine	production	 in	comparison	 to	NK	cells	 taken	from	healthy	donors.		Intracellular	 staining	 for	 cytokine	 production	 was	 carried	 out	 initially	 without	prior	 stimulation	of	 cells	 in	order	 to	assess	baseline	 cytokine	production	 in	 cells	analysed	 directly	 ex	 vivo.	 As	 anticipated,	 NK	 cells	 taken	 from	 healthy	 donors	displayed	 very	 low	 levels	 of	 cytokine	 production	 in	 the	 absence	 of	 mitogenic	stimulation.	Specifically,	IL-10,	IFN-γ	and	TNFα	production	was	seen	in	1.5%,	1.0%	and	0.6%	of	cells	respectively.	Remarkably	however,	D14-NK	cells	were	seen	to	be	producing	very	high	levels	of	cytokines	in	vivo	which	was	measured	directly	in	an	ex	 vivo	 assay	 without	 mitogens.	 In	 particular,	 71%	 of	 NK	 cells	 produced	 IL-10,	(p<0.0001	vs	healthy	donors),	32%	produced	IFN-γ	(p<0.0001)	and	30%	produced	TNF-α	(p<0.0001)	(Figure	5.5	and	5.6.A).			We	went	 on	 to	 examine	 the	 combinatorial	 profile	 of	 cytokine	 production	within	D14-NK	 cells	 (Figure	 5.6.B).	 The	 most	 common	 profile	 was	 of	 isolated	 IL-10	production,	which	was	seen	in	26%	of	cells,	followed	by	combined	IL-10	and	TNF-
α	or	IL-10	and	IFN-γ	 in	19%	and	18%	respectively.	A	further	7%	of	D14-NK	cells	were	 shown	 to	 be	 spontaneously	 producing	 all	 three	 cytokines	 whilst	 20%	produced	 none.	 Of	 note,	 only	 9%	 of	 cells	 showed	 evidence	 of	 TNF-α	 or	 IFN-γ	production	in	the	absence	of	IL-10,	indicating	that	an	immunoregulatory	profile	is	dominant	within	NK	cells	at	this	early	stage	of	immune	reconstitution.	
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Figure	5.3	D14-NK	cells	are	donor-derived		
Microsatellite	chimerism	analysis	was	performed	on	magnetically	selected	and	purified	CD3-
CD56+	 cells	 taken	 at	 day	 14	 and	 revealed	 that	NK	 cells	were	 derived	 exclusively	 from	 the	
transplant	donor	at	this	very	early	time	point	(n=3).		
	
	
	
	
	
	
Figure	 5.4	 D14-NK	 cells	 have	 near	 100%	 Ki67	 expression	 indicating	 they	 are	
undergoing	intense	proliferation	
Whilst	2.8%	of	NK	cells	from	healthy	donors	expressed	Ki-67,	expression	within	the	D14-NK	
cells	was	nearly	100%	indicating	intense	proliferation.	D14-NK	(n=5);	healthy	donors	(n=5).	
Graph	depicts	mean	and	standard	error	of	the	mean.	**p<0.01,	Mann-Whitney	test.			
D14-NK
94
96
98
100
%
 d
on
or
 c
hi
m
er
is
m
Healthy donors Day 14 patients
0
10
20
80
90
100
K
i-6
7 
ex
pr
es
si
on
 o
n 
N
K
 c
el
ls
 (%
) **
Chapter 5: The functional profile of D14-NK cells 
!M[W!
!
!!
'
!"#$%&'C)C'H(AL67'8&00-'.&/+2-9%59&'-,+2952&+$-',%+.$89"+2'+1'b_L(PU'b!6! '52.'D6!" )'
H4')&.-**(*&)$8'&,4,4@$ 61)$.;'1+,4-8$I&8$2-)61)3-/$14$W!:C%K$.-**8$&4/$'>18-$ 6)13$>-&*'>;$
/141)8"$X-&*'>;$/141)$%K$.-**8$/,/$41'$/-3148')&'-$8214'&4-1(8$2)1/(.',14$16$&4;$.;'1+,4-8$
3-&8()-/[$I>-)-&8$&$*&)@-$2)121)',14$16$W!:C%K$.-**8$I-)-$8214'&4-1(8*;$2)1/(.,4@$HaC!T[$
HR%C!$ &4/$ B%RC""$ B>-8-$ /1'$ 2*1'8$ &)-$ )-2)-8-4'&',0-$ 16$ '>-$ W!:C%K$ &4/$ >-&*'>;$ /141)$
.1>1)'8$'-8'-/"$r$&4/$;$&Q-8$61)$2*1'8$&)-$N,-Q214-4',&*"$$
!
!
!
Chapter 5: The functional profile of D14-NK cells 
	155	
	
	
Figure	5.6	Overall	and	combinatorial	cytokine	production	in	D14-NK	cells	and	healthy	
donor	NK	cells		
(A)	Cytokine	production	 is	 significantly	 higher	 in	D14-NK	 cells	 compared	 to	healthy	donor	
NK	cells.	 (B)	Combinatorial	assessment	of	cytokine	production	 in	D14-NK	cells	and	healthy	
donor	 NK	 cells	 highlights	 that	 many	 D14-NK	 cells	 are	 producing	 a	 combination	 of	 IL-10,	
TNFα	 and	 IFN-γ.	 D14-NK	 (n=11);	 healthy	 donors	 (n=8).	 Graphs	 depict	 the	 mean	 and	
standard	error	of	the	mean.	*p<0.05,	**p<0.01,	***p<0.005,	two-tailed,	Mann-Whitney	test	for	
unpaired	 analyses,	 Wilcoxon	 matched-pairs	 signed	 rank	 test	 for	 paired	 analyses	 between	
CD56bright	and	CD56dim	NK	cell	subsets.				
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	Cytokine	 production	 is	 generally	 considered	 to	 be	 a	 feature	 of	 CD56bright	 rather	than	 CD56dim	 NK	 cells	 and	 we	 therefore	 compared	 the	 pattern	 of	 expression	 in	these	 two	 subsets	 in	D14-NK	 cells.	 Interestingly	 this	 pattern	was	 reversed,	 such	that	 higher	 levels	 of	 expression	 of	 all	 three	 cytokines	 was	 observed	 within	 the	CD56dim	subset	(Figure	5.7).			
		 		
Figure	5.7	At	day	14	CD56dim	NK	cells	are	the	predominant	cytokine	producing	NK	cell	
subset		
D14-NK	(n=11),	graphs	depict	the	mean	and	standard	error	of	the	mean.	*p<0.05,	**p<0.01,	
Wilcoxon	matched-pairs	 signed	 rank	 test	 used	 for	 paired	 analyses	 between	 CD56bright	 and	
CD56dim	NK	cell	subsets.		
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5.8	 D14-NK	 retain	 their	 cytotoxic	 function	 in	 the	 early	 period	 of	 immune	
reconstitution	D14-NK	 cells	 were	 enriched	 through	 magnetic	 negative	 selection	 and	 their	cytotoxic	activity	against	K562	target	cells	was	determined	using	a	flow	cytometry-based	cytotoxicity	assay.	38%	of	target	cells	were	 lysed	by	NK	cells	 from	healthy	donors	during	the	incubation,	compared	to	37%	of	cells	when	exposed	to	D14-NK	cell	populations.	As	such,	NK	cells	taken	from	patients	at	day	14	retain	comparable	levels	of	cytotoxic	potential	compared	to	NK	cells	from	normal	donors	(Figure	5.8).			
	
	
Figure	5.8	D14-NK	cells	retain	their	cytotoxic	potential	
There	 is	no	significant	difference	 in	the	cytotoxicity	demonstrated	by	NK	cells	 from	healthy	
donors	and	those	from	patients	at	D14	following	SCT.	D14-NK	(n=5),	healthy	donors	(n=5),	
The	 central	 line	 is	 placed	at	 the	mean	with	 error	 bars	 depicting	 the	 standard	 error	 of	 the	
mean.	The	Mann-Whitney	test	was	used	for	statistical	comparison.		
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5.9	 NK	 cells	 suppress	 T	 cell	 proliferation	 in	 an	 MHC	 mismatched	 mixed	
lymphocyte	reaction	A	mixed	lymphocyte	reaction	(MLR)	was	proposed	to	test	the	hypothesis	that	NK	cells	 could	 suppress	 T	 cell	 proliferation	 in	 the	 context	 of	 MHC	 mismatch.	 The	majority	 of	 transplant	 recipients	 are	 matched	 for	 the	 most	 immunogenic	 HLA	types	(HLA-A,	-B,	-C,	-DRB1,	DQB1),	so	the	degree	of	MHC	mismatch	is	at	the	minor	antigen	 level.	However,	we	 first	 sought	 to	optimize	 the	experiment	using	PBMCs	from	healthy	laboratory	donors,	which	were	presumed	to	be	HLA-mismatched,	as	it	would	be	technically	difficult	to	find	HLA-matched	healthy	donor	cells,	which	we	could	use	for	optimization.				PBMCs	were	obtained	from	two	healthy	laboratory	donors	and	PBMCs	from	donor	2	 were	 designated	 the	 stimulator	 cells	 and	 irradiated	 to	 render	 them	 non-proliferative.	In	this	way,	only	cells	from	donor	1	were	able	to	proliferate.	PBMCs	from	donor	1	were	then	 labeled	with	Violet	CellTraceTM,	which	diffuses	 into	cells	and	covalently	binds	to	intracellular	amines	resulting	in	stable	fluorescent	staining	with	 minimal	 effect	 on	 the	 proliferative	 ability	 of	 cells	 or	 their	 biology.	 Excess	unconjugated	reagent	passively	diffuses	into	the	extracellular	medium	where	it	is	quenched	with	complete	media.			Figure	5.19	presents	the	results	of	the	first	experiments	carried	out	to	optimize	the	ratio	of	stimulator	and	responder	cells	 in	 the	MLR	and	 the	best	 time	at	which	 to	measure	 the	degree	of	T	cell	proliferation.	Phytohemagglutinin	 (PHA)	stimulated	PBMCs	were	used	as	a	positive	control.	The	flow	cytometry	dot-plots	display	CD3	
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on	 the	 x-axis	 and	 Violet	 CellTraceTM	 labeled	 cells	 on	 the	 y-axis.	 The	 boxplot	highlights	CD3+	T	cells	that	are	also	labeled	with	Violet	CellTraceTM	(i.e.	from	donor	1).	These	cells	are	shown	on	the	histogram	plot	with	the	successive	generations	of	proliferation	clearly	visible	in	the	positive	control.	This	was	used	to	set	the	gate	for	live	proliferating	T	cells	in	the	histogram	and	the	percentage	within	the	histogram	is	shown	in	the	top	right	of	each	panel.	There	is	minimal	proliferation	seen	in	the	MLR	experiments	at	day	4	(ranging	from	2.9%	-	5.9%)	regardless	of	the	ratio	and	number	 of	 stimulator:responder	 cells	 used	 in	 the	 experiment.	 Proliferation	increases	 successively	 for	 the	 following	 two	 days,	 but	 by	 day	 6	 some	 cells	 have	proliferated	 to	 the	 extent	 that	 the	 CellTraceTM	 labeling	 has	 diluted	 and	 is	equivalent	to	unstained	cells.	Therefore,	we	opted	to	measure	proliferation	after	5	days	of	incubation.			A	 2:1	 ratio	 of	 stimulator:responder	 cells	 provided	 robust	 proliferation	 –	 up	 to	26.4%	when	 4x105	 stimulator	 and	 2x105	 responder	 cells	were	 used.	 A	 4:1	 ratio	resulted	 in	 23%	 proliferation	when	 4x105	 stimulator	 and	 1x105	 responder	 cells	were	mixed	and	interestingly	when	the	number	of	cells	was	doubled	this	led	to	a	reduction	in	the	observed	proliferation	to	18.6%.	The	rapid	cell	expansion	in	this	cell	 ratio	may	 have	 exceeded	 the	 ability	 of	 the	 cell	medium,	 in	which	 they	were	suspended,	 to	 support	 further	 growth.	 For	 the	 final	 MLR	 experiments	 we	 used	2x105	 stimulator	 and	 1x105	 responder	 cells,	 even	 though	 this	 combination	resulted	 in	 the	 least	 proliferation	 (15.6%)	 of	 the	 combinations	 tested	 at	 day	 5.	Using	 higher	 numbers	 of	 cells	 may	 have	 resulted	 in	 more	 proliferation	 but	 the	need	 to	 repeat	 the	 experiment	with	 varying	 numbers	 of	 suppressor	 cells	 and	 in	
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triplicate	 would	 have	 rendered	 the	 experiment	 unfeasible	 due	 to	 the	 very	 high	total	number	of	cells	(and	therefore	blood)	needed	to	conduct	the	experiment.			For	 the	 final	 experiment,	multiple	mixed	 lymphocyte	 reactions	were	 carried	 out	using	PBMCs	from	two	unrelated	healthy	laboratory	donors	(presumed	to	be	HLA	mismatched).	Varying	numbers	of	purified	NK	cells	from	donor	1	were	added	in	to	the	MLRs	 to	 investigate	whether	 they	were	 able	 to	 suppress	T	 cell	 proliferation.	Chimerism	 studies	 have	 established	 that	 D14-NK	 cells	 are	 100%	 donor	 derived	(Figure	 5.3)	 and	 so	we	 did	 not	 need	 to	 account	 for	mixed	 chimerism	within	 the	suppressor	cell	population	when	devising	this	experiment.	Responder	cell:NK	cell	ratios	of	1:0	(no	NK	cells),	16:1	(6250	NK	cells),	4:1	(2.5x104	NK	cells),	1:1	(1x105	NK	cells)	and	1:2	(2x105	NK	cells)	were	used.	Within	each	experiment,	each	ratio	was	 performed	 in	 triplicate	 with	 unstained,	 negative,	 positive	 and	 autologous	stimulator	controls	carried	out	in	duplicate.	The	entire	experiment	was	carried	out	three	 times	 with	 similar	 results	 and	 Figure	 5.10	 displays	 the	 results	 from	 one	representative	experiment.			Figure	5.10.A	demonstrates	the	efficacy	of	the	EasySepTM	NK	enrichment	kit,	which	resulted	 in	 >95%	pure	NK	 cells.	 The	 experimental	 controls	 are	 shown	 in	 Figure	5.10.B	 and	 the	 PHA	 stimulated	 PBMCs	 in	 the	 positive	 control	 exhibit	 abundant	proliferation,	whilst	there	is	minimal	proliferation	in	either	the	negative	control	or	those	 cells	 stimulated	 with	 autologous	 cells.	 Histogram	 plots	 in	 Figure	 5.12(C)	demonstrate	that	proliferation	is	reduced	when	NK	cells	are	added	into	the	MLR.	Figures	5.12.D+E	display	the	mean	of	the	three	replicates,	revealing	that	both	the	
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number	and	percentage	of	proliferating	T	cells	is	suppressed	by	NK	cells	in	a	dose	dependent	manner.			 	
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5.10	Discussion	Immunophenotypic	analysis	of	D14-NK	cells	demonstrated	that	 the	CD56bright	NK	cell	subset,	presumed	to	be	a	more	immature	cell,	made	up	a	higher	proportion	of	these	 cells	 compared	 to	 NK	 cells	 from	 healthy	 donors.	 This	 was	 supported	 by	initial	 analysis,	 which	 also	 demonstrated	 increased	 NKG2A	 expression	 and	reduced	CD57	expression	at	day	14,	in	keeping	with	a	more	immature	phenotype.	In	 addition,	 more	 detailed	 analysis	 into	 the	 composition	 of	 the	 CD56bright	 and	CD56dim	NK	cell	subsets	gave	interesting	results.	NKG2A	expression	was	higher	in	both	NK	cell	 subsets	when	compared	 to	healthy	donors,	whilst	 the	expression	of	CD57	 (a	marker	 of	 terminal	 differentiation)	was	 lower	 in	 CD56dim	 D14-NK	 cells	compared	to	healthy	donor	NK	cells.	This	suggests	that,	even	within	the	immature	CD56bright	and	mature	CD56dim	NK	cell	subsets,	D14-NK	cells	display	a	phenotype	indicative	of	an	earlier	stage	of	differentiation.			A	striking	feature	of	NK	cells	at	day	14	was	that	almost	all	cells	were	undergoing	proliferation	with	nearly	complete	expression	of	Ki67	by	all	cells.	This	is	likely	to	be	 a	 reflection	 of	 intense	 homeostatic	 proliferation	 and	 correlates	 with	 results	from	 murine	 studies	 that	 have	 shown	 equally	 intense	 proliferation	 in	 both	immature	 and	mature	NK	 cell	 populations	during	 lymphopenia	 in	 a	process	 that	was	dependent	on	IL-15	(Prlic	2003)(Jamieson	2004)(Cooper	2002	Blood).			NK	 cells	 at	 day	 14	 also	 express	 increased	 levels	 of	 chemokine	 receptors,	 which	allows	them	to	traffic	to	a	range	of	tissues.	In	particular,	CCR7	guides	trafficking	to	lymph	nodes	(Forster	2008),	CXCR4	mediates	bone	marrow	homing	(Mohle	2013)	
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and	 CCR9	 directs	 cells	 towards	 the	 gastrointestinal	 tract	 (Mora	 2003)(Stenstad	2006)(Svensson	2002).	Expression	of	CCR5	(de	Nadai	2006)(Ottaviani	2006)	and	ChemR23	were	also	increased	and	play	a	role	in	the	homing	of	NK	cells	to	the	skin	and	 joints.	 Overall,	 this	 pattern	 indicates	 that	 NK	 cells	 undergoing	 homeostatic	proliferation	acquire	the	ability	to	enter	a	range	of	lymphoid	and	peripheral	tissue.		Expression	of	receptors	for	the	chemokines	that	regulate	homeostasis	(CCR7,	CCR9	and	CXCR4)	were	particularly	elevated	in	D14-NK	cells	relative	to	healthy	donors,	in	 keeping	with	 the	 intense	 levels	 of	 homeostatic	 proliferation	 that	 supports	 the	rising	NK	cell	numbers.			Perhaps	the	most	striking	feature	of	NK	cells	at	day	14	was	the	pattern	of	intense	and	spontaneous	production	of	cytokines.	This	profile	was	observed	in	the	absence	of	any	mitogenic	stimulation	 in	vitro	 and	was	not	observed	 in	cells	 isolated	 from	healthy	donors.	Furthermore,	IL-10	was	the	dominant	cytokine,	being	expressed	in	70%	 of	 cells,	 compared	 to	 IFN-γ	 or	 TNF-α	 expression	 in	 less	 than	 half	 this	proportion.	Also	notable	was	the	finding	that	isolated	production	of	either	of	these	two	TH1	cytokines,	 in	the	absence	of	 IL-10	was	seen	in	 less	than	10%	of	cells.	As	such,	NK	cells	undergoing	homeostatic	proliferation	develop	a	strongly	dominant	immunoregulatory	profile.	The	mechanism	by	which	this	occurs	is	not	clear	but	the	observation	 is	 comparable	 to	observations	 from	Tarrio	and	colleagues	 in	murine	NK	 cells,	 which	 undergo	 epigenetic	 reprogramming	 of	 the	 IL-10	 locus	 during	homeostatic	 proliferation	 to	 switch	 to	 IL-10	 production.	 This	 phenomenon	 was	termed	 proliferation-dependent	 conditioning	 of	 NK	 cells.	 Indeed	 these	 authors	speculate	that	this	observation	may	explain	why	mature	NK	cells,	which	are	found	
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at	high	levels	in	the	resting	state,	undergo	proliferation,	as	this	serves	to	switch	NK	cells	 from	 an	 inflammatory	 to	 regulatory	 phenotype	 and	 takes	 advantage	 of	 the	high	 frequency	 of	 these	 innate	 cells	 to	 apply	 negative	 pressure	 on	 adaptive	immunity.		IL-10	 can	 directly	 regulate	 T	 cell	 function	 (Mehrota	 1998)(Higuma-Myojo	2005)(Perona-wright	 2009)	 and	 also	 acts	 through	 suppression	 of	 NK-mediated	licensing	of	DC	activation	(Mandaric	2012)	and	modulation	of	NK	deletion	of	DCs	(Alter	2010).	The	combination	of	our	findings	that	NK	cells	strongly	outnumber	T	cells,	 express	 high	 levels	 of	 IL-10	 and	 can	migrate	 to	 secondary	 lymphoid	 tissue	indicate	 that	 they	 are	 likely	 to	 play	 an	 important	 role	 in	 suppressing	 the	generation	of	 the	T	 cell	mediated	alloreactive	 immune	 response	 and	as	 such	are	implicated	in	reducing	the	incidence	of	acute	GVHD.			We	set	up	an	MHC	mismatched	mixed	lymphocyte	reaction	using	PBMCs	from	two	healthy	 donors.	 In	 this	 in	 vitro	 model,	 NK	 cells	 were	 found	 to	 reduce	 T	 cell	proliferation	 in	 a	 dose-dependent	 manner.	 Although	 this	 result	 provides	supportive	 evidence	 for	 our	 hypothesis	 that	 NK	 cells	 can	 suppress	 T	 cell	proliferation	 induced	 by	 MHC	 mismatch,	 the	 mechanism	 behind	 this	 regulatory	effect	 has	 not	 been	 fully	 elucidated	 due	 to	 limitations	 of	 time	 in	 the	 research	project.	It	would	have	been	particularly	interesting	to	test	the	supposition	that	the	NK	 cells	 exerted	 their	 regulatory	 effect	 through	 cytokine	 release.	 Transwell®	Permeable	 Supports	 are	 cell	 culture	 inserts	 comprising	 a	well	with	 a	 permeable	membrane	 (with	 defined	 pore	 size)	 that	 can	 insert	 into	 standard	 multiple	 well	
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plates.	It	enables	co-culture	of	cells	with	or	without	cell-to-cell	contact.	Using	this	insert	 to	 separate	 the	 NK	 suppressor	 cells	 from	 the	 MLR,	 whilst	 allowing	circulation	of	cytokines	in	the	media	would	be	of	interest	in	defining	whether	the	suppressive	 effect	 of	 NK	 cells	 requires	 direct	 cell-to-cell	 contact	 or	 whether	 it	could	be	mediated	by	free-floating	cytokines.			Further	studies	could	include	performing	enzyme	linked	immunoadsorbent	assays	(ELISA)	 to	 assess	 levels	 of	 cytokines	 in	 the	well	media,	 although	 this	would	 not	elucidate	whether	cytokines	were	produced	specifically	by	the	suppressor	NK	cells	or	by	other	cells	within	the	well	such	as	T	cells	or	DCs.	 Intracellular	staining	and	flow	cytometric	 analysis	 assessment	of	 cytokine	production	would	provide	extra	information	 as	 to	 which	 cell	 type	 was	 producing	 the	 cytokines	 of	 interest.	 We	hypothesise	that	the	marked	production	of	IL-10	seen	in	our	NK-14	cells	may	be	a	result	of	proliferation	 induced	epigenetic	reprogramming	resulting	 in	a	switch	to	IL-10	production.	Irradiating	the	suppressor	NK	cells	prior	to	addition	to	the	MLR	would	render	them	non-proliferative	and	would	help	test	the	hypothesis	that	it	is	proliferation	that	induces	IL-10	production	in	NK	cells.		It	would	also	be	optimal	to	repeat	this	experiment	using	cells	 from	a	patient	and	their	 donor,	 although	 this	 would	 be	 technically	 demanding	 as	 cell	 numbers	available	will	be	limited	due	to	lymphopenia.	Although	the	MLR	demonstrated	that	healthy	donor	NK	cells	can	suppress	T	cell	proliferation,	it	is	important	to	note	that	previous	 experiments	 have	 shown	 NK	 cells	 from	 healthy	 donors	 do	 not	spontaneously	produce	IL-10.	It	must	be	considered	that	the	suppressive	effect	of	
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NK	cells	in	the	MLR	may	be	exerted	by	an	another	mechanism,	or	alternatively,	it	is	possible	 that	 the	 experimental	 conditions	 in	 the	 MLR	 are	 able	 to	 recreate	 the	conditions	in	our	patients	post	allo-SCT	to	induce	them	to	spontaneously	produce	IL-10.	 Further	 experiments	 are	 undoubtedly	 required	 to	 unpick	 the	mechanisms	behind	this	result.			To	conclude,	we	have	established	that	D14-NK	cells	are	very	different	to	NK	cells	found	in	healthy	donors.	They	display	an	immature	immunophenotype	both	within	the	whole	NK	cell	population	and	within	the	CD56bright	and	CD56dim	NK	cell	subsets.	They	exhibit	 intense	proliferation,	 as	determined	by	Ki67	expression,	 thought	 to	be	 due	 to	 robust	 homeostatic	 proliferation;	 a	 fact	 that	 is	 supported	 by	 their	increased	 expression	 of	 homeostatic	 chemokine	 receptors.	 Moreover,	 they	demonstrate	spontaneous	cytokine	production	with	a	dominant	regulatory	pattern	and	retain	their	cytotoxic	capacity.	Furthermore,	we	have	shown	that	NK	cells	can	suppress	 MHC	 mismatch	 induced	 T	 cell	 proliferation	 providing	 support	 for	 our	hypothesis	that	NK	cells	may	regulate	the	allogeneic	T	cell	response	following	allo-SCT	and	so	reduce	the	risk	of	acute	GVHD.						 	
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CHAPTER	6:		INVESTIGATING	THE	TRANSCRIPTIONAL	PROFILE	OF	
D14-NK	CELLS	
6.1	Introduction	The	 preceding	 chapters	 have	 demonstrated	 that	 NK	 cells	 reconstitute	 rapidly	following	 allo-SCT	 and	 that	 the	 number	 of	 reconstituting	 NK	 cells	 at	 day	 14	following	 transplantation	 is	 an	 independent	 predictor	 of	 the	 subsequent	 risk	 of	acute	 GVHD	 in	 T	 cell	 deplete	 allo-SCT.	 Studies	 into	 the	 functional	 capabilities	 of	D14-NK	cells	 in	Chapter	5	have	demonstrated	 they	are	 cells	 that	are	undergoing	intense	 proliferation	 and	 are	 donor	 derived,	 suggesting	 that	 the	 rapid	reconstitution	 occurring	 in	 the	 first	 weeks	 following	 transplant	 are	 a	 result	 of	homeostatic	 proliferation	 of	 donor	 derived	 NK	 cells.	 Moreover,	 D14-NK	 cells	exhibit	spontaneous	production	of	a	range	of	cytokines,	including	IL-10,	IFN-γ	and	TNF-α,	 although	 combinatorial	 analysis	 reveals	 that	 cytokine	 production	 has	 a	predominantly	 immunoregulatory	 profile.	 D14-NK	 cells	 retain	 their	 cytotoxic	potential	and	possess	the	potential	to	traffic	to	lymphoid	tissues	and	organs	within	the	body	through	expression	of	a	range	of	chemokine	receptors.			To	 further	 investigate	 their	 unique	 functional	 profile	 and	 potential	 clinical	importance	in	the	pathophysiology	of	acute	GVHD,	we	went	on	to	study	the	gene	expression	profile	of	D14-NK	cells	using	a	high	resolution	microarray:	Affymetrix	GeneChip®	Human	Transcriptome	Array	2.0.		
Chapter 6: The transcriptional profile of D14-NK cells 
	170	
6.2	Methods	The	 detailed	 methodology	 is	 described	 in	 Section	 2.5.	 Briefly,	 NK	 cells	 were	purified	from	PBMCs	from	both	healthy	donors	and	stem	cell	transplant	recipients	at	day	14	 following	 transplantation.	 In	 a	 two-step	procedure,	NK	 cells	were	 first	isolated	 using	 magnetic	 negative	 selection	 prior	 to	 cell	 sorting	 as	 an	 added	enrichment	step.	Total	RNA	was	extracted,	 labeled	and	hybridized	 to	GeneChip®	Human	 Transcriptome	 Array	 2.0	 (Affymetrix,	 USA).	 Dr	 Wayne	 Croft	 performed	data	 analysis	 and	 produced	 figures.	 Raw	 data	 was	 processed	 using	 Affymetrix’s	Expression	Console	software	using	default	RMA	parameters	and	statistical	analysis	of	 differential	 expression	 and	 gene	 set	 enrichment	 analysis	 was	 performed	 in	Rv3.3.1	using	packages	limma	and	GAGE	respectively.			
6.3	Purification	of	NK	cells	sent	for	microarray	analysis	The	EasySepTM	Human	NK	cell	enrichment	kit	isolated	NK	cells	from	PBMCs	with	a	purity	of	>95%	(Figure	6.1	left	panel).	However,	in	order	to	obtain	an	even	higher	purity	of	NK	cells	 to	send	 for	microarray	analysis	we	added	an	extra	enrichment	step.	The	magnetically	 isolated	NK	cells	were	stained	with	anti-CD3	PE	and	anti-CD56	APCCy7,	and	the	CD3	negative	and	CD56	positive	live	cells	were	sorted	using	an	Astrios	 cell	 sorter	 (BD	Biosciences).	 Subsequently,	NK	cell	populations	with	a	purity	 of	 99.5%	 were	 collected	 and	 sent	 to	 AROS	 Applied	 Biotechnology	 A/S	(Aarhus	N,	Denmark)	as	dry	cell	pellets.			
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second	is	based	on	statistical	measures	and	assesses	the	significance	of	the	change	in	 signal	 between	 experimental	 groups	 by	 using	 a	 t-test	 and	 calculating	 the	probability	value	(p-value)	for	each	probe	set.	As	each	array	contains	thousands	of	probe	sets,	 this	 results	 in	 thousands	of	 statistical	 tests	with	a	high	risk	of	 type	1	error	 (i.e.	 falsely	 detecting	 a	 significant	 difference)	 when	 conducting	 multiple	comparisons.	 The	Benjamini-Hochberg	 procedure	was	 utilized	 in	 our	 analysis	 to	adjust	 the	 p-value	 and	 control	 the	 false	 discovery	 rate(Benjamini	 and	Hochberg,	1995).	 	 The	 Microarray	 Quality	 Control	 consortium	 publication	 in	 2006	recommended	 the	 use	 of	 both	 fold	 change	 and	 p-value	 in	 generating	 signature	gene	 lists.	 The	 transcriptional	 profile	 of	 NK-14	 cells	 (n=4)	was	 compared	 to	 the	profile	 of	 NK	 cells	 from	 healthy	 donors	 (n=5).	 The	 great	majority	 of	 transcripts	were	 expressed	 at	 a	 lower	 level	 in	 D14-NK	 cells	 compared	 with	 NK	 cells	 from	healthy	donors	(Figure	6.2).				Differential	gene	expression	analysis	was	completed	and	the	heatmap	in	Figure	6.3	displays	the	differentially	expressed	genes	with	an	absolute	log	fold	change	>	1	and	for	which	the	adjusted	p-value	is	<0.1.	Cluster	analysis	of	this	group	of	genes	was	performed	and	the	dendrogram	demonstrates	that	the	D14-NK	cells	and	NK	cells	from	healthy	donors	 cluster	 together	providing	evidence	 that	 the	 transcriptional	profile	 of	 D14-NK	 cells	 is	 different	 to	 that	 of	 NK	 cells	 from	 healthy	 donors	 and	corroborating	our	findings	in	Chapter	5.		
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Expression	of	the	killer	cell	immunoglobulin-like	receptor	KIR3DX1	was	increased	by	 5.5	 fold	 in	NK-14	 cells	 compared	 to	 healthy	 donors,	 although	 to	 date	 little	 is	known	regarding	the	function	of	this	protein	(Figure	6.2).		The	 most	 significantly	 downmodulated	 genes	 included	 CARD8,	 which	 regulates	caspase	activations,	NF-kB	and	the	serine/threonine	protein	kinase	AKT3.	
	
Figure	6.2	Overall	gene	transcript	levels	are	downregulated	in	D14-NK	cells	compared	
to	healthy	donor	NK	cells		
This	volcano	plot	displays	 the	overall	 transcript	 levels	 in	NK	cells	at	day	14	 following	allo-
SCT	(D14-NK)	compared	to	NK	cells	 from	healthy	donors	(D14-NK	n=4	and	healthy	donors	
n=5).	 The	majority	 of	 genes	 display	 negative	 fold	 change	 indicating	 reduced	 expression	 in	
D14-NK	cells	compared	to	healthy	donor.		
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6.5	Genes	 for	 cytokines	and	growth	 factors	are	specifically	enriched	within	
the	D14-NK	upregulated	transcripts	Differential	gene	expression	analysis	highlighted	 the	overall	downregulation	 that	is	evident	in	NK-14	cells	compared	to	NK	cells	from	healthy	donors.	However,	the	list	 of	 genes	 that	 demonstrated	 the	 largest	 differences	 in	 expression	 were	 a	heterogenous	group	without	a	clear	unifying	functional	annotation	and	this	limited	our	 efforts	 to	 understand	 the	 underlying	 biological	 differences	 between	 the	 two	populations	of	NK	cells.	This	situation	is	not	uncommon	and	reflects	the	inherent	limitations	 in	 the	 methodology	 of	 differential	 gene	 expression	 analysis.	 After	correcting	 for	 multiple	 hypotheses	 testing,	 individual	 genes	 that	 are	 important	biologically	 may	 not	 meet	 the	 arbitrarily	 defined	 threshold	 for	 statistical	significance	 because	 the	 biological	 differences	 are	 modest	 relative	 to	 the	 noise	inherent	in	the	microarray	experiment.	Furthermore,	single-gene	analysis	does	not	account	 for	 important	 effects	 on	 pathways	 that	 define	 cellular	 processes.	 For	example,	 a	 small	 corresponding	 increase	 in	all	 genes	encoding	 the	members	of	a	pathway	may	have	a	more	 important	 impact	on	cell	biology	 relative	 to	a	20-fold	increase	in	a	single	gene	(Subramanian	et	al.,	2005).			Gene	 set	 enrichment	 analysis	 (GSEA)	 offers	 a	 powerful	 method	 for	 interpreting	gene	 expression	 data	 by	 focusing	 on	 gene	 sets.	 These	 are	 groups	 of	 genes	 that	share	a	common	biological	function	or	chromosomal	location	and	are	repositories	of	 biological	 knowledge	 that	 are	 constantly	 updated	 as	 new	 information	 is	published.			
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most	likely	to	reflect	the	fact	that	human	NK	cells	have	a	turnover	time	of	around	2	weeks	within	the	blood	and	thus	most	cells	are	likely	to	be	undergoing	senescence	following	14	days	of	intense	activation	and	proliferation(Zhang	et	al.,	2007).			Of	 note	was	 the	 observation	 that	 the	mRNA	 level	 of	 the	KIR	 gene	KIR3DX1	was	increased	 by	 5.5	 fold	 in	 NK	 cells	 at	 day	 14.	 The	 function	 of	 KIR3DX1	 is	 largely	unknown	although	 it	 is	 the	 sole	member	of	 one	of	 the	 two	divergent	 lineages	of	primate	KIR	genes.	Interestingly,	the	only	non-primate	species	for	which	expansion	of	 the	KIR	 gene	 families	 has	 been	 reported	 is	 cattle	 and	 here	 their	 variable	 and	functional	KIR	 genes	 correspond	 to	 the	 primate	KIR3DX1	 gene	 (Guethlein	 et	 al.,	2007).	 It	 is	 unclear	 why	 the	 KIR3DX1	 gene	 family	 has	 undergone	 selective	expansion	 within	 cattle	 but	 our	 data	 suggest	 that	 the	 protein	 also	 plays	 a	functional	role	in	human	NK	cells.			
CARD8	and	AKT3	are	the	two	genes	with	the	most	significant	reduction	 in	mRNA	levels	 in	 D14-NK	 cells.	 CARD8	 encodes	 caspase	 recruitment	 domain-containing	protein	8,	which	alongside	other	caspase	 recruitment	domain	 (CARD)-containing	proteins,	is	involved	in	pathways	leading	to	activation	of	caspases	or	nuclear	factor	kappa-B	(NF-kB)	in	the	context	of	apoptosis	or	inflammation,	respectively.	A	meta-analysis	has	suggested	that	the	mutant-type	CARD8	gene	polymorphism	rs2043211	may	 be	 protective	 in	 subtypes	 of	 Crohn’s	 disease(Zhang	 et	 al.,	 2015)	 and	 other	studies	have	identified	functional	variants	in	CARD8	associated	with	an	increased	incidence	 of	 gout	 in	 susceptible	 individuals	 due	 to	 increased	 inflammasome	activity(McKinney	et	al.,	2015).	The	AKT3	gene	is	one	of	three	highly	homologous	
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isoforms	 of	 the	 serine/threonine	 kinase	 AKT.	 The	 family	 of	 AKT	 kinases	 are	important	 mediators	 of	 the	 phosphoinositide	 3-kinase	 (PI3K)	 pathway	 and	 are	involved	 in	many	cellular	processes,	 ranging	 from	cell	proliferation	and	survival,	glucose	sensitivity,	tumour	metastasis	and	angiogenesis(Cheung	and	Testa,	2013).			Although	 differential	 gene	 expression	 analysis	 and	 hierarchical	 clustering	 has	highlighted	 the	 contrasting	 patterns	 of	 gene	 transcription	 between	D14-NK	 cells	and	healthy	donor	NK	cells,	the	list	of	genes	with	largest	differences	in	expression	do	not	demonstrate	a	clear	unifying	functional	annotation.	The	arbritrarily	defined	cut	 off	 values	 of	 absolute	 log2	 FC	 >	 1	 and	 adjusted	 p-value	 of	 <0.1	 may	 have	excluded	some	important	genes.	Therefore,	we	proceeded	to	gene	set	enrichment	analysis,	 which	 identifies	 whether	 specific	 gene	 families	 or	 genes	 involved	 in	specific	 pathways	 are	 enriched	 within	 the	 upregulated	 or	 downregulated	transcripts.			We	found	that	genes	associated	with	cytokines	and	growth	factors,	defensins	and	extracellular	 matrix	 proteins	 were	 selectively	 enriched	 within	 upregulated	transcripts,	in	keeping	with	our	findings	that	D14-NK	cells	are	functional	cells	that	are	 prolific	 cytokine	 producers	 and	 retain	 cytotoxic	 capacity.	 Genes	 associated	with	 transcription,	 cell	 cycle	 and	 RNA	 metabolism	 were	 enriched	 within	 the	downregulated	 transcripts	 of	 D14-NK	 cells.	 Our	 results	 from	 Chapter	 3	 and	Chapter	5	have	clearly	demonstrated	the	intense	proliferation	that	is	occurring	in	the	D14-NK	cells,	as	demonstrated	by	the	near	100%	expression	of	Ki67	in	these	cells	compared	to	5%	in	healthy	donor	NK	cells.			
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Overall,	the	results	from	the	analysis	of	the	transcriptional	profile	of	D14-NK	cells	in	 comparison	 to	 that	 of	 healthy	 donor	 NK	 cells	 support	 our	 findings	 in	 the	previous	chapters.					 	
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7.	CONCLUSION	
	This	research	project	was	directed	towards	understanding	NK	cell	 reconstitution	in	 our	 cohort	 of	 patients	 undergoing	 predominantly	 T	 cell	 depleted	 allo-SCT.	Previous	 studies	 had	 demonstrated	 the	 importance	 of	 effective	 NK	 cell	reconstitution	 in	 improving	patient	outcome	although	 these	had	 largely	assessed	NK	 cell	 reconstitution	 at	 day	 30,	 or	 later	 time	 points,	 after	 transplant.	Cyclophosphamide	is	an	extremely	effective	prophylaxis	against	acute	GVHD	when	given	at	day	3	 following	allo-SCT,	suggesting	that	the	alloreactive	T	cell	response	responsible	for	GVHD	is	determined	in	the	first	few	days	following	transplantation.	The	 increasing	 awareness	 that	 NK	 cells	 can	 modulate	 the	 adaptive	 immune	response	led	us	to	hypothesise	that	NK	cell	reconstitution	and	NK	cell	function	in	the	 first	 few	days/weeks	 following	allo-SCT	 is	crucial	 in	understanding	how	they	may	 be	modulating	 the	 alloreactive	 T	 cell	 response	 and	 potentially	 determining	clinical	outcomes	following	this	procedure.			We	first	determined	whether	NK	cell	reconstitution	was	affected	by	differences	in	transplant	type	by	comparing	patterns	of	recovery	in	T	cell	deplete,	T	cell	replete	and	 umbilical	 cord	 stem	 cell	 transplants.	 We	 were	 able	 to	 directly	 compare	reconstitution,	up	to	day	14,	in	patients	receiving	TCD,	TR	and	umbilical	cord	allo-SCT.	As	expected,	cell	numbers	dropped	rapidly	after	transplant	conditioning	and	NK	cell	recovery	was	rapid	in	all	three	transplant	types,	with	little	difference	in	the	reconstitution	 of	 total	 NK	 cell	 number	 between	 the	 transplant	 types.	 However,	there	 were	 important	 differences	 in	 T	 cell	 reconstitution	 between	 the	 three	
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transplant	 types.	 We	 observed	 minimal	 T	 cell	 recovery	 in	 TCD	 transplants	compared	 to	 TR	 or	 umbilical	 cord	 transplants.	 This	 resulted	 in	 a	 dramatically	skewed	 NK:T	 cell	 ratio	 at	 day	 14,	 which	 was	 particularly	 marked	 in	 TCD	transplants.			We	 also	 observed	 contrasting	 patterns	 of	 NK	 cell	 subset	 reconstitution	 when	assessed	according	to	expression	of	CD56.	The	absolute	numbers	of	CD56bright	and	CD56dim	 NK	 cells	 increased	 in	 all	 transplant	 types	 between	 days	 7	 and	 14,	 and	whilst	 the	 rate	 of	 increase	 for	 CD56dim	NK	 cells	 exceeded	 CD56bright	 NK	 cells	 for	both	 TCD	 and	 umbilical	 cord	 transplants,	 the	 rates	 for	 both	 subsets	 were	comparable	 in	 TR	 transplants	 (Figure	 3.16.A).	 When	 these	 two	 subsets	 were	assessed	as	a	proportion	of	the	total	NK	cell	population,	it	became	evident	that	the	CD56dim	 NK	 cell	 populations	 increased	 for	 TCD	 and	 umbilical	 cord	 transplants	between	day	7	and	day	14	whilst	the	opposite	was	true	in	TR	transplants	(Figure	3.16.B).		The	presence	of	mature	T	cells	in	TR	transplants	may	predispose	towards	the	 development	 of	 CD56bright	 NK	 cells	 de	 novo	 from	 lymph	 node	 HPCs	 or	 may	compete	for	essential	cytokines	and	other	signals	required	for	NK	cell	maturation	so	 that	 adoptively	 transferred	 NK	 cells	 fail	 to	 develop	 into	 the	 more	 mature	CD56dim	phenotype.	Conversely,	 an	abundance	of	 cytokines	 in	TCD	and	umbilical	cord	blood	transplants,	due	to	lack	of	mature	T	cells	competing	with	NK	cells,	may	specifically	induce	proliferation	within	the	CD56dim	NK	cell	population.			We	next	went	on	to	assess	the	effect	of	NK	cell	reconstitution	on	the	clinical	end-points	 of	 overall	 survival,	 relapse,	 transplant	 related	mortality,	 acute	 GVHD	 and	
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chronic	 GVHD.	 In	 view	 of	 the	 marked	 differences	 in	 NK	 subset	 recovery	 in	 the	transplant	types,	we	restricted	this	portion	of	 the	study	to	the	82	patients	 in	our	cohort	who	received	T	cell	depleted	allo-SCT.	We	found	that	D14-NK	cell	count	<5	cells/µl	 was	 an	 independent	 risk	 factor	 for	 impaired	 survival	 in	 a	 multivariate	model,	which	included	conditioning	intensity	as	significant	variable.	 	D14-NK	cell	count	 <5	 cells/µl	was	 associated	with	 an	 increased	 transplant	 related	mortality,	and	 notably,	 there	 was	 no	 significant	 relationship	 with	 relapse	 or	 relapse	mortality.	 Interestingly,	 a	 D14-NK	 cell	 count	 <25cells/µl	 was	 better	 at	distinguishing	 patients	 who	 went	 on	 to	 develop	 acute	 GVHD.	 This	 provides	 an	interesting	biological	 insight	and	suggests	 that	whilst	a	relatively	modest	NK	cell	recovery	 of	 >5	 cells/µl	 is	 sufficient	 to	 provide	 protection	 against	 mortality	following	 TCD	 allo-SCT,	 further	 increments	 in	 NK	 cell	 reconstitution	 provide	additional	benefits	in	patient	outcome.		We	went	on	 to	 assess	 the	biological	 function	of	D14-NK	cells	 in	more	detail	 and	found	that	they	are	donor-derived	and	display	intense	levels	of	proliferation.	This	allows	 NK	 cells	 to	 reconstitute	 rapidly	 and	 is	 likely	 to	 reflect	 homeostatic	proliferation	 in	 response	 to	 the	 lymphopenic	 environment	 with	 additional	stimulation	 from	 the	 abundant	 cytokines	 present	 as	 a	 result	 of	 transplant	conditioning.	 Compared	 to	 NK	 cells	 from	 a	 healthy	 donor,	 D14-NK	 cells	 have	 a	higher	 proportion	 of	 immature	 CD56bright	 NK	 cells.	 Moreover,	 even	 within	 the	CD56bright	 and	 CD56dim	 NK	 subsets,	 they	 appear	 phenotypically	 more	 immature	with	higher	expression	of	NKG2A	and	reduced	expression	of	NKG2C.			
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D14-NK	 cells	 also	 have	 a	 generally	 higher	 expression	 of	 chemokine	 receptor	relative	 to	 healthy	 donor	 NK	 cells,	 allowing	 them	 to	 traffic	 to	 tissues	 and	 organ	sites	 around	 the	 body.	 These	 cells	 spontaneously	 produce	 a	 range	 of	 cytokines	including	 IL-10,	 IFN-γ	 and	 TNF-α, with	 a	 striking	 skew	 towards	 an	immunoregulatory	phenotype.	Over	70%	of	NK-14	cells	spontaneously	produce	IL-10	 and,	whilst	 a	 single	 cell	 often	produces	 a	 combination	 of	 cytokines,	 less	 than	10%	produce	either	IFN-γ	or	TNF-α	in	the	absence	of	IL-10.	Furthermore,	D14-NK	cells	are	cytotoxic	and	retain	a	similar	level	of	activity	to	healthy	donor	NK	cells.			Interestingly,	the	immunophenotype	of	D14-NK	cells	is	similar	to	that	described	in	cytokine-induced	memory-like	(CIML)	NK	cells	induced	in	vitro	by	IL-12,	IL-15	and	IL-18	 stimulation	 (Romee	 2012).	 Allo-SCT	 conditioning	 is	 characterized	 by	 the	induction	of	a	relative	cytokine	storm	and	as	such	 this	may	represent	 the	 in	vivo	correlate	 of	 CIML	 development	 (Melenhorst	 2012).	 Moreover,	 both	 populations	demonstrate	vigorous	cytokine	production	with	retention	of	these	properties	even	after	multiple	 rounds	 of	 homeostatic	 proliferation.	 Both	 CIML	 cells	 and	 D14-NK	cells	 are	 effective	 cytotoxic	 cells	 and	 CIML	NK	 cells	 even	 demonstrate	 enhanced	responses	 in	 unlicensed	 NK	 cells,	 thus	 recruiting	 a	 previously	 anergic	subpopulation	of	NK	cells	into	a	GVL	response	(Romee	2016)	(Wagner	2016).		Assessment	of	 the	D14-NK	 cell	 transcriptome	 relative	 to	healthy	donor	NK	 cells,	found	 a	 profile	 of	 generalized	 downregulation	 in	 transcription,	 reflecting	 a	population	 of	 cells	 that	 are	 undergoing	 senescence	 after	 two	 weeks	 of	 intense	proliferation.	 To	 corroborate	 this,	 the	 genes	 in	 the	 pathways	 involved	 in	
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transcription,	 cell	 cycle	 and	RNA	metabolism	are	 enriched	 in	 the	downregulated	portion	 of	 the	 transcriptome.	 Furthermore,	 the	 genes	 encoding	 cytokines	 and	growth	 factors	 are	 enriched	 in	 the	 upregulated	 portion	 of	 the	 transcription,	 in	keeping	with	our	observations	that	D14-NK	cells	spontaneously	produce	a	variety	of	cytokines.		These	findings	revealed	that,	even	at	this	very	early	period	of	reconstitution	after	allo-SCT,	 D14-NK	 cells	 are	 fully	 functional	 cells.	 The	 striking	 immunoregulatory	profile	of	spontaneous	cytokine	production	led	to	the	hypothesis	that	D14-NK	cells	can	suppress	the	alloreactive	T	cell	response	that	causes	acute	GVHD	in	a	cytokine	dependent	 mechanism.	 An	 MHC	 mismatched	 mixed	 lymphocyte	 reaction	 (MLR)	was	set	up	to	provide	an	in	vitro	model	for	T	cell	proliferation	occurring	after	allo-SCT.	We	found	that	NK	cells	are	able	to	suppress	T	cell	proliferation	in	an	MLR	in	a	dose	dependent	manner	further	supporting	our	hypothesis.	The	ability	of	NK	cells	to	 directly	 kill	 antigen-presenting	 cells	 (DCs)	 or	 activated	 T	 cells	 may	 also	 be	important	 in	modulating	 the	 alloreactive	T	 cell	 response	 (Morandi	 2012)(Chiesa	2003)(Walzer	 2005)(Wilson	 1999)	 (Waggoner	 2012)(Cook	 2014).	Immunoregulatory	 NK	 cells	 within	 peripheral	 tissues	 may	 serve	 to	 limit	 tissue	damage	mediated	by	the	established	alloreactive	immune	response.		To	conclude,	this	research	project	has	identified	that	NK	cells	rapidly	reconstitute	following	allo-SCT	and	there	is	a	striking	numerical	dominance	of	NK	cells	over	T	cells	in	the	first	two	weeks,	which	is	particularly	notable	in	TCD	allo-SCT.		Higher	numbers	 of	 D14-NK	 cells	 are	 strongly	 correlated	 with	 a	 reduced	 risk	 of	 acute	
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GVHD	and	our	finding	that	such	cells	express	high	levels	of	IL-10,	and	are	targeted	to	 lymphoid	 and	 peripheral	 tissue,	 provides	 a	 direct	 mechanism	 for	 this	association.	NK	cells	may	traffic	to	the	lymph	node,	where	IL-10	could	suppress	the	generation	 of	 alloreactive	 T	 cell	 responses,	 or	 their	 effect	 may	 be	 mediated	 by	suppression	 of	 alloreactive	 T	 cells	 within	 peripheral	 tissue	 (Figure	 7.1).	 These	findings	 have	 relevance	 for	 clinical	 practice.	 D14-NK	 cell	 number	 may	 be	 a	biomarker	 for	 clinical	 outcome,	 particularly	 when	 combined	 with	 additional	measures	such	as	serum	analysis(Thiant	et	al.,	2010)(Armand	et	al.,	2007)(Barrett,	2015)	or	T	cell	count(Bipin	N	Savani	et	al.,	2007)(Petersen	et	al.,	2004)(Fujioka	et	
al.,	 2012)(Rubio	 et	 al.,	 2012).	 Furthermore,	 optimization	 of	 early	 donor	 NK	 cell	engraftment	may	impact	on	patient	outcome,	possibly	through	graft	engineering	or	by	manipulation	of	the	cytokine	microenvironment.												
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